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Synthetic peptides hold great promise as well-defined antigens for immunotherapy of 
cancer.  The exact sequence and length of synthetic long peptides (SLPs) derived from 
cancer antigens can be designed and SLPs are readily produced in quantities suited 
for therapeutic vaccination. However, the formulation of SLPs for in vivo administration 
still needs to be improved. So far, SLPs have been formulated in Montanide-based 
water-in-oil (w/o) emulsions in (pre-)clinical trials. However, the use of Montanide as an 
adjuvant has some important limitations, such as: non-biodegradability; significant local 
side effects; poor control of release rate; lack of specific dentritic cell (DC)-activating 
capacity; and the presence of organic solvents (needed to dissolve the peptides prior 
to mixing with the adjuvant) in the final formulation. Therefore, alternative formulations 
containing an effective delivery system for peptide-based cancer vaccines are highly 
needed. 
Among the numerous vaccine delivery systems, poly(lactic-co-glycolic acid) (PLGA) 
biodegradable particulate delivery systems are particularly interesting because they 
are biocompatible; can protect soluble antigens from degradation and rapid clearance 
once administered; allow for co-encapsulation of (multiple) antigens and adjuvants; and 
mimic the size and structure of a pathogen, being more efficiently taken up by DCs than 
soluble antigen [1, 2].
This thesis describes fundamental studies on the design and applicability in a pre-




Vaccination is one of the greatest achievements in the history of medicine, being 
the most effective biomedical intervention against infectious diseases, since it was 
introduced by Edward Jenner in the 18th century, who showed that humans could be 
protected against smallpox after inoculation with material scraped from the blisters of 
cowpox infected cows. The mechanism of vaccination works by activating the immune 
system against a specific agent, in order to rapidly recognize and remove the threat on 
a later encounter. The concept was further developed by Louis Pasteur, who developed 
rabies and anthrax vaccines by using live attenuated strains or inactivated pathogens 
[3]. Since then, worldwide vaccination campaigns using whole inactivated or live 
attenuated microorganisms have led to the eradication of smallpox and a dramatic 
reduction of other diseases such as polio and measles. 
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1Traditionally, vaccines were generated empirically, without deep insight into the nature 
of the pathogen or the immune response, usually based on live attenuated or chemically 
or heat inactivated bacteria or viruses. Though live attenuated or whole inactivated 
pathogens have proven very effective at eliciting both humoral and cellular immune 
responses [4], the possibility of adverse effects associated with these vaccines, such 
as disease symptoms resulting from the inability of immune-compromised or elderly 
patients to clear the vaccine [5], unwanted inflammation or the possibility of reversion 
of the microorganisms to virulence [6], has raised safety concerns. 
The demand for safer alternatives led to the development of subunit vaccines, which 
instead of a whole organism contain only specific antigenic compounds derived from 
it. Based on this principle, numerous subunit vaccines have been developed based on 
purified proteins and capsular polysaccharides obtained from the respective pathogens. 
Since a couple of decades, vaccines have become available or are being developed 
based on substances that do not require the pathogen as a production source, such 
as recombinant proteins, synthetic peptides, and genetic vaccines containing DNA or 
RNA encoding the antigen(s) of interest [7]. Examples of subunit vaccines successfully 
applied for widespread vaccination include hepatitis B, tetanus, diphtheria, and human 
papillomavirus (HPV) vaccines.
The use of individual antigens rather than whole pathogens diminishes safety concerns. 
However, soluble antigens often are weakly immunogenic, as they are poorly taken 
up and processed by antigen-presenting cells (APCs), lack danger signals, and 
are rapidly cleared when administered in vivo [8]. The generation of strong immune 
responses upon vaccination requires the uptake of antigens by APCs, which process 
them intracellularly into small peptide fragments (epitopes) and present these on their 
surface bound to major histocompatibility complex (MHC) class I and II molecules [9]. 
The identification of dendritic cells (DCs) as the most important and potent APCs of 
the immune system, scavenging the environment for potential pathogens and directing 
the immune response, has made them the main target of antigen delivery [10-12]. 
Activated DCs are able to cross-present antigens to antigen-specific B cells, T helper 
(Th) cells and cytotoxic T lymphocytes (CTLs), which are able to attack virus-infected 
or tumor cells [11, 12]. 
In order to strengthen the immune response against subunit vaccines, soluble antigens 
should be combined with adjuvants. An adjuvant (from the latin word adiuvare, to aid) 
can be any substance, such as an immunostimulatory molecule or a delivery system, 
that is used to enhance the efficacy of a vaccine. This can be attained by prolonging 
or boosting the otherwise poor immune response, or modulating it towards a specific 
cellular (Th1) or humoral (Th2) response. Although the clinical use of these types of 
adjuvants has been around for about 90 years, only a few have been approved for use in 
humans [13]. As prophylactic vaccines are widely administered to healthy populations, 
mostly young children, the safety of an adjuvant is of utmost importance [13]. The most 
commonly used adjuvants are aluminium salts (generally, Al(OH)3 and AlPO4), also 
known as alum [14]. Being the only FDA approved vaccine adjuvant for prophylactic 
vaccines for almost eight decades, alum has benefitted from unparalleled monopoly 
[13]. Alum’s adjuvanticity relies mainly in depot formation from where the antigen is 
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slowly released in a sustained manner in particulate form; but other mechanisms have 
been recently discovered, such as facilitated antigen uptake by DCs and inflammasome 
activation through NOD-like receptor protein 3 [14-16]. Still, there are also drawbacks 
associated with alum. Alum promotes primarily a humoral response, i.e., antibody 
production, rather than a cellular response [13, 17]. Additionally, alum is known to 
cause local adverse effects, such as granuloma at the site of injection [13]. Over the 
past two decades, other adjuvants have been approved for use in the clinic, including 
nano-emulsions such as MF59 (Novartis), an oil-in-water emulsion containing squalene, 
polysorbate 80, and sorbitan trioleate used in the Fluad® influenza vaccine;  AS03™ 
(GlaxoSmithKline (GSK)), another emulsion containing squalene, tocopherol, and 
polysorbate 80 used in the Pandemrix™ influenza vaccine; and AS04 (GSK) containing 
alum and monophosphoryl lipid A (MPLA) which is used in two licensed vaccines, 
Fendrix® for hepatitis B and Cervarix® for cervical cancer caused by HPV [13, 18-20]. 
Other vaccines such as Epaxal® or Inflexal® include virosomes [21, 22].  However, 
also these systems fail to stimulate strong cellular responses, required for therapeutic 
vaccines against intracellular pathogens or cancer. 
The low immunogenicity associated with subunit vaccines makes them poorly effective 
against diseases that require a cellular immune response for protection, posing a 
challenge in designing new formulations. Incorporation of antigens into particulate 
systems, such as liposomes and polymeric particles, can potentially achieve a better 
immune response. The particulate form of these systems and their ability to co-
encapsulate immune stimulatory molecules, often based on viral or bacterial structures, 
mimic a natural invading pathogen, being more likely taken up by DCs. These systems 
can be used to attain a long-lasting stimulation of DCs by sustained antigen release 
and to induce an adequate T-cell response. Furthermore, unlike traditional adjuvants 
like alum, which predominantly elicit humoral responses, particulate systems may elicit 
both humoral and cellular responses [23].
1.2. Dendritic cell-mediated immunity
The immune system is a network of cells that work together to protect the body from 
infection. These cells originate in the bone marrow and migrate to peripheral tissues 
to detect and eliminate potentially harmful agents [24]. The immune system can be 
divided into an innate and an adaptive branch, which mainly differ in response time 
and the level of specificity. The innate immune system is activated almost immediately 
after the detection of danger signals and involves the migration of phagocytic cells to 
the site of infection forming the first line of defense [1]. Innate immune cells recognize 
genetically conserved patterns, but lack antigen-specificity and immunological memory. 
In contrast, adaptive immunity is antigen-specific and retains memory of a previous 
infection. There are two branches of the adaptive immune response that contribute 
to the memory of a specific antigen: the humoral response, carried out by B cells and 
type 2 CD4+ T cells; and the cellular response, which is performed by type 1 CD4+ 
and CD8+ T cells [1]. These cells differ from the innate immune cells by their antigen-




APCs play an important role in inducing an adaptive immune response. APCs are a 
group of immune cells that are able to process and display both endogenous and 
exogenous antigens through the MHC molecules on their surface in a process known 
as antigen presentation. This process is responsible for the activation of T cells, which 
do not identify and respond directly to native antigens like B cells do, but can recognize 
processed antigen presented by MHC complexes through their T-cell receptors (TCRs). 
This allows detection of unexposed antigens, like those expressed by intracellular 
pathogens and mutated proteins in cancer cells [25]. 
APCs can be divided into two main categories: professional and non-professional ones. 
The so-called non-professional APCs include fibroblasts, thymic epithelial cells and 
vascular endothelial cells, and do not constitutively express the MHC class II molecules, 
though they can be induced to present antigens for short periods upon stimulation 
under specific circumstances [1, 25]. Professional APCs include DCs, which are 
specialized in priming of naïve T cells [24] and macrophages and B cells specialized 
in activating specific CD4+ T cells. These cells express both MHC class I and class 
II molecules, being able to stimulate antigen-specific CD4+ and CD8+ T cells, which 
differentiate into Th cells and CTLs, respectively [11, 12]. CTLs are able to eliminate 
virus-infected or tumor cells, while Th cells promote B cell activation, macrophage 
function and maturation of other T cells [1].
Different APCs have different main functions, with the efficiency of antigen uptake, 
processing and presentation varying accordingly. B cells’ main function is to produce 
antibodies against specific antigens; they have limited uptake capacity, as their membrane 
B cell receptors are restricted to a single specific antigen [25]. As for macrophages, their 
primary function is to clear tissues from pathogens, having extraordinary endocytosis 
and degradation capacity, though poorer antigen presentation ability [25]. Conversely, 
DCs’ main specialized function is antigen presentation, thus efficiently uptaking, storing, 
processing and presenting antigens to initiate a T cell immune response [26].
Depending on the nature of the antigen, either endogenous or exogenous, it will be 
processed and presented through MHC class I or class II molecules, respectively. 
Intracellular antigens such as proteins produced by viruses or tumor cells are processed 
in the cytosol and presented by MHC class I molecules to CD8+ T cells. Extracellular 
pathogens can be actively internalized by pinocytosis, phagocytosis or endocytosis, 
being processed in the endosome and presented by MHC class II molecules to CD4+ T 
cells [25, 27]. However, DCs also have a superior ability to process exogenous antigens 
and present these peptides in the MHC class I pathway, leading to the activation of 
antigen-specific CD8+ T cells, a phenomenon that is called cross-presentation [8, 25]. 
It is this ability that allows them to cross-present tumor antigens and generate tumor-
specific CTL responses, reason why DCs have become the main target of cancer 
vaccines [1, 25].
DCs are the most professional APCs, scattered throughout the body at peripheral 
tissues, such as the skin and mucosal surfaces, the most probable entry sites for 
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pathogens, functioning as the sentinels of the immune system [12, 27]. 
Immunostimulatory molecules activate the immune system through their interaction 
with specific receptors of APCs, which can recognize certain evolutionary conserved 
molecular motifs associated with groups of pathogens, the pathogen-associated 
molecular patterns (PAMPs), via membrane-bound pattern recognition receptors 
(PRRs) [8].  PRRs are used by DCs to detect invading pathogens and increase the 
efficiency of uptake and include nucleotide-binding oligomerization domain (NOD)-
like receptors (NLRs), C-type lectin receptors (CLRs) and Toll-like receptors (TLRs). 
As part of the innate immune system, TLRs recognize cell-wall components such 
as lipopolysaccharides, lipopeptides or lipoproteins associated with bacteria, or 
nucleic acids associated with bacteria and viruses such as double-stranded RNA 
fragments, acting as communicators between innate and adaptive immunity [8, 25]. 
These components are known as TLR ligands (TLRL). DCs use their PRRs to detect 
invading pathogens, and attachment to PRRs increases the efficiency of uptake. After 
internalization of pathogens, activated DCs migrate to the draining lymph nodes where 
they mature and come in contact with naïve or memory CD4+ or CD8+ T cells or B cells, 
presenting the antigen via MHC complexes [1, 25]. After recognition of the antigen-
MHC class II complex by T cells, additional co-stimulatory signals are produced by 
DCs, leading to activation of the B and T cells [1, 25]. TLRs are also able to stimulate 
DC activation and antigen presentation to naïve T cells through MHC class I complex, 
triggering T cell maturation into Th1 through the secretion of pro-inflammatory cytokine 
release and expression of co-stimulatory molecules, stimulating CTL responses [8].
A number of strategies have been developed to efficiently deliver antigen to DCs, 
such as emulsions, viral vectors, liposomes, and biodegradable polymeric particles 
[27]. Different formulations may be processed via different pathways, affecting their 
overall immunogenicity. It has been suggested that the antigen uptake mechanism is 
of importance in determining how antigen is processed and presented on MHC class I 
and II molecules [28]. Though the exact mechanism of cross-presentation pathways is 
poorly understood, they have been arranged into two distinct routes: the phagosomal/
cytosolic pathway and the endosomal/vacuolar pathway [29]. Similarly to the classical 
endogenous antigen processing pathway, in the phagosomal/cytosolic route the 
internalized antigen is processed in the cytosol, after escape from the endosome, 
where it is transferred to the proteasome and degraded into smaller peptides, which 
are then transported to the endoplasmic reticulum (ER) by the transporter associated 
with antigen processing (TAP), before being loaded on MHC class I molecules [25]. 
In contrast, the endosomal/vacuolar pathway is TAP independent, and the antigen is 
processed into smaller peptides in the endosome in a pH-dependent manner by active 
endolysosomal proteases. Some of these peptides bind to MHC class I molecules 
inside the endosome and migrate to the cell surface [25]. Soluble antigens appear 
to be mainly processed through the cytosolic route, whereas particulate antigens are 
processed predominantly via the endosome [30].
One requirement for effective T cell activation is the appropriate delivery of antigens 
to DCs, which is often poorly attained when using soluble antigens. Encapsulation 
of antigens in particulate systems facilitate the delivery process and uptake by DCs, 
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1promoting long-lasting stimulation by sustained antigen release, which is critical to 
induce an adequate T-cell response [31, 32]. Though immunogenicity is noticeably 
enhanced by specifically targeting antigens to DCs, additional stimuli are required to 
properly activate DCs. By co-encapsulating TLR agonists together with the antigen 
within delivery systems, DCs can be targeted through their TLRs, improving antigen 
delivery and modulating the immune response in order to achieve a strong cellular 
response [33]. So, the design of a potent vaccine obviously is not only dependent on 
the nature of the antigens but also on the way they are formulated.
1.3. Immunotherapy of cancer
Cancer is one of the leading causes of death worldwide. The conventional treatments 
for cancer consist of surgery, radiotherapy and/or chemotherapy, which are unspecific 
and poorly effective against metastasized tumors, usually causing severe side effects 
and decreasing the patient’s quality of life. For this reason, there has been a growing 
interest in new treatment strategies. 
It is well known that the immune system is able to respond against tumors, allowing 
the development of novel therapeutic strategies aiming to activate the immune system 
against tumor cells [34]. The use of the specificity of the immune system to treat cancer 
is referred to as cancer immunotherapy. Several studies have been conducted in the 
area of immunotherapy of cancer, leading to the development of several cancer vaccine 
strategies that are now extensively studied in multiple clinical trials or have already been 
approved for standard therapy. Current approaches comprise cell-based, antibody and 
cytokine therapies [25, 28]. These include adoptive CD8+ T cell transfer [28] and DC-
based vaccines [35, 36], such as Provenge® (Dendreon) against prostate cancer [37, 
38]; monoclonal antibodies (mAbs) such as rituximab (Rituxan®, Genentech) against 
B-type leukemias and lymphomas, and trastuzumab (Herceptin®, Genentech) against 
breast cancer; and the administration of interleukin 2 (IL-2) and interferon alpha (INF-α) 
used in the treatment of various cancer types [39]. A therapeutic cancer vaccine called 
Oncophage® against renal cell carcinoma has been approved by the FDA, consisting 
of an autologous heat shock protein (HSP)–peptide complex produced from each 
patient’s own tumor [25]. 
One of the most promising strategies in cancer immunotherapy is the use of immune 
checkpoints blockers [40]. These approaches use mAbs that target immune checkpoints 
in T cells rather than cancer cells, and have strongly contributed to making cancer 
immunotherapy the breakthrough of the year in 2013 according to Science magazine 
[41]. Ipilimumab (YERVOY®, Bristol Myers Squibb), is a mAb that works as an immune 
checkpoint blocker by targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-
4), a protein receptor on the surface of T cells that downregulates CTL responses when 
bound to an inhibitory signal [39-42]. By blocking this inhibitory mechanism, it activates 
cancer-specific CTLs. Ipilimumab has been approved by the FDA for the treatment of 
melanoma, significantly extending patients’ lives. In addition to melanoma, ipilimumab 
is undergoing clinical trials for the treatment of prostate and lung cancer [40, 41]. 
16
Chapter 1
Another target for immunotherapy of cancer is programmed cell death protein 1 (PD-1), 
a cell surface receptor expressed on T cells and pro-B cells, which can bind to ligands 
PD-L1 and PD-L2 [43, 44]. Similarly to CTLA-4, PD-1 downregulates the immune 
system, promoting self-tolerance and reducing autoimmunity, by inducing apoptosis 
in antigen-specific T cells while simultaneously reducing apoptosis in regulatory T 
cells [43, 45]. PD-1/PD-L1 treatment strategies use mAbs that block PD-1 and PD-
L1 interaction, thereby enhancing T-cell antitumor activity [41, 45]. Several mAbs 
targeting PD-1 receptors have shown promising results in clinical trials and are being 
developed as cancer treatments, such as nivolumab (Opdivo, Bristol Myers Squibb) 
for lung cancer, melanoma, and renal-cell cancer [46]. Pembrolizumab/lambrolizumab 
(Keytruda, Merck) has been approved by the FDA as a treatment against metastatic 
melanoma following treatment with ipilimumab [40, 41, 47]. Treatments combining 
PD-1 and CTLA-4 blockers have shown greater impact than when used alone, with 
very promising results [46]. Whereas ipilimumab treatment has been associated with 
severe immunological adverse effects due to T cell activation and proliferation, resulting 
in autoimmunity, PD-1 treatments seem to lead to milder side effects [41, 45]. These 
adverse effects should be taken into account during risk assessment when considering 
the treatment.
These early clinical successes with checkpoint-blocking antibodies unequivocally 
demonstrate that immunity to cancer exists but is however in a silenced state in a 
tumor environment. Therefore, the immune system can be successfully recruited 
towards tumors but requires adequate activation of the tumor-specific T cells, e.g., by 
specific vaccination.
1.3.1. Cancer vaccination
In recent years, in addition to the traditional prophylactic vaccines against infectious 
diseases, there has been an increased interest in broader application of vaccination for 
protection against other diseases, such as cancer [8, 27]. 
Currently only few prophylactic cancer vaccines have been approved: two that protect 
against the high-risk serotypes of HPV (Gardasil, Merck; Cervarix, GSK) and other two 
against the hepatitis B virus (HBV) (Recombivax HB, Merck; Engerix-B, GSK), which 
are the leading causes for cervical and liver cancer, respectively. However, prophylactic 
vaccines do not have therapeutic effects against pre-existing infections and do not 
prevent their development, as these vaccination strategies rely on antibody protection 
against the virus upon infection, whereas therapeutic vaccines must have the capability 
of inducing CTL responses to kill the infected cells of (pre-)malignant lesions [27]. 
Two main approaches have been used to target DCs in cancer immunotherapy: 
administration of ex vivo tumor antigen loaded DCs and in vivo delivery of tumor 
antigens. Though ex vivo loaded DC-based cancer vaccines have been extensively 
studied with promising therapeutic results, this approach requires each vaccine to be 
tailor made for each patient, involving extensive and time-consuming lab work as well 
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1as logistics, thus making such vaccines extremely expensive [25]. These limitations may 
be overcome by delivering tumor associated antigens (TAAs) and adjuvant together to 
DCs in vivo. 
Identification of TAAs for a variety of cancers has led to development of vaccines 
that target these antigens [25, 28]. Most prophylactic vaccines work by inducing an 
antibody response against specific viral or bacterial antigens. In contrast, therapeutic 
cancer vaccines require the induction of potent T cell responses against TAA-bearing 
cells [27, 48]. Cancer vaccines rely on the administration of TAA in order to induce 
the killing of tumor cells by cytotoxic T lymphocytes (CTLs) orchestrated by activated 
DCs, resulting in tumor regression. Quite a few cancer vaccines have been tested in 
the clinic, however, most of these trials have resulted in disappointing clinical results, 
due to insufficient generation of cell-mediated immunity [27, 28].  Several factors must 
be considered when developing a cancer vaccine, which in order to be effective must 
comprise the following three essential elements: an antigen, an immune potentiator, 
and a delivery system. 
1.3.2. Peptide-based cancer vaccines
Several vaccination strategies against cancer have been able to the elicit tumor-specific 
T cell responses in vivo, including whole tumor cells or cell lysates, viral vectors or DNA 
encoding TAAs, as well as recombinant proteins or synthetic peptides, both of which 
have been the most popular form of therapeutic vaccines [49, 50]. 
The first step for developing subunit cancer vaccines is to select the target TAA(s), 
which can be (a) protein(s) or peptide(s) specific for tumor cells. In order to achieve a 
successful vaccine, these antigens must include 8-10 amino acid peptide sequences 
that can be processed and bind to the MHC class I molecules of DCs and will be 
recognized by T cells to elicit a strong tumor-specific CTL response [27, 28]. The cloning 
of the first gene reported to encode a CTL-defined human tumor antigen (MAGE-A1) 
paved the way to the discovery of more TAAs, allowing the production of vaccines 
for these targets and the study of vaccines against different types of cancer, such as 
melanoma and cervical cancer [28, 50-55]. 
Vaccination with TAA-derived synthetic short peptides (SSPs) covering exact MHC class 
I epitopes initially appeared to be a promising approach for immunotherapy of cancer, 
as T cells recognize target antigens as peptide fragments presented by MHC class I 
molecules at the cell surface [27]. However, this approach showed major drawbacks 
[51, 56], such as peptide-specific immunological tolerance, associated with enhanced 
tumor growth instead of protection [57, 58], as well as short-lived and suboptimal CTL 
responses, caused by the lack of proper co-activation of CD4+ T cells and subsequent 
induction of memory  CD8+ T cells  [59, 60]. 
Tolerance was mainly induced because of the exogenous binding of these short 
peptides to MHC class I molecules that are present not only on professional APCs 
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like DCs, but also on all somatic cells which generally lack the ability of expressing the 
surface co-stimulatory molecules that are required to the generation of effector T cells 
[27, 56-63]. In a direct comparison, vaccination with a SLP bearing both CTL and Th 
epitopes in Montanide ISA 51 elicited much stronger CTL responses after vaccination 
than vaccination with a SSP covering an exact HPV16E7 MHC I binding epitope. The 
former approach resulted in effective eradication of established tumors in a mouse 
model of HPV16-induced tumors, owing to the activation of both CD4+ and CD8+ T 
cells [64]. Therefore, the use of longer peptides, such as SLPs, covering both CTL and 
Th epitopes has been launched as a strategy to overcome the problem of suboptimal 
CTL responses [27, 65]. These peptides cannot bind to MHC I molecules directly, but 
have to be taken up and processed by DCs before being presented to T-cells, inducing 
a more effective immune response [57, 63, 64]. It has been suggested that such SLPs 
considerably facilitate MHC class I presentation and induce stronger CTL responses in 
comparison to proteins because SLPs are more efficiently internalized, processed, and 
cross-presented by DCs [33, 64]. 
Another disadvantage about the use of SSPs is that the polymorphic nature of MHC 
molecules (human leukocyte antigen, HLA) in genetically diverse populations restricts 
their broad use as there is a risk of missing important epitopes [27]. Due to the multiple 
HLA class I and II molecules, it is unlikely to identify immunogenic CTL and Th epitopes 
that would cover all individuals, requiring patient selection according to their HLA type. 
The use of vaccines consisting of overlapping SLPs covering the whole sequence of 
highly immunogenic regions of TAA proteins may overcome the HLA-dependency 
problem, allowing the in vivo epitope selection according to each HLA-profile after 
uptake by DCs [27]. Following this concept, numerous SLP vaccines have been studied 
in clinical trials against different types of cancer and other diseases, one of the most 
prominent example being HPV-induced cancers [27, 42]. 
HPV-induced cancers often have viral sequences integrated into the cellular DNA. Some 
of the HPV “early” genes, such as E6 and E7, are known to act as oncogenes that 
promote tumor growth and malignant transformation. Because the majority of HPV-16 
derived cancers express E6 and E7 oncoproteins, they are attractive candidates as 
target antigens for immunotherapy of HPV-induced cancer [66-72]. 
Several protein and peptide vaccines against HPV E6 and/or E7 have been successfully 
tested in preclinical and clinical models. A cancer vaccine consisting of 13 overlapping 
SLPs covering the entire sequence of the E6/E7 oncogenic proteins of high-risk HPV16 
has been investigated in several (pre-)clinical trials [65]. Therapeutic vaccination with 
a HPV16 SLP vaccine emulsified in the mineral oil adjuvant Montanide ISA 51 has 
shown to be able to increase both HPV16-specific CD4+ and CD8+ T cells in murine 
models of cervical cancer [33, 66, 73]. In clinical trials, this vaccine has shown robust 
immunogenicity in end-stage cervical cancer patients, and caused complete regression 
of premalignant HPV16-induced l lesions and eradication of virus in 9 of 20 women with 
high-grade vulvar intraepithelial neoplasia [52, 65]. 
Despite these promising results, there is still room for improvement, especially regarding 
the SLP vaccine formulation. Montanide has been used as the “gold-standard” adjuvant 
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1for protein- and SLP-based cancer vaccines [65, 74, 75]. Montanide is a clinical-grade 
version of incomplete Freund’s adjuvant (IFA) with similar properties. The w/o emulsion 
is composed of a mineral oil, a surfactant and an aqueous phase, slowly releasing the 
dispersed antigen when injected subcutaneously. These emulsions are known to elicit 
long-lasting IgG responses as well as stimulate the activation of CTL and Th cells [53, 
76-80], its adjuvant activity being attributed to depot formation and the ability to trigger 
inflammation at the site of injection [81], while emulsion droplets can promote antigen 
uptake by DCs [82, 83]. 
However, the use of Montanide w/o emulsions is far from ideal, not only since they have 
poorly defined immunogenic properties, but also because their non-biodegradability 
causes significant local side effects, such as tenderness, swelling, granuloma, local 
pain, erythema and discomfort, reason why they have not been approved for routine 
human immunotherapy but are only being used in investigational clinical trials [17, 54, 
81, 84]. Furthermore, their use as an adjuvant has some other important limitations: 
they show poor control of the peptide release rate and lack specific DC-activating 
capacity. Moreover, the pharmaceutical development and scalability of w/o emulsions 
is hampered by limited long-term stability and the complexity of the manufacturing 
process. In addition, formulation of peptides is hampered by the need for organic 
solvents (like dimethylsulfoxide) to dissolve them prior to parental administration, 
whereas distribution of peptides in the emulsion is dependent on peptide polarity, 
making the release of a multipeptide vaccine difficult to predict and control. Thus, there 
is an urgent medical need for the development of better adjuvants with improved safety 
and efficacy profiles that can be formulated into vaccine products that are stable during 
preparation, storage and administration. This can be achieved via different formulation 
strategies which allow co-delivery of antigens and adjuvants, such as encapsulation in 
biodegradable particles [79, 85], use of antibody-mediated targeting [86, 87] and/or 
SLP-TLRL conjugates [78, 88].
1.4. Adjuvants
Adjuvants can be categorized into two groups: immunostimulatory molecules and 
delivery systems. Immunostimulatory molecules play a major role in directing immunity 
towards either a bacterial or viral/tumoral defense pathway [1]. Though vaccine 
delivery systems are often sufficient to induce a long-lasting protective immunity, poorly 
immunogenic antigens, such as synthetic peptides, are often unable to induce strong 
responses when incorporated alone, requiring the inclusion of immune-potentiating 
molecules [89]
1.4.1. Immunostimulatory molecules
DCs are critically involved in the generation and maintenance of an effective CTL 
response. Therefore, vaccines need to mimic the most successful natural triggers of 
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DC activation. Immunostimulatory molecules play a major role in directing immunity 
towards either a bacterial or viral/tumoral defense pathway [1]. Therefore, selecting ‘the 
right’ immunostimulatory molecule(s) is crucial in the design of a successful subunit 
vaccine. 
TLRs are the most commonly used target as TLR stimulation is critically involved in the 
uptake and processing of antigens by DCs, and are able to trigger cross-presentation. 
TLR activation induces the secretion of proinflammatory cytokines and type I interferon, 
and leads to upregulation of CD40, CD80 and CD86 costimulatory molecules on the 
surface of APCs, as well as release of Th1 cytokines such as IL-1, IL-2, IL-6, and 
TNF, leading to T cell activation [90]. There are at least 10 types of TLRs in humans, 
which can either be surface bound or expressed intracellularly, recognizing different 
extracellular or intracellular pathogenic components (Table 1) [1, 8]. 
Recent research is aimed at activating DCs by targeting TLRs [6, 53, 91-94]. TLRs can 
be located either on the cell surface or inside intracellular compartments, ultimately 
indicating their roles at detecting extracellular or intracellular pathogens [8].  TLR1, 2 and 
6 are mainly surface TLRs that detect surface bacterial lipoproteins and lipopeptides, 
which are usually recognized by TLR2 dimerized with TLR1 when triacylated, and 
TLR2 dimerized with TLR6 when diacylated [8]. A well-known TLR1/2 agonist is 
Pam3CSK4, a synthetic tripalmitoylated lipopeptide that mimics the acylated amino 
terminus of bacterial lipoproteins, whereas Pam2CSK4, being a diacylated lipopeptide, 
induces signaling through TLR2/6. Lipopolysaccharide (LPS), an endotoxin from Gram-
negative bacteria, is a potent activator of TLR4 with the subsequent induction of NF-
κB and the production of pro-inflammatory cytokines. TLR5 recognizes flagellin, the 
protein monomer that constitutes the filament of bacterial flagellae, found on nearly all 
motile bacteria. TLR3, and 7 to 9 are expressed intracellularly, within the endosomal 
compartments, and are able to detect bacterial and viral nucleic acids. TLR3 
recognizes viral double-stranded RNA (dsRNA), a molecular pattern associated with 
viral infection, for which polyinosinic-polycytidylic acid (poly(I:C)) is a synthetic analog. 
TLR7 and TLR8 recognize single-stranded RNA (ssRNA) and small synthetic molecules 
like imidazoquinolines and nucleoside analogs, such as the imidazoquinoline drug 
compounds resiquimod (R848) and imiquimod. Finally, TLR9 recognizes unmethylated 
CpG (cytosine–phosphate–guanine) oligonucleotide (ODN) motifs in DNA molecules, 
common elements in viruses and bacteria, but not in humans.  
Several synthetic TLRLs have been shown to enhance antigen-specific CTL responses 
in mice when mixed or conjugated with antigen (see Table 1 for examples) [6, 8]. The 
co-delivery of TLR agonists and antigens through co-encapulation in delivery systems 
can be an efficient strategy to increase the strength and modulate the quality of the 
immune response against antigens. Furthermore, as most pathogens present multiple 
TLR agonists to APCs, simultaneous stimulation of multiple TLRs can result in a 
synergistic upregulation of inflammatory cytokine production. Hence, the combination 
of multiple TLRLs may be a promising strategy to induce strong immune responses [6]. 
In this thesis, either TLR2L Pam3CSK4 or TLR3L Poly(I:C), or a combination of both, 






























































































































































































































































































































































































































































































































































































































































































































































potency of anti-cancer vaccines.
1.4.2. Particulate delivery systems
Most peptide-based cancer vaccine strategies have used Montanide as an adjuvant 
to increase specific T cell immunity. Over the recent years, because of its drawbacks, 
alternatives from various types of biomaterials have been used to formulate particulate 
vaccine carriers, such as liposomes (vesicles formed from phospholipid bilayers) and 
micro- (MPs) or nanoparticles (NPs) made from polymers like PLGA, poly-lactic acid 
(PLA) or (derivatives of) chitosan, a polysaccharide obtained by deacetylation of chitin 
[74, 81, 95]. These particulate systems are biocompatible and biodegradable and 
can be manufactured reproducibly according to Good Manufacturing Practice (GMP). 
Furthermore, studies have shown that DC targeted vaccination strategies benefit from 
encapsulation of antigens in biodegradable particulate systems, as they (i) are able to 
protect the antigen from premature enzymatic degradation and clearance by the kidneys, 
increasing their residence time; (ii) serve as depot for sustained antigen release; (iii) are 
able to co-encapsulate multiple components, delivering antigen and adjuvant together 
to DCs; and (iv) can be efficiently targeted to specific tissues or immune receptors 
through targeting moieties coupled to the particle surface [1, 87]. Moreover, particulate 
antigens enhance antigen-specific humoral and cellular responses more efficiently than 
soluble ones, as particulate formulations mimic the size and structure of a pathogen 
facilitating uptake by DCs, and prolong antigen cross-presentation owing to sustained 
intracellular release of the antigen following uptake [2, 32, 96-99]. These features make 
biodegradable particles attractive candidates as vaccine delivery systems for peptide-
based cancer immunotherapy.
1.4.2.1. Liposomes
Liposomes are artificially-prepared spherical vesicles, with particle sizes ranging between 
30 nm to several microns, composed of a lipid bilayer. This bilayer usually consists 
of synthetic and/or naturally occurring, biodegradable phospholipids and cholesterol, 
which can be manipulated in order to influence the liposome’s physicochemical 
characteristics, such as size, surface charge and rigidity [32, 98-102]. Liposomes 
have been extensively studied because of their ability to carry both hydrophilic and 
hydrophobic compounds, as hydrophilic molecules can be encapsulated in the inner 
aqueous phase, whereas hydrophobic compounds can be dissolved into the lipidic 
membrane, and amphiphilic ones can partition between both phases [103, 104]. This 
ability has rendered interest in liposomal vaccines, as they are suitable to carry a variety 
of molecules with different characteristics, such as antigens and immunomodulatory 
compounds; moreover, targeting moieties can be embedded in or covalently attached 
to the liposomal bilayer to facilitate targeted delivery to DCs [104].
The adjuvant effect of liposomes is highly dependent on their physicochemical properties, 
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1such as vesicle size, surface charge, composition of phospolipid head groups, length 
and saturation of the lipid tail, and rigidity of the bilayer, which can be customized 
by adjusting their composition and method of preparation. The surface charge is of 
particular importance, as cationic liposomes have shown superior adjuvant capacity 
compared to neutral or negatively charged ones, probably because of electrostatic 
interactions with the negatively charged surface of DCs [99, 105]. Furthermore, cationic 
liposomes facilitate adsorption of negatively charged antigens to their surface, such as 
synthetic peptides, proteins and nucleic acids.
Numerous other liposomal vaccines have been in clinical trials, with shown efficacy, 
including cancer vaccine candidates, most prominent being Stimuvax® (or 
L-BLP25, Oncothyreon) against non-small cell lung cancer (NSCLC); and MAGE-A3 
(GlaxoSmithKline) against metastatic MAGE-A3-positive melanoma and NSCLC [105-
107]. 
1.4.2.2. PLGA nanoparticles
Polymeric particulate delivery systems can consist of bio-degradable or non-
biodegradable materials, and can derive from either natural or synthetic sources. Natural 
polymers include starch, gelatin, alginate, or chitosan, and offer the benefits of being 
biocompatible, hydrophilic and inexpensive, but their production often results in batch-
to-batch inconsistency and incidence of unwanted impurities or contaminants [13]. In 
contrast, synthetic polymers can be manufactured with high purity and reproducibility 
and can be tailored to achieve the desired molecular weight, co-polymer composition 
and rate of degradation [108].
Synthetic particles made from synthetic polymers have been widely explored as peptide 
antigen delivery vehicles as they offer many advantages over other systems. They are 
biodegradable and biocompatible and can act as antigen depots, slowly releasing 
peptides for a pre-determined period of time that can range from a few days to several 
months, depending on the customized particle degradation rate, potentially eliminating 
the need for booster doses [6]. 
PLGA (Figure 1) is a copolymer which is Food and Drug Administration (FDA) approved 
for therapeutic devices and drug delivery systems, owing to its biodegradability and 
biocompatibility, with several slow-release formulations currently on the market [109-
111]. These properties have made PLGA a common choice in the production of a 
variety of biomedical devices, such as sutures, implants and prosthetic devices, as well 
as delivery systems, such as micro- and nanoparticles [112, 113].
PLGA undergoes hydrolysis in the body to produce the original monomers, lactic acid 
and glycolic acid, which, under normal physiological conditions, are by-products of 
various metabolic pathways in the body. Since the body effectively deals with the two 




Several forms of PLGA with different properties can be obtained, either depending 
on the ratio of lactide to glycolide used for the polymerization, or the type of end 
group (ester-terminated (capped) or carboxylic acid terminated (uncapped)), offering 
the possibility to tailor the polymer degradation time and regulate drug release [114-
117]. Degradation rate of PLGA is related to the lactide/glycolide ratio: the higher the 
content of glycolic acid, the more hydrophilic it becomes and, consequently, the faster 
its hydrolysis rate. Also, unlike the homopolymers of lactic and glycolic acid (polylactide 
and polyglycolide, respectively) which show poor solubilities, PLGA can be dissolved in 
a wide range of common organic solvents.
PLGA
(x: lactic; y: glycolic)
Figure 1: Chemical structure of poly-(lactic-co-glycolic) acid, with x standing for the number of 
lactide monomers and y for the number of glycolide monomers.
Consequently, biodegradable particles composed of PLGA have many desirable features 
for antigen delivery. These particle systems are biocompatible and can be manufactured 
reproducibly according to Good Manufacturing Practice in a scalable, affordable and 
reproducible way. Importantly, PLGA is very well suited for making particles of different 
size, resulting in either MPs or NPs, with controllable release properties [108]. For these 
reasons, PLGA particles have been studied extensively for the delivery of a wide variety 
of macromolecules, from DNA to proteins and peptides [53, 81, 112, 118]. Moreover, 
antigen loaded PLGA particles have been shown to induce cellular immune responses 
comparable to those elicited with Montanide 51 or IFA [119-121].
PLGA particles can be prepared by a variety of different methods, most commonly used 
for protein and peptide antigens being the double emulsion with solvent evaporation 
method [108]. In brief, the polymer is dissolved in an organic volatile solvent (e.g. 
dichloromethane, ethyl acetate) to which the antigen is added in aqueous solution (the 
inner water phase, w1) followed by emulsification by homogenization or sonication; this 
first water in oil (w1/o) emulsion is added to an external aqueous phase (w2) containing 
a surfactant (e.g., polyvinyl alcohol, polysorbate 20), followed by a second emulsification 
step, forming the double emulsion (w1/o/w2); the second emulsion is then transferred 
to an aqueous phase under magnetic stirring at room or reduced temperature to allow 
for solvent evaporation, leading to precipitation of the polymer and solidification of the 
particles, which are finally recovered by centrifugation and then freeze-dried [122].
The use of PLGA particles for vaccine delivery offers several advantages from both 
pharmaceutical and immunological perspectives as compared to soluble antigens or 
w/o emulsions. Several immunotherapeutic approaches have successfully used both 
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1PLGA MPs and NPs to target DCs [10, 81, 97]. Particles allow for the concomitant 
delivery of antigen and adjuvant [76, 79], and vaccination with PLGA NPs containing 
TAA and TLRL has been demonstrated to be as effective as vaccination with IFA [66, 
81, 123]. Particles also facilitate endosomal escape, which is a known mechanism 
leading to antigen cross-presentation by DCs [64, 124]. Furthermore, they allow the 
coupling of targeting molecules to specific receptors such as CD40 or DEC-205, which 
can efficiently direct particles to DCs, increasing specific uptake and cellular immune 
responses [42, 87, 114].
Several factors affect the efficiency of PLGA particles as vaccine delivery vehicles. 
Particle size is a critical factor, as it can influence bio-distribution and uptake efficiency 
by APCs. Particles can be defined as NPs or MPs according to their size ranges: 
NPs for particles within the nano range (10 nm to 1 mm); and MPs for particles in the 
micron range (1 mm to 1000 mm). It is generally accepted that NPs are advantageous 
over MPs for drug targeting, as NPs can more easily permeate biological barriers and 
efficiently reach target tissues [125-127]. However, the ideal size for vaccine delivery 
is still not consensual [116, 128, 129]. Particle size is known to influence the efficiency 
and mechanism of uptake, depot formation, and release kinetics [129-132]. The way 
a cell takes up an antigen-loaded particle can determine how it processes the antigen: 
MPs are mainly phagocytosed, whereas NPs are generally taken up by endocytosis or 
pinocytosis. Sustained release of antigen and adjuvants is essential to properly stimulate 
DCs, whereas a low burst release eliminates potential loss of antigen before the particle 
is taken up by DCs, increasing antigen presentation and CD8+ T cell activation [31, 32]. 
However, there are also disadvantages of the use of PLGA, as encapsulation in PLGA 
particles may result in loss of antigen integrity during preparation and storage, but 
also after administration, especially regarding protein antigens, where denaturation or 
degradation can occur due to local acidification of the inner core due to the hydrolysis 
of the polymer [133]. Though peptides do not require a tertiary structure and may be 
less susceptible to acidic degradation, their encapsulation in PLGA particles can lead 
to accelerated deamidation or formation of peptide adducts due to acylation of lysine 
residues with lactic and glycolic units [134]. These issues are more predominant for 
MPs than NPs, as their inner core takes longer to degrade the polymer and release the 
antigen, allowing higher accumulation of acidic molecules [133]. Furthermore, PLGA 
particles must be freeze-dried to ensure long-term stability during storage and must 
be re-hydrated prior to administration. Still, formulation of SLPs in PLGA NPs may 
be advantageous, provided that the formulation is carefully designed and optimized. 
Nevertheless, despite encouraging results obtained in clinical trials, there are still no 
PLGA-based particulate vaccines on the market [1, 135].
Incorporating multi-SLP antigens together with TLRL in PLGA particles may result in a 
‘pathogen-mimicking’ particle that displays slow antigen release and may be actively 
phagocytosed by DC, representing a promising approach for generating specific T 
cell immunity.  In the present thesis, PLGA particles were studied to gain better insight 
into the critical factors influencing delivery and immunogenicity in order to formulate 




2. Aim and outline of this thesis
The aim of this thesis is to gain a better insight into the role of the formulation of 
particulate delivery systems in the effectiveness of cancer vaccines through the 
preparation, physicochemical characterization, and immunological evaluation of a 
biodegradable, PLGA-based particulate delivery system, incorporating protein or SLP 
antigens as well as TLRL. The main objectives of this research include:
• Determination of the best size range of particles for vaccine delivery
• Development of SLP loaded PLGA NP formulations 
• Development of formulations based on PLGA NPs co-encapsulating SLPs and  
TLRLs
The overall goal is gaining fundamental insight into how to improve the immunogenicity, 
clinical efficacy and safety of SLP-based vaccines for cancer immunotherapy, to be 
used as a safer and more effective alternative to Montanide ISA 51. 
In Chapter 2 the literature regarding PLGA-based particulate systems for protein- and 
peptide-based vaccine delivery is reviewed, with a strong focus on particle properties 
affecting immunogenicity.
In Chapter 3 and 4 of this thesis we use ovalbumin (OVA), a 45-kDa protein purified 
from chicken egg, as a model protein antigen to conduct initial studies regarding the 
formulation of PLGA particles as vaccine delivery vehicles. The following chapters 
(Chapters 5-7) focus on the development of formulations for SLP delivery, using SLPs 
derived from OVA covering CTL and/or Th epitopes as our model antigens. 
The optimal size range of PLGA-based particulate vaccines in order to achieve the 
most efficient cellular immune responses is studied in Chapter 3, where MPs and 
NPs encapsulating OVA and a TLR3L are compared head-to-head for their capacity 
to activate B and T cell responses. Having determined that NPs are more efficiently 
delivered to DCs than MPs, resulting in more effective immune responses in vivo, in 
Chapter 4 we describe the application of PLGA-OVA NPs as a delivery vehicle for ex 
vivo loading of DCs, in order to enhance DC-mediated stimulation of antigen-specific T 
cells to be used for adoptive T cell immunotherapy.
In Chapter 5 the development of a new method for SLP encapsulation in PLGA NPs 
is studied, focusing on formulation conditions required to successfully encapsulate 
an SLP in PLGA NPs, and optimization of the formulation to improve the efficacy of 
cross-presentation by DCs of PLGA-SLP NPs in comparison to soluble SLP in vitro. 
Subsequently, in Chapter 6 we study the co-encapsulation of SLP and TLR2L in PLGA 
NPs, which are used to study the intracellular mechanisms via which DC process 
PLGA-SLP NPs and to determine the in vivo vaccine potency of PLGA-SLP-TLRL NPs 
in comparison to soluble SLP and TLRL.
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1In Chapter 7 we study the co-encapsulation of two SLPs covering the CTL and Th 
epitopes of model antigen OVA and two TLRLs in PLGA NPs and liposomes, which 
were used to ascertain the in vivo vaccine efficacy in a direct comparison to Montanide 
and MF59 analogs, with properties that are very similar to adjuvants currently used in 
the clinic.
Finally, in Chapter 8 we discuss the achievements described in this thesis and the 
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Vaccination has had a major impact in global health, and continuous efforts in this field 
have led to the development of newer and safer vaccines based on subunit antigens 
rather than whole inactivated or live attenuated vaccines. Among the emerging subunit 
vaccines are recombinant protein- and synthetic peptide-based vaccine formulations. 
However, proteins and peptides have a low intrinsic immunogenicity. A common 
strategy to overcome this is to co-deliver (an) antigen(s) with (an) immune modulator(s) 
by co-encapsulating them in a particulate delivery system, such as poly(lactic-co-
glycolic acid) (PLGA) particles. Particulate PLGA formulations offer many advantages 
for antigen delivery as they are biocompatible and biodegradable; can protect the 
antigens from degradation and clearance; allow for co-encapsulation of antigens and 
immune modulators; can be targeted to antigen presenting cells; and their particulate 
nature can increase uptake and cross-presentation by mimicking the size and shape of 
an invading pathogen. This review discusses the use of PLGA particulate formulations 
for subunit vaccine delivery and provides an overview of the formulation parameters 
influencing their adjuvanticity, such as size, charge, antigen localization, release profile, 
and the co-delivery of immune modulators and/or specific targeting molecules, and 
further outlines how these characteristics affect uptake, processing and antigen 
presentation by dendritic cells and the ensuing immune response. Finally, we address 
the use of PLGA delivery systems for peptide-based vaccines.
Keywords: Vaccine, delivery systems, antigen, synthetic peptide, adjuvant, dendritic 
cells, PLGA, nanoparticles, microparticles.
1. Introduction
Vaccination consists of the administration of antigens in order to elicit an adaptive 
antigen-specific immune response and confer long-term protection against 
subsequent exposure to the antigen [1]. Traditional vaccine formulations, consisting 
of either live attenuated or killed pathogens, have been very successful in the last 
century to prevent widespread infectious diseases [2, 3]. Still, despite their success 
[4, 5], there are serious safety concerns associated with these vaccines, which include 
the possibility of reactivation of the attenuated pathogens [6, 7] and the inability of 
immune-compromised patients to clear the vaccine leading to disease symptoms [8]. 
These issues have led to the demand for safer alternatives and vaccine development 
shifted from using whole inactivated pathogens to subunits of the pathogen. These 
subunits may be antigenic proteins, peptides, capsular polysaccharides or any specific 
part of the pathogen which has been demonstrated to stimulate a protective immune 
response. Examples of subunit vaccines include hepatitis B, tetanus, diphtheria, and 
human papillomavirus (HPV) vaccines. However, the need for eliciting both humoral 
and cellular immune responses has limited the efficacy of subunit vaccines against 
certain diseases for which effective vaccines are still unavailable, such as AIDS, 
malaria, tuberculosis, or cancer. While subunits are safer than whole pathogens, they 
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generally are less immunogenic, demanding the use of adjuvants [5]. Adjuvants are 
immunostimulatory molecules and/or delivery systems [9] used in vaccine formulations 
to enhance the magnitude of  antigen-specific immune responses. 
Immunostimulatory molecules activate the immune system through their interaction 
with specific receptors of APCs, which can recognize certain evolutionary conserved 
molecular motifs associated with groups of pathogens, the pathogen-associated mo-
lecular patterns (PAMPs). The identification process is regulated by membrane-bound 
pattern recognition receptors (PRRs) on the DC surface or internal compartments. 
PRRs present on DC include nucleotide-binding oligomerization domain (NOD)-like re-
ceptors (NLRs), C-type lectin receptors (CLRs) and Toll-like receptors (TLRs). These 
receptors recognize molecules such as bacterial lipopolysaccharides, viral nucleic ac-
ids, bacterial peptides, peptidoglycans or lipoproteins, acting as communicators be-
tween innate and adaptive immunity and has been intensively studied over the last few 
decades  [10, 11]. TLRLs have been shown to enhance and modulate the immune 
response when mixed, conjugated, or co-delivered together with antigen [7, 11]. This 
knowledge opens the door to the rational design of vaccine formulations that co-deliver 
TLRLs to increase the immunogenicity of the antigen. 
Next to immunostimulatory molecules, subunit vaccines may benefit from encapsulation 
in particulate delivery systems, which include microparticles (MP) (> 1 µm) and 
nanoparticles (NP) (< 1000 nm). Particles may promote immunogenicity through the 
following mechanism:
(1) Stability improvement of the antigen: particulate delivery systems can protect 
encapsulated or associated antigen from chemical and enzymatic degradation 
and rapid clearance via the kidneys, resulting in increased residence time [1, 
9]; 
(2) Controlled antigen release: particulate formulations can be tailored to serve as 
intra- and/or extracellular depot for sustained release of the antigen, increasing 
antigen exposure to DCs and prolonged antigen presentation [12]; 
(3) Facilitated DC uptake: particulate delivery systems can mimic the size and 
shape of an invading pathogen, which facilitates uptake by DCs [11, 13];
(4) Targeted delivery: particles per se are passively directed to APCs because of 
their particulate form, but can also be specifically targeted to specific tissues or 
subsets of immune cells (like DCs) via targeting moieties, such as TLR ligands 
or DC-specific antibodies [14-17];
(5) Enhanced cross-presentation: particles may facilitate endosomal escape, 
which is a known mechanism leading to antigen cross-presentation by DCs 
and induction of a CTL response [18, 19];
(6) Concomitant delivery of multiple components: particulate formulations can co-
deliver a combination of molecules, such as (multiple) antigens and/or immu-
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nostimulatory molecules and/or targeting ligands, mimicking pathogens and 
facilitating uptake by antigen APCs and stimulating immune activation [12, 13]; 
(7) Regulation of the type of immune response: immunological properties of par-
ticles can be tailored by changing their size, surface charge, or hydrophobicity, 
amongst others [1, 9]. 
(8) Dose reduction: owing to the potential synergistic effect of all the above-men-
tioned effects, particles can serve to decrease the dose of antigen required to 
elicit an immune response [11].
A large number of particulate systems has been reported, such polymeric particles, 
liposomes, virus like particles and virosomes, immune stimulatory complexes (ISCOMs), 
emulsions, or inorganic nanobeads, but  particularly, poly(D,L-lactide-co-glycolide) 
(PLGA)-based delivery systems are well studied and are promising candidates for 
antigen delivery [20]. Since the initial description of PLGA particle as potential adjuvants 
by O’Hagan et al [21], PLGA particles have been formulated in a wide variety of ways 
resulting in various size, charge, antigen stability, loading capacity and release profiles. 
These key formulation aspects can greatly affect the end product characteristics and 
consequently the potency of the vaccine. These factors will be discussed in detail in 
this review, as well as the latest advances in peptide-based vaccines using PLGA-
based particulate systems.
2. Poly(D,L-lactide-co-glycolide) particulate 
systems for subunit vaccine delivery
Poly(lactic-co-glycolic acid) (PLGA) and its derivatives are aliphatic polyesters that are 
available in different ratios of lactic acid and glycolic acid, various molecular weights, 
and type of end groups (ester-terminated (capped) or carboxylic acid terminated 
(uncapped)). PLGA polymers have been widely studied over the past few decades 
for several biomedical applications due to their excellent safety records, varying from 
sutures to bone reconstruction, as well as in implants for sustained drug delivery, and 
it has long been approved for parenteral human use by the FDA [22-24]. After their 
administration, PLGA particles undergo degradation by bulk erosion, during which 
water diffuses into the polymeric matrix, hydrolyzing the ester bonds throughout the 
polymer and reducing its molecular weight until degradation products are formed 
that can be dissolved [9]. This process increases porosity in the matrix, allowing the 
sustained release of the entrapped material as degradation continues. Finally, PLGA 
is hydrolyzed into the original monomers, lactic acid and glycolic acid, which are by-
products of various metabolic pathways and therefore are not associated with significant 
toxicity [25]. Degradation rate of PLGA is related to molecular weight, hydrophilicity and 
crystallinity, but also other factors such as pH of the medium, water uptake rate, process 
of ester hydrolysis, swelling ratio and degradation by-products [9, 26]. Lower molecular 
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weight molecules degrade faster, as shorter molecules can be more easily hydrolyzed 
and dissolved, leaving the polymeric matrix. Higher hydrophilicity can also lead to faster 
degradation: the hydophilicity is mainly influenced by the monomers’ ratio, with glycolic 
acid being more hydrophilic than lactic acid, so the higher the content of glycolic acid, 
the more hydrophilic, increasing hydrolysis rate [25]. An exception to this rule is the 
co-polymer with 50:50 lactide:glycolide ratio, which has the fastest degradation rate, 
even among polymer compositions with higher glycolic acid content. This is due to the 
influence of crystallinity: the higher the crystallinity, the slower the degradation, and at 
a 50:50 ratio the polymer is the least crystalline, resulting in the fastest degradation 
rate [9, 27]. Uptake of PLGA particles by APCs may further expedite the degradation 
of PLGA, as the acidic environment of the endosomal compartment (pH ~4.5 – 6.5) 
[28] accelerates degradation compared to physiological pH (pH 7.4) since low pH 
catalyzes breakage of the ester linkage of the polymer backbone enhancing polymer 
erosion [29, 30].Thus, depending on the type of PLGA polymer used, PLGA particles 
can be made with distinct release kinetics [15, 31-33]. Next to release characteristics 
various other physical trades of PLGA particle can manipulated including particle size 
and size distribution, zeta potential, polydispersity index, encapsulation efficiency and 
drug loading [26]. All these characteristics can be controlled during the synthesis of the 
particles which can be manufactured according to good manufacturing practice in a 
scalable, affordable and reproducible way [25].. 
While many properties are favorable and controllable, there are also drawbacks in using 
PLGA particles as a delivery system, especially concerning the stability of encapsulated 
protein antigens, which will be discussed in more detail later on. Therefore, antigen 
stability after encapsulation and storage should be evaluated, and each formulation 
should be specifically customized for each antigen, accordingly to its properties [5].
3. PLGA particle characteristics affecting 
adjuvanticity
Depending on the preparation method and conditions, PLGA particles can be made 
with diameters ranging from 80 nm to 250 μm [7]. Moreover, various experimental 
conditions can be chosen and varied, such as type of solvents and polymer, polymer 
molecular weight, polymer concentration, type and concentration of surfactants, 
homogenization mechanism, duration and intensity, or volume ratio of phases. Each 
of these different factors can affect the particle size, size distribution, zeta potential, 
encapsulation efficiency, drug loading and release profile [26], which in turn affect the 





Particle size is one of the most critical factors affecting interaction with APCs as well as 
their biodistribution. Particle size is strongly dependent on the type and concentration 
of surfactants, polymer concentration, phase volume ratios and homogenization speed 
[26]. Higher polymer concentration leads to bigger particles, due to higher viscosity of 
the oil phase, making it harder to break the droplets, as well as and higher (w1/o)/w2 
ratios; while higher surfactant concentrations lead to more stable emulsions and can 
produce smaller particles [26]. The method of homogenization and its speed are also 
among the most important factors: for instance, microparticles are usually produced 
using an homogenizer and/or magnetic stirring, whereas nanoparticles are produced 
by sonication, since the higher the homogenization speed, the smaller the particles.
Particle size is also known to influence the loading capacity, depot formation and release 
kinetics [34-36]. The particle size and size distribution are determinant for antigen release 
rate, as the total surface area for protein delivery depends on the particle size [26]. The 
smaller the particle, the faster the antigen release, as smaller particles have a larger 
surface area, and therefore a greater proportion of antigen located near its surface, 
which can lead to a higher burst release [37, 38]. On the other hand, microparticles 
have larger cores from which the encapsulated antigen slowly diffuses out, and require 
more time to be degraded, usually showing very low antigen release rates and overall 
antigen release when comparing to nanoparticles, affecting the total amount of antigen 
actually being delivered to DCs [38]. 
Smaller particles are generally regarded as more effective delivery vehicles, since their 
size would allow easier travel through membranes and other biological barriers and 
efficiently reach target tissues [39-41]. However, there is still no definitive answer to 
which size PLGA particles are the most effective for vaccine delivery, and results of 
different studies comparing nanoparticles and microparticles are contradictory [32, 35, 
36]. A strong correlation between particle size and the mechanism of antigen uptake, 
processing and presentation by APCs has been reported in different studies [34-36, 
42-44]. APCs are known to take up and process particles with dimensions comparable 
to viruses and bacteria [45]. The way APCs take up the vaccine can determine how it 
processes the antigen. Soluble antigens which are preferentially presented by the MHC 
class II pathway and are only poorly cross-presented. Particles in the range of 20-200 
nm are efficiently taken up by DCs via endocytosis or pinocytosis and facilitate the 
induction of cellular immune responses, whereas microparticles of 0.5-5 µm are taken 
up via phagocytosis or macropinocytosis mainly generating humoral responses [35, 
36, 46]. Particles larger than 10 µm are hardly taken up, leading to defective immune 
activation [47-49]. It has also been postulated that large microparticles  (> 10 µm) 
preferentially attach to the surface of macrophages thus serving as an extracellular 
depot system for continuous antigen release [36]. Comparative studies about the 
effect of PLGA particle size on the observed immune response have been summarized 
on Table 1. These studies suggest that the efficiency of internalization significantly 
affects the resulting immune response. However, one should bear in mind that particle 
properties other than size may also affect their fate and biological effects (see following 
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sections).
The size of MPs should not be too large, as Thomas et al. showed that hepatitis B 
surface antigen (HBsAg) in PLGA MPs with a size of 5 µm elicited a significantly higher 
serum antibody response than 12 µm MPs upon pulmonary administration in rats [50]. 
Confocal imaging also showed that smaller particles were taken up more efficiently by 
alveolar macrophages, which might explain the increased immunogenicity. 
A study investigating the immunogenicity of differently sized PLGA particles (200, 
500 and 1 µm) encapsulating bovine serum albumin (BSA) reported that 1000 nm-
sized particles were capable of inducing stronger IgG responses in vivo than 200 and 
500 nm NPs, which induced similar IgG titers to soluble BSA and alum, following 
immunization via intranasal, oral and s.c. routes in mice [51]. Similar studies were 
conducted also with PLA MPs encapsulating HBsAg, showing that MPs of 2-8 µm 
induced stronger anti-HBsAg antibody responses than NPs of 200-600 nm after 
intramuscular (i.m.) immunization of rats [52]. However, NPs were efficiently taken up 
by macrophages, whereas PLA MPs were not taken up but found attached to the 
surface of the macrophages. Immunization with PLA MPs (2–8 μm) promoted IL-4 
secretion, upregulated MHC class II molecules and favored a Th2 response, whereas 
immunization with PLA NPs (200–600 nm) was associated with higher levels of IFN-γ 
production, upregulation of MHC class I molecules along with antibody isotypes related 
to a Th1 response [52]. Comparable results were obtained with i.m. vaccination of rats 
with tetanus toxoid (TT) in PLA particles: PLA MPs sized 2 to 8 µm were more effective 
in generating antibody titers than particles smaller than 2 µm, potentiating humoral 
immune response [49]. The choice of particle size may be dependent on the type of 
immune response desired: NPs favored a Th1 bias, whereas MPs promote Th2 based 
responses.
After comparing the immunogenicity of TT loaded PLGA NPs (500-600 nm) to MPs (4 
µm), both types of particles were mixed together into a formulation that included both 
NPs and MPs loaded with TT [53]. After i.m. immunization of rats, this mixture elicited 
higher antibody responses compared to the NPs or MPs alone, which elicited similar 
responses. A mixture of both size classes could also be considered to stimulate both 
Th1 and Th2 type responses. 
Joshi et al. compared 17 μm, 7 μm, 1 μm, and 300 nm sized PLGA particles co-
encapsulating OVA and CpG , by selectively recovering different sized particles with 
different centrifugation cycles, showing a size-dependent burst release over 48 h 
followed by a plateau, with total OVA and CpG release ranging from 100% for 300 nm 
NPs to circa 10% for 17 μm MPs [35]. In a direct comparison, they observed that the 
efficiency of particle uptake and upregulation of MHC class I and CD86 expression on 
BMDC was correlated with smaller particle size [35]. The same trend was observed 
following intraperitoneal (i.p.) vaccination, with the 300 nm NP generating the highest 
antigen-specific cytotoxic T cell responses, and the highest IgG2a:IgG1 ratio of OVA-
specific antibodies, in proportion to DC uptake. These results concur with our own 
observations, since we have recently compared PLGA NP circa 300 nm with MP > 
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properties, for their capacity to induce MHC class I cross-presentation in vitro and 
improve immune responses in vivo [48]. NPs were efficiently internalized by DCs in vitro, 
whereas MP were not. Subcutaneous vaccination of C57BL/6 mice with NPs resulted 
in significantly better priming of Ag-specific CD8+ T cells compared to MP. NP also 
induced a balanced TH1/TH2-type antibody response, whereas MP failed to increase 
antibody titers [48]. NP also outperformed IFA as an adjuvant, by more efficiently 
boosting CD8+ T cell activation and (IgG2a) antibody production [48]. Conversely, in 
a study by Lee et al., MPs in the range of 1.11∼1.44 µm more efficiently induced 
in vitro MHC class I cross-presentation of OVA peptides via than 0.56 µm NPs [54]. 
However, since only 1.11 µm MPs were fully characterized and evaluated in vivo, we 
cannot exclude that differences in (burst) release may be responsible for the differences 
observed in vitro, neither if the results would be translated in vivo. 
The impact of antigen delivery system size on the resultant immune response also 
depends on the route of administration employed. Particles in the size range of 20-
50 nm are suitable for transport through lymphatic vessels to reach lymph nodes, 
where they can increase the probability of immune cell interaction [9]. In contrast, 
large particles (500–2000 nm) depended on cellular transport by skin DCs [40]. These 
studies suggest that particulate vaccines should be formulated in the nano-size range 
to achieve efficient uptake, significant MHC class I cross-presentation and effective 
CTL responses.
3.2. Controlled antigen/adjuvant release
In addition to their ability to protect antigens, favor uptake by APCs and enhance the 
immune response, controlled release systems can extend antigen release for prolonged 
periods of time [55, 56]. Antigen/adjuvant release from PLGA particles is dependent 
on a variety of factors, such as size, polymer composition, porosity of the matrix, 
antigen loading or the way it is associated with PLGA particles, i.e. encapsulated/
entrapped or adsorbed onto the surface. In the first case, antigen release depends on 
the degradation, erosion or dissolution of the polymer; whereas in the second case it is 
dependent on the interactions between the polymer and the antigen [57]. Entrapment 
of the antigen within the particle matrix protects antigen from external environment 
but may lead to incomplete release, which could lead to a weak immune response; 
in contrast, adsorption may lead to high burst release, prematurely releasing the 
antigen from the particulate carrier before uptake by DCs, which can lead to deficient 
immune responses [37]L. Frequently, a combination of adsorbed and encapsulated 
antigen occurs, resulting in a characteristic triphasic release profile with an initial burst 
release followed by a lag phase and a final sustained release phase of the encapsulated 
antigen dictated by polymer erosion [57, 58]. Initial burst release of antigen can be 
generally explained by two mechanisms: either it occurs mainly due to the release 
of antigens that are adsorbed or located in the surface layer, or the morphology of 
NP/MP causes the initial antigen escape through pores and cracks that may form 
during the NP/MP fabrication process [59-61]. Several factors affect burst release: 
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higher hydrophilicity, lower molecular weight and lower polymer concentration can lead 
to higher burst release [26]. The higher glycolide content makes the polymer more 
hydrophilic, facilitating water uptake from the release medium which results in a higher 
initial burst release, whereas the higher lactide content makes it more hydrophobic, 
thus resulting in much slower release [62]. Other parameters may be altered that impact 
release, such as switching the molecular weight or to ester end-capped version of the 
respective polymer [33]. By adding salts to the inner water phase (w1), the porosity of 
the resulting particles can be controlled by increasing the osmotic gradient and the 
flux of water from w2 into the w1/polymer phase, increasing antigen release rate [48]. 
Suspensions of sugars [63] or salts in the oil phase are expected to act in a similar way, 
resulting in a major increase in water-uptake, e.g., by incorporation of suspended NaCl, 
which has been shown with PLGA films [64]. A larger inner surface, induced by a higher 
porosity of the particles, can potentially increase the uptake of the release medium into 
the particles and accelerate the drug pore-diffusion and release [65]. After burst, the 
release of encapsulated material from such systems is dependent on diffusivity through 
the polymer barrier (a more hydrophobic polymer will create a higher barrier), porosity, 
size of antigen molecule and distribution throughout the matrix, leading to prolonged 
antigen release, thereby enhancing the duration of antigen exposure to APCs and thus 
the potency of the resultant response [66].
Antigen release kinetics regulates the antigen exposure to the immune system. If most 
of the cargo is burst released immediately after immunization and before uptake, antigen 
will be delivered to APCs in soluble form, losing the benefit of particulate delivery [37]. 
In contrast, if the release profile is too slow or incomplete, there will not be enough 
antigen available for presentation by APCs. Moreover, Hailemichael et al. showed that 
Montanide-based persisting vaccine depots can induce specific T cell sequestration, 
dysfunction and deletion at vaccination sites; whereas short-lived formulations may 
overcome these limitations and result in greater therapeutic efficacy of peptide-based 
cancer vaccines [67]. Still, sustained release of antigen/adjuvant seems crucial to 
properly activate DCs, whereas a low burst eliminates potential antigen loss before 
uptake, increasing antigen presentation and CD8+ T cell activation [12, 37]. Kanchan 
et al. reported that slow and continuous release of antigen/adjuvant may prolong MHC 
antigen presentation, which play a key role in T cell stimulation and activation, and 
played a critical role in eliciting memory antibody responses [68]. It has been reported 
that extended antigen release may enhance not only the level, but also the quality of 
immune responses [36]. Johansen et al. demonstrated that antigenic delivery increasing 
exponentially over time induced more potent CD8+ T cell responses and antiviral 
immunity than a single dose or multiple equivalent doses (zero order) [34]. Shen et al. 
showed that OVA-loaded PLGA MPs enhanced exogenous antigen MHC class I cross-
presentation at 1000-fold lower concentration than soluble antigen, and served as an 
intracellular antigen reservoir, leading to sustained MHC class I presentation of OVA for 
72 h [19]. Likewise, Waeckerle-Men et al. showed that MHC classes I and II-restricted 
presentation of encapsulated proteins and peptides by DCs was markedly prolonged 
and presented 50-fold more efficiently on class I molecules than soluble antigens [69]. 
A difference in performance between PLGA NPs connected to the kinetics of antigen 
delivery was showed by Demento et al., with “slow” releasing NPs eliciting prolonged 
antibody titers comparing to “fast” releasing ones, and favored long-term effector-
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memory cellular responses [12]. Finally, Zhang et al. formulated OVA-loaded PLGA 
NPs by encapsulating antigen within NPs or by simply mixing soluble antigen with 
the NPs, observing that the combined formulations induced more powerful antigen-
specific immune responses than each single-component formulation. The enhanced 
immune responses elicited by the combined vaccine formulation may be ascribed to 
the combination of a depot effect at the injecton site, adequate initial antigen exposure 
and long-term antigen persistence leading to prolonged antigen presentation [70]. 
3.3. Surface characteristics
Surface characteristics such as shape, hydrophobicity, and zeta potential are reported 
to influence phagocytic uptake by APCs. Because cells are negatively charged, cationic 
particles induce more efficient phagocytic uptake than anionic particles owing to 
electrostatic attraction to the negatively charged APC membranes [71, 72]. Strategies 
aimed at improving the efficacy of PLGA particles as antigen delivery vehicles involve 
coating them with ionic surfactants or polymers such as poly(ethylene glycol) (PEG), 
sodium dodecyl sulphate (SDS), aminodextran, chitosan, poly(ethylene imine) (PEI), 
poly(L-lysine), protamine or cetyltrimethylammonium bromide (CTAB) [57, 73, 74]. 
Coating can be achieved either by incorporating these agents in the particle matrix either 
together with the polymer or in the external aqueous phase during the emulsification 
process, or by adsorption to the surface of pre-formed particles by resuspending 
them in a solution containing the coating and incubating for a determined amount of 
time. Besides changing surface charge, some of these molecules have bioadhesive 
properties, such as chitosan [1], which has been employed to develop formulations 
for mucosal delivery. Polycations can also aid in phagosomal/endosomal escape after 
being internalized by APCs [1], potentially influencing the antigen presentation pathway 
and type of immune response.
Wishke et al. studied the impact of the surface properties of MPs (5 – 10 µm) on 
phagocytosis and the phenotype of DCs, using bovine serum albumin bearing 
fluorescein isothiocyanate groups (FITC-BSA) as model antigen [74]. Anionic particles 
were obtained by using polyvinyl alcohol (PVA) as stabilizing agent; whereas for cationic 
surfaces CTAB and chitosan/PVA or diethylaminoethyl cellulose (DEAE)-dextran/PVA 
blends were evaluated. Whereas CTAB modified MPs lost their positive charge and 
aggregated due to CTAB desorption, the modification with chitosan and DEAE-dextran 
resulted in stable MPs. DEAE-dextran modified MPs increased the cellular uptake of 
the protein loaded MPs.
Positively charged PLGA microspheres (1 – 5 µm) containing hepatitis B surface antigen 
(HBsAg) were prepared with cationic agents stearylamine and PEI in the external 
aqueous phase [71]. Compared to unmodified formulations, positive surface charge 
enhanced both the systemic and mucosal immune response upon immunization of 
rats via the intranasal route, showing increased levels of IgG in serum and sIgA in 
salivary, vaginal and bronchoalveolar lavages. PLGA microspheres coated with chitosan 
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were developed for nasal immunization using recombinant HBsAg [75]. The modified 
PLGA microspheres showed the lowest nasal clearance rate and a 30-fold increase 
of serum IgG levels in comparison with unmodified PLGA microspheres upon nasal 
administration. OVA-loaded PLGA nanoparticles coated with N-trimethyl chitosan 
(TMC) were more efficiently taken up by DCs and showed a longer nasal residence 
time than uncoated particles [76].
Protamine, a cationic polypeptide, has been used as a surface coating material 
because of its ability of increasing cell penetration [77]. Protamine coating of PLGA 
microparticles (~7 µm) encapsulating the purified phospholipase A2 (PLA2) from bee 
venom or ovalbumin (OVA) as model antigens injected s.c. in mice led to increased 
antibody and T-cell responses as compared to uncoated particles (~3 µm). This was 
most likely mediated by an increased uptake, as protamine-coated particles (~3 µm) 
carrying green fluorescent protein plasmid were efficiently internalized in vitro by non-
phagocytic cells and impressively increased transfection [77]. In another study from 
the same group, PLGA microparticles containing PLA2 allergen in combination with 
adsorbed protamine and CpG (~8 µm) resulted in strong PLA2-specific antibody 
responses and the induction of the Th1-associated isotype IgG2a [78]. 
The CTL-restricted OVA peptide SIINFEKL was microencapsulated into bare PLGA 
MPs (~2.6 µm), chitosan-coated PLGA MPs with CpG either covalently coupled or 
physically adsorbed onto the MP surface (~3.1 µm), and protamine-coated PLGA MPs 
with adsorbed CpG (~2.2 µm) [79]. For the covalent coupling, chitosan coated MPs were 
functionalized with sulfo-MBS (m-maleimidobenzoyl-N- hydroxysuccinimide ester), a 
water-soluble heterobifunctional cross-linker which forms amide bonds with primary 
amino groups via the N-hydroxysuccinimide ester while the maleimido residue reacts 
with sulfhydryl groups to form stable thioether bonds, and then incubated with 5′-thiol-
modified CpG. However, only the uncoated PLGA MP with adsorbed CpG mediated 
a prominent CTL response in mice after s.c. immunization, eliciting the production of 
1.2% of IFN-γ secreting and SIINFEKL-specific CD8+ T cells, with failure of the other 
formulations being ascribed to the low release of antigen and CpG. 
During the encapsulation process antigens are exposed to the organic solvents 
required to dissolve the polymer (e.g. dichloromethane, ethyl acetate), emulsification 
steps (which may include interfaces, temperature excursions, sonication, and vigorous 
shaking) and drying (usually lyophilization), all of which may compromise antigen stability 
[9]. Moreover, after administration the degradation of the polymer matrix creates an 
acidic and potentially harmful microenvironment which can result in denaturation, 
chemical degradation or aggregation of the antigen, which may endanger the integrity 
and immunogenic potential of the vaccine [80, 81]. In particular, protein antigens tend 
to aggregate or degrade upon entrapment into PLGA or during release from the matrix 
[81]. Though peptide antigens may be less susceptible to the above-mentioned stress 
factors than proteins, as they do not possess a defined tertiary structure, that can also 
lead to deamidation or formation of peptide adducts due to acylation of lysine residues 
with lactic and glycolic acid units [82]. This may be partially solved by optimized 
manufacturing methods or addition of stabilizing agents, such as basic inorganic salts 
(e.g. magnesium hydroxide, calcium carbonate, sodium bicarbonate, zinc carbonate), 
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other proteins, surfactants or sugars [81, 83-85]. 
Attachment of antigens via covalent chemistry or adsorption through electrostatic 
interactions onto the surface particles might be an alternative to encapsulation to 
prevent antigen instability. Adsorption procedures can be performed under milder 
condition than encapsulation, the antigen is released faster and is immediately available 
from the particle surface to be processed following uptake, not being dependent on 
polymer degradation to release entrapped antigen, and antigen loading is often more 
efficient [21, 86]. However, adsorption may also result in burst or premature release, 
therefore release kinetics should be taken into account when considering adsorption or 
encapsulation of antigens into PLGA particles.
A single s.c. injection of HBsAg adsorbed to PLGA-CTAB microspheres (~5-7 µm) gave 
similar humoral and cellular responses a two injections of HBsAg in alum [87]. Anionic 
MPs with a mean size of 1 µm were prepared by adding SDS to the external water phase 
in the preparation process in order to adsorb p55 Gag protein [88]. SDS-coated PLGA 
particles with adsorbed p55 gag were able to induce high specific CTL responses after 
i.m. administration in mice. IgG titers were significantly increased compared to soluble 
p55 Gag protein [89]. The same group also investigated particles consisting of PLGA 
coated with the anionic surfactant dioctylsulfosuccinate (DSS). 1 µm sized PLGA-DSS 
particles with Neisseria meningitidis B antigen adsorbed elicited high antigen-specific 
IgG titers in mice after i.p. administration compared to an antigen-alum formulation 
[90]. Similar particles were used to adsorb gp120dV2, a recombinant HIV glycoprotein 
with an isoelectric point of 8.5 [91]. In contrast with encapsulated antigen, surface 
adsorption of this protein did not affect its binding capability to CD4 [91, 92]. 
In conclusion, modifying the surface charge may help increase particle uptake efficiency 
and result in a stronger immune response, especially when considering mucosal 
delivery. Furthermore, modification of the particle surface using either polycations or 
polyanions has been used to create cationic or anionic particles to which charged 
antigens/adjuvants can be adsorbed. Most protein antigens and/or adjuvants are 
negatively charged, so positive charge would allow such antigens to be adsorbed to 
the surface instead of being encapsulated into particles, which may be beneficial to 
improve antigen stability. 
3.4. Targeted delivery to DCs
3.4.1. TLRL co-delivery in PLGA systems
One of the greatest benefits of particulate antigen delivery systems is their ability to 
co-deliver antigens and immunomodulators simultaneously to the same APCs [93]. 
The concomitant delivery of TLRLs and antigens in PLGA particles has been proven.
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successful to enhance antigen-specific CTL responses [79, 94]. The appropriate 
selection of the TLRL for co-delivery will determine the bias towards Th1 or Th2 
responses [93]. Furthermore, as most pathogens simultaneously present multiple TLR 
agonists to APCs, the combination of multiple TLRLs may result in a synergistic effect 
and a promising strategy to induce strong protective immune responses [7]. Over the 
last decades, some of these ligands have been used in several vaccine formulations to 
target and activate TLRs. A summary of PLGA vaccine formulations containing TLRLs 
can be found in Table 2.
CpG is a ligand to TLR9 which is known to induce a MHC I class driven antigen 
presentation, resulting in a cellular immune response. Separate groups of C57BL/6 
mice were immunized s.c twice with TT and CpG  in PLGA NPs (test group), TT-loaded 
NPs, TT-loaded NPs mixed with soluble CpG, TT and CpG  both in solution (reference 
group), TT alone in solution, and alum adsorbed TT [95]. While CpG increased the 
immunogenicity of soluble TT antigens when co-delivered s.c. as a soluble adjuvant 
in mice, its effect was significantly higher when administered in a particulate PLGA 
formulation. The TT/CpG NPs group showed strong antigen-specific T cell proliferation 
ex vivo significantly higher than that observed for T cells isolated from the reference 
group, and was associated with higher levels of interferon γ secretion. IgG titers that 
were also 16 times higher than the reference group, and differences of 8-fold for 
IgG1 and IgG3, and 5-fold for IgG2b titers were observed. Overall, the results show 
that co-delivery of CpG and TT resulted in induction of both Th1 and Th2 immune 
responses with a bias towards Th1 type. Characterization studies showed that co-
encapsulation of CpG and TT in PLGA particles resulted in CpG localization on the 
outer side of the particles [95]. The importance of co-encapsulation was studied by co-
encapsulating ovalbumin (OVA) and CpG-chitosan complexes in PLGA MPs, showing 
that the co-encapsulation of CpG with OVA in PLGA MPs significantly improved the 
antibody response and isotype shifting in comparison with mice immunized i.d. with 
OVA-loaded MPs [96]. Heit et al. compared the in vivo immunogenicity of MPs (<10 µm) 
co-entrapping OVA and CpG with that of CpG-OVA conjugates, or a mixture CpG and 
OVA [97, 98]. In vivo, MP-based vaccination triggered clonal expansion of Ag-specific 
MHC class I-restricted CD8+ T cells comparable to CpG-Ag conjugates. Conjugation 
of antigens to adjuvants is however a difficult process that has to be performed and 
optimized for each individual antigen, whereas particulate formulations offer a more 
generic approach. Using infection- and tumor-model system, PLGA MP-based single 
step s.c. vaccination at the tail base of mice conferred protective and even therapeutic 
immunity against OVA-expressing B16 melanoma tumor cells [98]. 
TLR3 ligand poly(I:C) is also known to enhance cross-priming of CD8+ cytotoxic T 
lymphocytes [99]. Poly(I:C) adsorbed to (DEAE)–dextran-coated PLGA MPs containing 
FITC-BSA were effectively phagocytized by DCs ex vivo and induced a maturation 
similar to that achieved with a cytokine cocktail or higher concentrations of soluble 
poly(I:C) [100]. Schlosser et al. demonstrated that MHC I cross-priming in mice after 
s.c. vaccination with PLGA MPs was enhanced when OVA was co-encapsulated 
together with either a CpG or poly(I:C) as compared to co-inoculation of OVA-loaded 
MPs with soluble or separately encapsulated adjuvants [94]. Using four different 
read-out systems: (i) SIINFEKL/H-2Kb tetramer positive CTLs, (ii) IFN-γ production, 
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(iii) in vivo cytotoxicity against SIINFEKL-charged target cells, and (iv) the protection 
from infection with vaccinia virus encoding OVA, they found that co-encapsulated 
TLR ligand and antigen consistently yielded stronger CTL responses. For instance, a 
single immunization with MPs containing co-encapsulated OVA and CpG yielded 9% 
SIINFEKL/H-2Kb tetramer positive CTLs, whereas approximately half of the response 
was detected when a mixture of the two MP preparations was administered. This 
effect was observed for both adjuvants examined, though the responses to poly(I:C) 
were generally lower. Mueller et al. compared the immune response to IFA and a 
mixture of PLGA MPs combining both OVA and CpG (MP-OVA/CpG) or a mixture 
of MP-OVA/CpG and MP-poly(I:C), observing that the PLGA MP mixture was as 
efficient as or superior to IFA in eradication of pre-existing tumors and suppression 
of lung metastases [101]. PLGA MPs opsonized with mouse IgG, either loaded with 
OVA and either poly(I:C) or CpG, were incubated with DCs and significantly increased 
and prolonged both MHC class I- and class II-restricted OVA presentation, with each 
TLRL showing similar potency. A combination of the two TLR agonists synergistically 
increased the MHC class I-restricted, but not the class II-restricted, presentation of 
exogenous antigen [99]. 
Monophosphoryl lipid A (MPLA) is a detoxified form of lipid A derived from LPS which is a 
potent TLR4 agonist [7]. Immunization of mice s.c. with PLGA MPs incorporating MPLA 
with an OVA peptide, consisting of residues 323–339 containing Th and B epitopes of 
OVA, resulted in an increase in the production of IFN-γ, eliciting a specific Th1 immune 
response [102] Similar results were obtained with cancer-associated 24mer human 
MUC1 mucin peptide [103]. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-
glycolic acid. Hamdy et al. studied the co-delivery of MPLA and OVA in PLGA NPs (OVA/
MPLA NPs). The primary CD4+ T cell responses to OVA/MPLA NPs were investigated 
using OVA-specific T cells from DO11.10 transgenic mice. Following adoptive transfer 
of these cells, mice were immunized s.c. by NP formulations. For assessing the CD8+ T 
cell responses, bone marrow derived DCs were pulsed with different OVA formulations 
and co-cultured with CD8+ T cells from OT-1 mice. Co-delivery of MPLA and OVA 
in PLGA NPs induced a higher CD8+ T cell proliferative responses and IFN-γ in vitro 
and >13-folds increase in clonal expanded CD4+ T cells in vivo following either i.p. or 
s.c. route of immunization, compared to OVA-PLGA particles without MPLA [104]. 
The expanded T cells were capable of cytokine secretion and expressed an activation 
and memory surface phenotype. Similar studies also showed a significantly stronger 
cell-mediated response in mice after s.c. vaccination with hepatitis B core antigen 
(HBcAg) protein or peptide (HBcAg129–140) and MPLA in PLGA nanoparticles than when 
using the free antigen, the free antigen with MPLA, or particles loaded with antigen 
alone [105, 106]. Elamanchili et al. demonstrated that delivery of OVA and MPLA in 
PLGA NPs to DCs induced potent in vitro and in vivo  antigen-specific primary Th1 
immune responses in mice compared to OVA encapsulated alone or soluble OVA 
and MPLA, after adoptive transfer of antigen-pulsed DCs [13]. Similarly, co-delivery of 
MUC1 lipopeptide (BLP25, a cancer vaccine candidate) and MPLA loaded in PLGA 
NPs to human DCs significantly enhanced proliferation of antigen-specific T cells in 
vitro comparing to NP-MUC1, NP-MPLA, soluble MUC1, or soluble MUC1 mixed with 
NP-MPLA [13]. This combination of MUC1 and MPLA in PLGA NPs was shown to 
break tolerance and elicit strong T-cell responses against self-antigens in vivo after 
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adoptive transfer of DCs loaded with the vaccine formulations. Hamdy et al. showed 
that s.c. vaccination of mice bearing melanoma B16 tumors with PLGA NPs co-
encapsulating the poorly immunogenic melanoma antigen, tyrosinase-related protein 2 
(TRP2), along with TLR4 ligand (7-acyl lipid A, an analog for MPLA) was able to induce 
potent CD8+ T cell-mediated anti-tumor immunity and therapeutic anti-tumor effect 
in comparison to antigen encapsulated alone [107]. Zhang et al. observed that i.d. 
vaccination of mice with PLGA NPs carrying melanoma antigenic peptide TRP2180-188 
and MPLA significantly delayed growth of subcutaneously inoculated B16 melanoma 
cells in a prophylactic setting compared to NPs with TRP2180-188 alone, or soluble 
TRP2180-188 mixed with MPLA [108]. In another approach, enhanced immunogenicity 
in mice was obtained with i.p. vaccination with HIV-1 gp120 protein or antigen from 
Neisseria meningitidis serotype B  (Men B) adsorbed to the anionic surface of PLGA 
MPs treated with ionic surfactant DSS that contained either encapsulated MPLA or the 
synthetic LPS analog RC529 [109]. Delivery of MPLA or RC529 encapsulated in PLGA 
MPs with antigen adsorbed onto the MPs resulted in even further enhancement of IgG 
serum titers over those obtained with soluble TLRLs. This effect was observed for both 
antigens regardless of whether or not the TLRL and the antigen were used with the 
same or with separate particles.
In addition, PLGA NPs (~450 - 600 nm) and MPs (~1 – 3 µm or ~6 – 32 µm) have been 
used to deliver a lipid modified peptide (lipopeptide) from berghei circumsporozoite 
protein (CS252-260, SYIPSAEKI), coupled to TLR2 agonist Pam3Cys with a Ser-Lys-Lys-
Lys-Lys spacer (here designated Pam-CS252-260). Particles of mean size < 500 nm were 
better inducers of CTL than larger microparticles ( > 2 µm). Pam-CS252-260 loaded PLGA 
particles administrated i.p. to mice elicited higher levels of cytolytic activity than CS252-
260-MPs or soluble Pam-CS252-260 [110]. Recent work by our group using a 24 residue 
synthetic long peptide (SLP) from OVA SLP-OVA24 as vaccine antigen and TLR2 ligand 
Pam3CSK4 co-encapsulated in PLGA NPs showed that TLR2 stimulation enhanced 
MHC class I presentation by DCs and significantly enhanced prolonged antigen 
presentation and CD8+ T cell activation in vivo after adoptive transfer of antigen-loaded 
DCs [111].
The best way to deliver adjuvants in PLGA particles, either to entrap or to adsorb them 
onto their surface, is yet to be resolved. The better choice likely depends on the cellular 
location of their target receptors: if they act on the cell surface, it might be desirable 
to have the adjuvant readily available on uptake; but if they need to be internalized to 
interact with endosomal receptors, encapsulation within the particle might be preferable 
[112].
3.4.2. Targeted delivery to other DC receptors
Aside from TLR ligands, there are many more targeting ligands that have been used with 
PLGA particles to increase the immunogenicity of subunit vaccines (see Table 3). This 
can be achieved by modifying the particle surface with ligands that can target specific 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 [1, 5]. Physical association is driven by electrostatic and hydrophobic interactions, 
whereas preformed PLGA nanoparticles with carboxyl end groups can be chemically 
conjugated with molecules with terminal amine groups via amide coupling reactions 
using carbodiimide reagents [113]. To do that, the surface of PLGA is first derivatized 
by PEG-NH2 with functional end groups that can react with different ligands [113]. 
For instance, surface modification with biotin-PEG-NH2: as avidin and its homologues 
show very high affinity to biotin, biotinylated PEG-PLGA particles allow noncovalent 
binding with avidin-ligand conjugates or vice versa, allowing targeting ligands such as 
antibodies to be attached to PLGA particles using these methods [113]. Interaction 
between PLGA particles functionalized with specific ligands and/or antibodies against 
DC receptors may improve targeting to DCs, increase particle uptake by DCs through 
receptor-mediated endocytosis and modulate DC maturation, and thereby enhance 
the effectiveness of the vaccine formulation [10].
M-cell targeting can be considered if the vaccine is administered at a mucosal tissue 
[114, 115]. Integrins are heterodimeric transmembrane subunits that have specific 
affinities toward peptides with an arginine-glycine-aspartate (RGD) sequence [113]. 
Grafting of the integrin binding targeting peptide RGD can be used to promote the 
uptake of NPs via interaction with β1 integrins on M cells. Garinot et al. improved the 
efficiency of orally delivered vaccines in mice, using PEGylated OVA-loaded PLGA NPs 
displaying RGD molecules at their surface, which were able to elicit IgG responses in 
vivo [116]. Brandhonneur et al. studied the influence of target ligand-grafted PLGA 
MPs (~2.5 µm) on the rate of uptake by alveolar macrophages using three different 
ligands: WGA (lectin weat germ agglutinin, which interacts with lectin receptors), a RGD 
(arginine-glycine-aspartate) containing peptide (interacting on integrins), and mannose-
PEG3-NH2 (interacting with mannose receptor) covalently coupled the particle surface 
using the carbodiimide method, showing that a  much higher uptake was observed 
for targeted MPs because of the specific mechanism of phagocytosis. [117]. Mata et 
al. developed PLGA MPs (1 μm) containing a small percentage of alginate (PLGA-alg 
MP) or RGD-modified alginate (PLGA-alg-RGD MP). Two malaria synthetic peptides, 
SPf66 and S3, were microencapsulated into PLGA, PLGA-alg and PLGA-alg-RGD 
MP. Intradermal (i.d.) vaccination of mice demonstrated that incorporation of alginate 
elicited higher humoral and cellular immune responses leading to more balanced Th1/
Th2 responses, and that the addition of RGD increased cell targeting, enhancing cellular 
responses such as IFN-γ secretion and slenocyte proliferation [118].
C-type lectin receptors (CLRs) are endocytic receptors that recognize exogenous and 
endogenous carbohydrates which are present on the surface of DCs and macrophages 
[113]. Antigens associated with specific sugar residues can target to these receptors 
on DCs, including the mannose receptor, DEC-205 (also known as CD205), and DC-
specific intracellular adhesion molecule-3 (ICAM3)-grabbing non-integrin (DC-SIGN) 
[119]. Two main strategies can be used to target CLRs, either by grafting particles 
with specific sugar residues which are natural ligands to these endocytic receptors 
(e.g. sugars with terminal mannose, fucose or N-acetylglucosamine) or by coupling 
mAbs against them [120, 121]. Many CLRs expressed by DCs are directly implicated 
in immunoregulatory processes, such as antigen uptake, intracellular trafficking and 
antigen presentation [119]. 
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PLGA particles decorated with mannan, a natural polymannose isolated from the cell 
wall of Saccharomyces cerevisiae, have been designed for targeted DC delivery via 
mannose receptors. Incorporation of mannan in NPs (~400 – 500 nm) made from 
capped and uncapped PLGA was achieved either through addition in first or second 
aqueous phases during NP preparation or by attachment onto the surface of freeze 
dried NPs by physical adsorption or chemical conjugation to COOH terminated 
polymer. PLGA NPs containing chemically conjugated or physically adsorbed mannan 
significantly enhanced DC uptake [122] and induced DC maturation, as evidenced by 
the up-regulation of cell surface markers (CD40, CD86) and secretion of inflammatory 
cytokines (IL-12, IL-6 and TNF-α) [120]. PLGA NPs (~400 nm) with chemically 
conjugated mannan showed increased CD4+ and CD8+ T cell immune response 
against encapsulated OVA in comparison to their untargeted counterparts [123]. In 
addition to being a targeting ligand, mannan is also reported to have immunostimulatory 
properties, possibly due to TLR agonism [123]. The type of sugar can determine which 
receptor is targeted and the immunological outcome. The nature of mannan has been 
shown to guide the type of immune response, with antigens conjugated to oxidized 
mannan inducing mostly cellular responses, whereas antigens coupled to reduced 
mannan induced humoral responses [124]. Oxidized mannan facilitates endosomal 
escape of the mannosylated antigen into the cytoplasm, resulting in a CD8+ T cell 
response, whereas formulations with reduced mannan remain in the endosome, being 
degraded by the lysosomal enzymes, and resulting in a CD4+ T cell response [125]. A 
drawback of targeting mannose receptors is the fact that they are also expressed by 
other cell types, such as monocytes, macrophages, and other subsets of other cells, 
which might result in unspecific uptake [47].
DEC-205 is a CLR that has been used to target DCs in vivo, that is mainly expressed 
on mature DCs, and also by B cells, T cells, monocytes, macrophages and natural 
killer (NK) cells at lower levels [121]. DEC-205 is a membrane protein which binds to 
carbohydrates and mediates endocytosis and antigen presentation and [47]. However, 
delivery of OVA conjugated to mAb targeting DEC-205 without additional maturation 
stimuli results in the induction of regulatory T cells and immune tolerance, whereas 
concomitant delivery of agonistic α-CD40 mAb with targeted OVA results in strong 
induction of OVA-specific CD4+ and CD8+ T-cell responses [126]. Raghuwanshi et al. 
prepared OVA-loaded PLGA NPs (~200 nm) for targeted delivery to dendritic cells 
[127]. First, NPs were prepared by coupling of biotin-PEG2000-amine to the carboxylic 
group of PLGA. Then, NPs were mixed with a recombinant bifunctional fusion protein 
(bfFp) of strepatividin and a single chain antibody fragment that recognizes mouse 
DEC-205 receptors. In vitro studies showed a two-fold increase in uptake of targeted 
NPs, and s.c. immunization of mice using the targeted NPs in combination with a DC 
maturation agent (anti-CD40 mAb) showed enhanced IgG titers against OVA. However, 
co-administration of anti-CD40 mAb was shown to be required as DEC-205 targeting 
in its absence leads to antigen-specific tolerance, as shown in previous studies [126, 
127]. 
Invariant Natural Killer T (iNKT) can enhance cross-priming in a CD1d-dependent 
manner as they recognize (glyco)lipid antigens [128]. The most extensively studied 
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CD1d antigen is high-affinity α-galactosylceramide (α-GalCer), an immunostimulatory 
ligand that can elicit the secretion of a wide array of cytokines by iNKT cells upon 
recognition,  enhancing DC activation and acting as a strong adjuvant for Th1 and CTL 
responses [27]. Targeted delivery of immunostimulant α-GalCer analogue KRN7000 
and OVA by anti-DEC-205 conjugated NPs (~200 - 250 nm) triggered optimal antigen-
specific humoral and CTL responses and promoted potent antitumor responses 
mediated by iNKT cells [129].
DC-SIGN is the most DC-specific CLR and is mainly expressed on immature DCs [121]. 
A recent study by Cruz et al. using BSA- or TT-loaded MPs (2 µm) and NPs (200 nm) 
consisting of a PLGA core coated with a PEG-lipid layer conjugated to the humanized 
anti-DC-SIGN targeting antibody hD1 demonstrated that NPs were targeted more 
efficiently than MPs to DCs, leading to improved antigen presentation by human DCs 
and activation of antigen-specific T-cell responses at 10–100 fold lower concentrations 
of antigen compared to the non-targeted NPs [15]. In another study, similar PLGA NPs 
(~200 - 250 nm)  co-encapsulating OVA and TLRLs poly(I:C) and R848, were coupled 
to different mAbs against distinct DC surface molecules: DEC-205; TNF family receptor 
with known DC activating properties αCD40; and CD11c, an integrin receptor [14]. 
Targeted NPs were more efficiently internalized, and increased IL-12 production and 
expression of IFN-γ in vitro than their non-targeted counterparts, with CD40-targeted 
NPs performing slightly better than DEC-205 or CD11c targeted NPs. Upon s.c. 
vaccination, all targeted NP consistently showed higher efficacy than non-targeted NP 
to stimulate CD8+ T cell responses, though no significant differences were observed 
between NPs targeted to different receptors [14]. In a subsequent study, s.c. injection 
of αCD40-targeted PLGA NPs (~200 - 250 nm) loaded with OVA or HPV-E7 protein 
and TLRLs poly(I:C) and Pam3CSK4 led to very efficient and selective delivery to DCs 
and efficient CD8+ T cell priming.  CD40-targeted NPs encapsulating HPV-E7 protein 
significantly enhanced antigen-specific CD8+ T cells compared to non-targeted NPs for 
a mixture of soluble HPV-E7-protein and adjuvants. Therapeutic application of CD40-
targeted NPs improved priming of CD8+ T cells against the two independent tumor 
associated antigens and enhanced tumor control and prolonged survival of tumor-
bearing mice, showing that targeting to specific DC receptors is an effective way to 
increase the efficacy of particulate vaccines [17].
4. Recent advances in PLGA particles for 
peptide-based vaccine delivery
Peptide-based vaccine formulations offer several advantages, as peptides can be 
easily synthesized and characterized in a highly reproducible manner in large scale and 
are generally more stable than whole proteins [7]. Furthermore, they may be especially 
valuable as anticancer vaccines, where the use of the whole protein is inadequate 
due to its similarity to endogenous human protein or carcinogenic properties; and the 
lack of redundant components significantly reduces the risk of allergic or autoimmune 
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responses [72]. However, peptides alone are poorly immunogenic and need to be 
combined with adjuvants such as immune modulators and/or delivery systems in order 
to properly activate the innate and adaptive arms of the immune system [7]. Currently 
available experimental adjuvants such as Montanide are associated with side effects, 
while commercially available adjuvants are ineffective at inducing cellular immunity [72]. 
Encapsulation of synthetic peptides in PLGA particles has been shown to promote 
cross-presentation, resulting in both humoral and cell-mediated immunity [10]. Different 
synthetic antigenic peptides have been successfully entrapped into PLGA particles 
resulting in increased immunogenicity of the peptide vaccines. A summary of peptide-
based formulations is presented in Table 4.
Partidos et al. injected mice i.p. with the CTL epitope (LDRLVRLIG) representing the 
51-59 residues from measles virus nucleoprotein (MVNP51-59) encapsulated in PLGA 
MPs, which elicited a higher specific cytotoxicity compared with results obtained with 
IFA [130]. However, simply mixing empty PLGA MPs with the peptide resulted in the 
induction of CTL responses comparable to those induced by the encapsulated peptide 
formulation, likely due to surface adsorption of the peptide to the particles [131]. PLGA 
NPs (~500 nm) containing HBcAg129–140 peptide and MPLA induced a strong Th1-
type response with a predominant IFN-γ profile after a single s.c. immunization, which 
was enhanced after a booster immunization, while mice immunized with a CFA-peptide 
formulation showed a Th2 bias. Furthermore, mice primed with the CFA-peptide 
formulation still developed a strong Th1-type response when boosted with the NP 
formulation [132].
Peptides derived from malarial antigens have also been studied. In a study by Men 
et al., two synthetic peptides, P30B2 (composed of one universal T helper epitope 
from tetanus toxin P30 and a B cell epitope B2 derived from the repeat sequence 
of Plasmodium berghei) and  (NANP)6P2P30 (composed of P30 and another T 
helper epitope from tetanus toxin P2 and a B cell epitope B2 derived from the 
repeat sequence of Plasmodium falciparum), were incorporated into MPs (1-20 µm) 
of different compositions eliciting strong and sustained proliferative and antibody 
responses comparable to those obtained with IFA-peptide preparations after s.c. 
immunization at the tail base [133]. Malarial peptide SPf66, the first chemically 
synthesized vaccine to elicit a partial protective immune response against malaria, 
when encapsulated in PLGA MPs (~1 µm) induced a superior immune response in 
comparison to alum-adjuvanted SPf66, and a similar response compared with the 
peptide formulated with Freund’s complete adjuvant (FCA) [134]; leading to high 
antibody levels and protection against P. falciparum challenge when administered to 
Aoutus monkeys [135]. Another study by Mata et al. compared the immune response 
against the S3 malarial synthetic peptide injected s.c. using PLGA MPs (~3 µm), 
Montanide, and alum, with Montanide and MPs behaving comparably and resulting 
in mixed Th1/Th2 immune responses [136]. Prolonged antibody responses were also 
obtained by Mata et al. with two malarial peptides derived from the constant region 
of 3D7 and FC27 Plasmodium falciparum MSP2 dimorphic proteins encapsulated 
in PLGA MP formulations after s.c. or i.d. injections [137]. More recently, Mata et al. 
developed PLGA MPs (1 μm) containing a small percentage of alginate (PLGA-alg 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and S3 were microencapsulated into PLGA, PLGA-alg and PLGA-alg-RGD MP. 
Intradermal vaccination of mice demonstrated that incorporation of alginate elicited 
higher humoral and cellular immune responses leading to more balanced Th1/Th2 
responses, and that the addition of RGD increased cell targeting, enhancing cellular 
responses such as IFN-γ secretion and splenocyte proliferation.
An extensively studied application for peptide-based vaccines is for immunotherapy 
of cancer by encapsulation of tumor-derived peptides in PLGA particles. Vaccination 
with synthetic long peptides (SLPs), containing the CTL and/or Th epitopes of a TAA, 
has shown superior efficacy to protein antigen [138] or minimal MHC class I restricted 
epitopes in mouse models [18, 139]. In contrast to short peptides, SLPs cannot bind 
directly to MHC molecules, but have to be taken up and processed by DCs like regular 
pathogens, inducing the activation of both CD4+ and CD8+ T cells and eliciting a 
stronger cellular immune response [18, 140, 141]. 
Immunization of mice s.c. with PLGA MPs (1-10 µm)  incorporating MPLA with an OVA 
peptide, consisting of residues 323–339 containing Th and B epitopes of OVA, resulted 
in an increase in the production of IFN-g, eliciting a specific Th1 immune response [102]. 
Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid. Similar results were 
obtained with PLGA NPs (500-900 nm)  loaded with cancer-associated 24mer human 
MUC1 mucin peptide [103]. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-
glycolic acid. Elamanchili et al. showed that co-delivery of MUC1 lipopeptide (BLP25, 
a cancer vaccine candidate) and MPLA loaded in PLGA NPs (340-450 nm) to human 
DCs significantly enhanced proliferation of antigen-specific T cells in vitro comparing 
to NP-MUC1, NP-MPLA, soluble MUC1, or soluble MUC1 mixed with NP-MPLA [13]. 
This combination of MUC1 and MPLA in PLGA NPs was shown to break tolerance and 
elicit strong T-cell responses against self-antigens in vivo after adoptive transfer of DCs 
loaded with the vaccine formulations [13, 142].
Our group has demonstrated that encapsulation of OVA24, a model 24-residue synthetic 
long peptide (SLP) antigen covering a CTL epitope of ovalbumin (SIINFEKL) in PLGA 
NPs of circa 330 nm, engineered to diplay a low burst release, showed enhanced MHC 
class I restricted T cell activation in vitro when compared to high-burst releasing NPs 
and soluble OVA24 [37]. Co-encapsulation of OVA24 with TLR2 ligand Pam3CSK4 
in PLGA NPs enhanced MHC class I presentation by DCs in vitro and significantly 
enhanced prolonged antigen presentation and sustained CD8+ T cell proliferation in 
vivo after adoptive transfer of PLGA NP-loaded DCs [111]. Moreover, recent studies 
comparing the co-delivery of two SLPs containing the CTL and Th epitopes of OVA 
(OVA24 and OVA17, respectively), and the TLRLs poly(I:C) and Pam3CSK4 in different 
delivery systems, showed that subcutaneous vaccination in mice with PLGA NPs 
resulted in enhanced OVA-specific CD8+ T cell proliferation in vivo at least comparable 
to the formulations that are currently used in clinic, MF59 and Montanide (Varypataki 
et al., manuscript in preparation). NPs (~400 – 500 nm) based on hydrophilic polyester 
poly(D,L lactic-co-hydroxymethyl glycolic acid) (pLHMGA) were loaded with a 27-
mer SLP containing the CTL epitope RAHYNIVTF of HPV E7 oncoprotein (E743–69) 
together with poly(I:C) and compared to E743–69 and poly(I:C) formulated in IFA [143]. 
Encapsulation of antigen substantially enhanced the population of HPV-specific CD8+ 
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T cells when combined with poly(I:C) either co-encapsulated or in its soluble form, and 
vaccination with NPs substantially prolonged the survival of mice (three weeks) in a 
therapeutic tumor setting, with a therapeutic efficacy in tumor eradication equivalent to 
that of the IFA formulation. Moreover, as opposed to IFA, subcutaneous administration 
of pLHMGA NPs was not associated with local adverse effects.
Some melanoma specific antigens that have been studied for cancer vaccines include 
MART-1, gp100, TRP1, and TRP2. Encapsulation of MHC class Ia, Ib, and class II-
restricted peptide epitopes MART-127-35, gp100209-217 and mSTEAP326-335 in PLGA 
NPs (180-280 nm), resulted in a significantly enhanced antigen presentation of the 
encapsulated peptides upon internalization of the NPs by DCs in vitro, and confirmed 
that the improved peptide presentation is actually associated with more efficient 
generation of peptide-specific CTL and T helper cell responses [144]. 
Zhang et al. loaded PLGA NPs (~80 nm) with TAA peptides from melanoma (hgp10025–
33 or TRP2180–188) observing that the NPs were efficiently uptaken by murine DCs in vitro 
and in vivo and induced stronger cellular immune responses than the peptides mixed 
with CFA [108]. Moreover, i.d. vaccination with PLGA-NP carrying both TRP2180-188 and 
MPLA significantly delayed growth of s.c. inoculated B16-F10 melanoma tumor cells 
in a prophylactic setting compared to NPs with TRP2 alone, TRP2 peptide mixed with 
MPLA. Additionally, i.p. administration of IFN-γ from day 1 after the tumor inoculation 
was highly effective for controlling tumor growth in challenged mice. 
Similarly, subcutaneous administration of co-encapsulated TRP2180–188 and 7-acyl 
lipid A into PLGA NPs (350-410 nm) to B16-F10 tumor-bearing mice resulted in anti-
tumor activity related with increased levels of IFN-γ and pro-inflammatory Th1-related 
cytokines compared to control groups [107].
Silva et al. studied the co-entrapment of melanoma-associated antigens and the 
TLRLs poly(I:C) and CpG, in mannose-functionalized aliphatic polyester-based NPs 
(constituted by a blend of PLGA, poly(D,L-lactic-co-glycolide-b-ethylene glycol) (PEG-
b-PLGA) and poly(ε- caprolactone-b-ethylene glycol) (PEG-b-PCL) in a 70:15:15 w/w 
ratio) to be targeted to mannose receptors on antigen-presenting cells and induce 
anti-tumor immune responses [145]. The s.c. co-delivery of the model antigen OVA 
and the TLR ligands was crucial to induce high IgG2c/IgG1 ratios and high levels of 
IFN-γ and IL-2, while mannose-functionalization of PLGA-PEG-PCL NPs potentiated 
the Th1 immune response. The nanoparticulate vaccines decreased the growth rate 
of murine B16F10 melanoma tumors in therapeutic and prophylatic settings. The 
combination of mannose-functionalized NPs containing MHC class I- and class II-
restricted melanoma antigens (Melan-A:26 and gp100:209) co-entrapped in the same 
mannose-NPs demonstrated to have a detrimental effect on the anti-tumor immune 
response, whereas the combination of mannose-NPs containing either a MHC class 
I- or class II-restricted antigens along with both TLRLs demonstrated the most potent 
anti-tumor immune response, suggesting the importance of the activation of both CD4+ 
and CD8+ T-cells. 
Although there are still no PLGA-based particulate vaccines on the market [1], one has 
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reached clinical trial. A phase I clinical trial evaluated the safety and immunogenicity 
of a synthetic HIV peptide (HIV-1 MN V3) administered i.m. with alum or administered 
orally encapsulated into PLGA microspheres, unfortunately with poor results [5, 146]. 
Still, antigenic peptides incorporated into PLGA particulate carriers have demonstrated 
a considerable potential as prophylactic and therapeutic vaccines, and it is expected 
that more PLGA-based vaccines enter clinical trials in the near future.
5. Conclusions
Vaccination with subunit antigens is not always successful due to their limited 
bioavailability and poor immunogenicity. Moreover, soluble antigens are often inefficiently 
cross-presented. Delivery systems can be used in order to overcome these problems, 
by protecting antigens from degradation and increase their biodistribution and ability to 
reach and be uptaken by APCs. 
Depending on their physicochemical characteristics, delivery systems can modulate 
the immune response, mainly due to direct influence in the following mechanisms: 
facilitated uptake by APCs, regulation of the internalization pathways and ability to 
endosomal escape, and interaction with specific receptors that mediate the immune 
response towards humoral or cellular bias. The main immunogenic properties of viruses 
that elicit potent immune responses may serve as a base for rational vaccine design 
[147]. 
Most studies are clear: size plays a crucial role in vaccine efficacy. Smaller particles tend 
to be more immunogenic due to their easier uptake by DCs and more efficient transport 
in the lymphatic system, where they can reach immature DC subsets; still, microparticles 
can form stable antigen depots and are more suitable for intranasal or inhalable 
pulmonary vaccination [1]. Recent studies have suggested that smaller particles mostly 
induce cellular immunity while larger particles tend to induce humoral responses [1, 36]. 
Other important factors include release kinetics; surface characteristics; concomitant 
delivery of antigen and immunostimulants, allowing DCs to associate danger signals 
with the antigen, while co-encapsulation of multiple TLRLs may result in a synergistic 
effect; coating or coupling of DC-specific targeting moieties, increasing DC uptake and 
enhancing antigen presentation to T cells. Future developments in vaccine delivery will 
likely involve the combination of immunostimulants with delivery vehicles modified with 
DC-specific targeting ligands/antibodies.
In summary, vaccines that mimic the size, charge, release kinetics and PAMPs of 
pathogens may be the future of peptide-based immunotherapy of cancer and/or other 
diseases that cannot be treated by conventional vaccines.
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Poly(lactic-co-glycolic acid) (PLGA) particles have been extensively studied as 
biodegradable delivery system to improve the potency and safety of protein-based 
vaccines. In this study we analyzed how the size of PLGA particles, and hence their ability 
to be engulfed by dendritic cells (DC), affects the type and magnitude of the immune 
response in comparison to sustained release from a local depot. PLGA microparticles 
(MP, volume mean diameter ≈ 112 μm) and nanoparticles (NP, Z-average diameter ≈ 
350 nm) co-encapsulating ovalbumin (OVA) and poly(I:C), with comparable antigen (Ag) 
release characteristics, were prepared and characterized. The immunogenicity of these 
two distinct particulate vaccines was evaluated in vitro and in vivo. NP were efficiently 
taken up by DC and greatly facilitated MHC I Ag presentation in vitro, whereas DC 
cultured in the presence of MP failed to internalize significant amounts of Ag and hardly 
showed MHC I Ag presentation. Vaccination of mice with NP resulted in significantly 
better priming of Ag-specific CD8+ T cells compared to MP and OVA emulsified with 
incomplete Freund’s adjuvant (IFA). Moreover, NP induced a balanced TH1/TH2-type 
antibody response, compared to vaccinations with IFA which stimulated a predominant 
TH2-type response, whereas MP failed to increase antibody titers. In conclusion, we 
postulate that particle internalization is of crucial importance and therefore particulate 
vaccines should be formulated in the nano- but not micro-size range to achieve efficient 
uptake, significant MHC class I cross-presentation and effective T and B cell responses.
Keywords: Protein antigen, PLGA, microparticles, nanoparticles, adjuvants, 
immunotherapy, cellular immune response
1. Introduction
In the past few years, extensive efforts in the immunotherapy field have led to the 
development of several therapeutic vaccine strategies [1-3]. Protein vaccines are 
popular forms of therapeutic vaccines [3, 4] which have been tested successfully in (pre-)
clinical studies against various immunological diseases [5, 6]. The potency of protein 
vaccines can be significantly amplified via the encapsulation in biodegradable particles. 
The use of particles facilitates the uptake of the antigen (Ag) by dendritic cells (DC), 
allows the co-delivery of Ag and Toll-like receptor ligands (TLRL) [7, 8] and improves 
Ag processing, presentation and T cell priming by DC compared to use of soluble Ag. 
Generally, particulate Ag is better routed into MHC class I cross-presentation pathways 
and preserved inside intracellular compartments, resulting in sustained and  efficient 
priming of CD8+ T cell responses [9-13]. DC have superior capacity to cross-present 
exogenous Ag in MHC I molecules and are considered the major target for vaccines 
aimed at activating a robust CD8+ T cell mediated immunity [3, 14]
 
Most clinical trials for cancer immunotherapy have relied on the use of Montanide, a 
GMP-grade version of incomplete Freund’s adjuvant (IFA), which is a water-in-oil (w/o) 
emulsion for Ag delivery. The immune-activating properties of Montanide are partially 
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explained through the formation of a local Ag depot and the onset of inflammation, 
which attracts immune cells towards the site of injection [15] where the Ag is taken 
up primarily in its soluble form [16]. However, the use of Montanide is associated with 
significant local adverse effects [5], reason why there is an urgent need for alternatives 
[17].
Nanoparticles (NP) and microparticles (MP) prepared from biodegradable poly(L-lactic-
co-glycolic acid) (PLGA) have been studied extensively for the sustained delivery of 
proteins and therapeutic agents and as an potential alternative to w/o emulsions [18-
20]. Plain PLGA particles have sub-optimal adjuvant properties in vivo resulting in poor 
DC maturation [9, 21], which can be overcome by the inclusion of TLRL, leading to 
an efficient  induction of TH1-mediated T cell responses with the capacity to control 
tumors or protect against a viral challenge [7, 22-25]. 
It is generally assumed that NP, compared to MP, are better for targeted drug delivery 
due to a better biodistribution [26, 27] and ability to cross biological barriers [28]. Still, 
there is little agreement when it comes to therapeutic vaccines: which size leads to the 
most efficient MHC class I Ag cross-presentation remains controversial [29-31]. 
To study the importance of particle uptake for the induction of an immune response, we 
developed NP and MP containing equivalent amounts of Ag and TLRL with comparable 
release profiles in vitro. Particles co-encapsulating model Ag ovalbumin (OVA) and 
TLR3L poly(I:C) were formulated to obtain NP that will be efficiently internalized by DC 
[32], releasing the Ag mostly intracellularly [12], versus MP with a size (> 20 μm) that is 
too large to be taken up by DC [31], thus functioning exclusively as a local Ag/TLR3L 
depot under the skin, similarly to Montanide.
2. Materials and Methods
2.1. Reagents
PLGA Resomer RG502H (50:50 MW 5,000–15,000 Da) was purchased from Boehringer 
Ingelheim (Ingelheim am Rhein, Germany); PLGA Resomer RG752H (75:25 MW 
4,000-15,000 Da), Dichloromethane (DCM), dimethyl sulfoxide (DMSO), and Hepes 
from Sigma–Aldrich (Steinheim, Germany); Ovalbumin (OVA) grade V, 44 kDa from 
Worthington (New Jersey, USA); Alexa Fluor 488 (AF488) labeled OVA from Invitrogen 
(Merelbeke, Belgium); Tween 20 from Merck Schuchardt (Hohenbrunn, Germany); 
polyvinyl alcohol (PVA) 4 – 88 (31 kDa) from Fluka (Steinheim, Germany); Poly(I:C) LMW 
and rhodamine labeled poly(I:C) from InvivoGen (San Diego, USA); Phosphate-buffered 
saline (NaCl 8.2 g/L; Na2HPO4.12 H2O 3.1 g/L; NaH2PO4.2H2O 0.3 g/L) (PBS) from B. 
Braun (Melsungen, Germany); all fluorescently labeled antibodies from BD Pharmingen 
(San Diego, USA); incomplete Freund’s adjuvant (IFA) from Difco Laboratories (Detroit, 
USA). APC-SIINFEKL/H2-Kb tetramers, SIINFEKL (OVA8) and ASNENMETM (FLU9) 
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and carboxyfluorescein succinimidyl ester (CFSE)-labeled synthetic short peptides 
were produced in house. All other chemicals were of analytical grade and aqueous 
solutions prepared with Milli-Q water. 
2.2. Cells
D1 cells, a murine GM-CSF dependent immature dendritic cell line, were cultured as 
described previously [33]. Bone-marrow derived DC (BMDC) were freshly isolated from 
femurs from mice and cultured as published previously [34] and yielded cells which 
were at least 90% positive for murine DC marker CD11c. B3Z CD8+ T-cell hybridoma 
cell line, specific for the H-2Kb-restricted OVA257–264 CTL epitope SIINFEKL was 
cultured as described before [35].
2.3. Animals
C57BL/6 (Ly5.2/CD45.2; H-2b) mice were obtained from Charles River Laboratories. 
Ly5.1/CD45.1 congenic (C57BL/6 background) mice were bred in the specific pathogen-
free animal facility of the Leiden University Medical Center. All animal experiments were 
approved by the animal experimental committee of Leiden University. 
2.4. Preparation and characterization of OVA- and poly(I:C)-
loaded PLGA particles
2.4.1. Preparation of NP and MP and IFA
PLGA 50:50 and PLGA 75:25 NP were prepared as described [36], using 1 mg OVA, 
0.25 mg poly(I:C) and 1 µg poly(I:C)-rhodamine dissolved in 85 µl of 25 mM Hepes, pH 
7.4, as inner aqueous phase. For NP and MP used in the release and uptake studies, 
1% (w/w total OVA) of OVA-AF488 was added to the inner phase during preparation 
for detection purposes. 
PLGA 50:50 MP were prepared by adding 1 mg OVA, 0.25 mg poly(I:C), and 1 
µg poly(I:C)-rhodamine dissolved in 500 µl of 25 mM Hepes pH 7.4 to 1 ml DCM 
containing 125 mg PLGA 50:50. The mixture was homogenized for 30 s at 25,000 rpm 
(Heidolph Ultrax 900, Sigma, Germany) and transferred to 10 ml of 2% (w/v) PVA under 
magnetic stirring for 10 min at 750 rpm at room temperature, followed by 1 hour at 
500 rpm at 40ºC to allow evaporation of DCM. MP were harvested and washed twice 
by centrifugation (2000 g, 2 min). To separate particles bigger than 20 µm, MP were 
diafiltrated with 3 L water under continuous stirring, using a Solvent Resistant Stirred 
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Cell (Milipore, USA) filtration system with a 20-µm stainless steel sieve (Advantech, 
USA), the retentate collected and particles recovered by centrifugation at 2000 g for 2 
min. Particles >200 µm were eliminated by filtration through a 200-µm stainless steel 
sieve (Advantech, USA). Intactness of MP before and after filtration (see Supplemental 
Figure 1) was verified with an Axioskop microscope, equipped with Axiocam ICc 5 
(Carl Zeiss, Munich, Germany) and 20x amplification objective. Images were collected 
with ProgRes CapturePro v2.8.8 software (Jenoptik AG, Jena, Germany). Both NP and 
MP suspensions were aliquoted and freeze-dried. 
Preparation of IFA emulsion was performed by dissolving OVA and poly(I:C) in PBS and 
mixing with IFA for 30 min in a 1:1 ratio by using a vortex mixer.
2.4.2. Characterization of NP and MP
Size and polydispersity index (PDI) of NP in 5 mM Hepes pH 7.4 were determined by 
dynamic light scattering (DLS) using a NanoSizer ZS (Malvern Instruments, Malvern, 
UK). Zeta potential (ZP) was determined by laser Doppler velocimetry using the same 
apparatus. Size distribution of MP was determined by light obscuration (LO) using a 
PAMAS SVSS system (PAMAS GmbH, Rutesheim, Germany) equipped with HCB-
LD-25/25 sensor and 1-ml syringe. Each sample was measured three times, each 
measurement consisting of three runs of 0.2 ml at a flow rate of 10 ml/min. 
Encapsulation efficiency (EE) was calculated by fluorescence of OVA-AF488 (excitation 
495 nm, emission 520 nm) or poly(I:C)-rhodamine (excitation 546 nm, emission 576 nm) 
detected in the supernatant with Infinite® M 1000 Pro (Tecan, Switzerland) microplate 
reader. 
To study release kinetics NP/MP containing fluorescently labeled OVA and poly(I:C) 
were resuspended in PBS, containing 0.01% Tween 20 and 0.01% sodium azide, at 
10 mg PLGA/ml, and maintained at 37ºC under tangential shaking at 100 rpm in a GFL 
1086 shaking water bath (Burgwedel, Germany) for 30 days. At regular time intervals, 
250 µl aliquots were taken and centrifuged for 20 min at 18000 g. Supernatants 
were stored at 4ºC until fluorescence intensity was determined (Infinite® M 1000 
Pro, Tecan, Switzerland) [37]. OVA concentrations on remaining supernatant samples 
from the final day were also analyzed by BCA assay (Pierce, Rockford, IL, USA) after 
dissolving particles in DMSO and 0.5 M NaOH + 0.5% SDS as described [38] to validate 
fluorescence measurements, with comparable results (Supplemental Table 1).
2.5. Analysis of particle uptake by DC
Particle uptake by DC was determined by plating out D1 cells in 96-well plates (105 
cells/well) and pre-cooling on ice (10 min). Pre-cooled cells were cultured for 1 h at 
4ºC (on ice) or at 37ºC in the presence of PLGA particles containing OVA-AF488. After 
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incubation, cultured cells were washed and centrifuged twice with cold saline buffer 
to remove unbound particles and cells fixed with 4% paraformaldehyde (100 μl/well). 
Fixation was blocked by addition of 100 μl/well fetal calf serum (FCS) and washing 
with cold PBS. Cells were kept at room temperature and stained with rat anti-mouse 
CD45.2-APC fluorescent antibodies to allow detection of cells positive for particle 
association, based on OVA-AF488 fluorescence (excitation 495 nm, emission 520 nm) 
as analyzed using a BD LSRII flow cytometer. Data were acquired using the BD FACS 
DIVA software and analyzed with Flow Jo software (treestar).
2.6. MHC class I Ag presentation
DC were incubated for 2 h with PLGA-OVA formulations at the indicated concentrations, 
washed and followed by an overnight incubation (37ºC) in the presence of B3Z CD8+ T 
cell hybridomas to measure MHC class I presentation as described previously [39]. To 
determine the relative maximum B3Z T cell activation, DC were loaded with the minimal 
epitope SIINFEKL and the extinction value set as 100% (OD590nm = 2.53 = 100%).
2.7. Vaccination studies
Animals were vaccinated with PLGA-OVA/poly(I:C) formulations, soluble OVA/poly(I:C) 
in PBS, or OVA/poly(I:C) emulsified in IFA by s.c. injection into the right flank on day 
0 and day 28. Priming of cytotoxic CD8+ T cells was assessed seven days after the 
1st and 14 days after the 2nd vaccination by transferring splenocytes prepared from 
congenic Ly5.1 C57BL/6 animals which were pulsed with SIINFEKL (OVA8, vaccine 
specific  target cells) or ASNENMETM (FLU9, vaccine non-specific control target cells). 
Target cells were labeled with either 10 μM OVA8- or 0.5 μM FLU9-CFSE. Cells were 
mixed 1:1 and 107 total cells were injected intravenously into the vaccinated animals. 
18 h later, animals were sacrificed and single cell suspensions were prepared from 
isolated spleens [9]. Injected target cells were distinguished by APC-conjugated rat 
anti-mouse CD45.1 mAb (BD Pharmingen, San Diego, USA). In vivo cytotoxicity was 
determined by flow cytometry after 18 h using equation 1:
(1)
OVA-specific CD8+ T cells present in the spleens were analyzed by co-staining with 
APC-conjugated SIINFEKL/H2-Kb tetramers, AF488-conjugated anti-mouse CD8α 
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mAb and V500-conjugated rat anti-mouse CD3 mAb. Flow cytometry was performed 
as described above.
2.8. Detection of antibody responses
Antibody responses were determined by collecting serum samples on day 21 (1 week 
before 2nd vaccination) and on day 35 (1 week after 2nd vaccination). IgG1, IgG2a and 
IgG2b titers against OVA were determined by ELISA. In brief, high absorbent 96-wells 
Nunc immunoplates were coated with 5 μg/ml OVA in PBS and incubated with titrated 
serum samples in 10% FCS in PBS. Antibodies were detected using streptavidine 
conjugated rabbit anti-murine IgG1, IgG2a and IgG2b mAb, followed by addition of 
horse-radish-peroxidase conjugated biotin. 3,3’,5,5’-Tetramethylbenzidine (TMB) was 
used as a substrate and the color conversion was stopped after 10 min with 0.16 M 
H2SO4, which was then measured on a spectrophotometer by absorbance at 450 nm 
(OD450nm). To determine immune polarization the IgG2a/IgG1 ratios were determined 
using OD450nm values determined at 1:100 dilution if values applied were ≥ 2-fold 
OD450nm of the negative control (sera from non-immunized mice).
3. Results and Discussion
Particulate vaccines are promising modalities as the immune system reacts more 
vigorously to vaccines presented in a particulate form compared to soluble ones [9, 10]. 
However, the exact parameters needed to achieve robust immune responses against 
particulate vaccines are still a matter of debate [29-31]. This may be related to different 
parameters that can direct the type and potency of the immune response [40, 41], 
such as the route of administration upon vaccination and Ag release kinetics [27, 42, 
43]. The latter is critical as sustained Ag release is essential to properly stimulate DC 
[44]. We have recently shown that low-burst release of encapsulated Ag is crucial for 
efficient MHC class I Ag presentation and CD8+ T cell activation [39]. Of importance, 
there exists a strong correlation between (particle) size and the efficiency of Ag uptake, 
processing and presentation by APC [29, 32, 42].
APC may take up and process Ag with similar dimensions to pathogens, such as viruses 
and bacteria, with the size influencing the mechanisms of uptake and processing by 
APC [45]. It has been reported that particles in the range of 20-200 nm are efficiently 
taken up by DC and facilitate the induction of cellular immune responses, whereas 
particles of 0.5-5 µm mainly generate humoral responses; limited uptake of 10 µm 
or larger particles was observed, leading to defective immune activation [29, 31, 46]. 
Also, nano-sized particles supported DC maturation by TLR9 triggering in contrast 
to micro-sized particles [31]. These studies suggest that the efficient internalization 
of particles significantly dictates the ensuing vaccine induced immune response. In 
contrast, others have reported that vaccinations with MP also induce CTL responses, 
comparable to IFA- or Montanide-based delivery systems [17, 47].
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Using PLGA particles co-encapsulating protein Ag and a TLR3L, we compared NP 
(which can be engulfed by DC) with > 20-μm MP (which are too large to be taken up) 
for their capacity to induce MHC class I cross-presentation in vitro and improve immune 
responses in vivo. To study the effect of particle uptake on the subsequent immune 
response, we designed NP and MP of similar compositions and with similar release 
properties. So, we engineered MP (PLGA 50:50) to match the release properties of 
NP by adding salt to the inner water phase to increase porosity and accelerate drug 
diffusion and release (see Supplemental Figure 2 for inner phase compositions) [48-
51]. MP were also diafiltrated to eliminate particles smaller than 20 µm that could be 
internalized by DC, as well as particles larger than 200 µm, and size distribution before 
and after filtration was determined (Supplemental Table 2 & Supplemental Figure 
3). Number-based mean-diameter of MP increased from 5±1 µm before filtration (BF) 
to 17±5 µm after filtration (AF), showing that the filtration step effectively decreased the 
number of particles smaller than 20 µm. Importantly, volume-based mean-diameters 
indicate that less than 1% of the total volume, and consequently less than 1% of the 
OVA content, corresponded to particles smaller than 20 µm, making it unlikely that 
residual particles <20 µm would have a significant effect on Ag uptake, MHC class 
I Ag presentation and CD8+ T cell activation. Physicochemical characterization of all 
formulations was done in terms of encapsulation efficiency (EE), drug loading (DL), size, 
PDI and ZP as summarized in Table 1 (for NP size distributions see Supplemental 
Figure 4).
Table 1: Physical characteristics of OVA/poly(I:C)-loaded PLGA NP and MP in terms 
of size (Z-average obtained by DLS for NP; and number (n) and volume (v) average 





EE (%) DL (%) EE (%) DL (%)
NP 50: 50 357 ± 25 nm 0.16 ± 0.03 -41 ± 7 52 ± 7 2.01 ± 0.27 66 ± 8 0.63 ± 0.07
NP 75: 25 400 ± 16 nm 0.25 ± 0.02 -25 ± 3 75 ± 1 2.87 ± 0.03 59 ± 7 0.56 ± 0.07
MP 50: 50
17 ± 5 µm (n)
112 ± 26 µm (v)
n/a -14 ± 3 86 ± 2 0.68 ± 0.01 81 ± 2 0.16 ± 0.00
* Values represent mean +/- standard deviation of 3 independently prepared batches 
PDI: polydispersity index; ZP: Zeta-potential; EE: encapsulation efficiency; DL: drug loading.
As release studies showed faster Ag and TLR3L release from NP 50:50 compared to 
MP 50:50, NP were also prepared with PLGA 75:25, which is more hydrophobic and 
therefore degrades slower, to achieve particles comparable in size to NP 50:50 and 
closer in release kinetics to MP 50:50. Release studies showed sustained release over 
30 days (Figure 1) with NP 75:25 exhibiting similar long-term release characteristics 
to MP, but remaining closer to NP 50:50 in the early stages (<10 days), due to higher 
burst release. These profiles contrast with a  previous study by Joshi et al. (2013) where 
drastic differences in release kinetics were observed: whereas the initial (burst) release 
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accounted for nearly total Ag and TLRL release from 300-nm NP, the release from MP 
with a size of about 17 μm was only 10% after 15 days [31]. Besides the difference in 
size, this could have contributed to the distinct immunological properties of their NP 
and MP formulations.
Figure 1: In vitro release kinetics of OVA and poly(I:C) from NP and MP. OVA (closed circles) 
and poly(I:C) (closed squares) release in PBS/0.01% Tween-20/0.01% NaN3 (pH 7.4) of A) NP 
50:50, B) NP 75:25, and C) MP 50:50 were monitored for 30 days at 37°C. Data are presented 
as average ± SD of 3 independent batches.
Efficiency of particle association with DC was studied by culturing DC in the presence of 
the 3 different particle formulations at 4ºC (binding) and 37ºC (binding & internalization) 
with various concentrations of encapsulated Ag. DC showed very high capacity to bind 
and internalize NP compared to MP (Figure 2A), and we observed consistently that 
both NP 50:50 and 75:25 were engulfed with higher efficiency than MP (Figure 2B & 
C). In line with these results, we have recently shown that NP are internalized by CD11c+ 
DC in vivo at the site of injection [52]. Internalized NP function as an intracellular Ag 
depot gradually releasing the encapsulated Ag into MHC class I processing and cross 
presentation pathways, leading to sustained intracellular release [12, 53]. 
In contrast, MP are poorly internalized, likely because of their large size at the early 
phases of PLGA degradation, releasing the encapsulated Ag and TLRL locally via an 
initial burst followed by a more gradual release due to polymer hydrolysis (Figure 1). 
Consequently, MP essentially deliver soluble Ag and TLRL to DC and function as a local 
Ag depot under the skin at the site of injection. We and others have previously shown 
that DC poorly cross-present protein Ag when it is delivered in soluble form [9, 10]. 
Therefore, if the aim is to induce a robust CD8+ T cell response through vaccination, 
micron-sized particulate vaccines might not be the right candidates. 
MHC class I Ag cross-presentation by DC of OVA encapsulated in NP or in MP was 
studied in vitro. Soluble OVA is poorly cross-presented in MHC class I processing 
routes, unless very high amounts are added to DC cultures [9].  We observed that NP 
performed 8 - 10 fold better compared to MP in routing Ag into MHC class I processing 
pathways, whereas NP 50:50 and NP 75:25 showed similar efficiency, possibly due to 
the similar release kinetics at early time-points (Figure 3A). CD8+ T cell activation was 
calculated relative to that induced by 5 nM SIINFEKL as 100%, and no Ag as baseline 
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(see Figure 3B for raw data). Our observations are supported by the report of Joshi et 
al., who observed that the efficiency of particle uptake and upregulation of MHC class I 
and CD86 expression on BMDC was correlated with small particle size [31].
Figure2: Binding and uptake of NP-encapsulated protein Ag by dendritic cells compared 
to MP-encapsulated Ag. A) D1 dendritic cells cells were incubated for 1 h with titrated 
amounts (µM) of OVA (and poly(I:C)) encapsulated in NP 50:50, NP 75:25 and MP 50:50 also 
containing OVA-AF488 dye. Ag incubation with DC was performed in parallel at B) 4ºC (binding) 
and C) 37ºC (binding & internalization), followed by extensive washing to remove unbound Ag 
and cell fixation with 4% paraformaldehyde. Cells were analyzed by flow cytometry to determine 
green fluorescence. Percentages of DC positive for OVA-AF488 were quantified at different Ag 
concentrations. Data shown are measurements from one experiment. 
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Figure3: Efficient MHC class I cross-presentation of protein Ag incorporated in NP but 
not MP.  A) D1 cells were pulsed for 2 h with titrated amounts (nM) of OVA (and poly(I:C)) 
encapsulated in NP 50:50,  NP 75:25 or MP 50:50. MHC class I presentation of processed OVA 
protein antigen was detected by co-culture with H-2Kb/SIINFEKL-specific B3Z CD8+ T cells. 
Normalized values in panel A were calculated based on the OD590nm values obtained by using 
DC loaded with SIINFEKL cultured together with B3Z CD8+ T cells (OD590nm = 2.53 = 100% 
CD8+ T cell activation). B) OD590nm values obtained with the highest concentration of OVA (250 
nM) (and poly(I:C)) encapsulated NP 50:50, NP 75:25, MP 50:50 or SIINFEKL (5 nM, known 
to result in maximal CD8+ T cell activation in this assay). Data shown are means of triplicate 
measurements ± SD as % from one representative example out of at least three independent 
experiments. 
We subsequently analyzed whether the enhanced MHC class I presentation observed 
in vitro would translate into better CD8+ T cell priming in vivo. For this purpose, we 
vaccinated animals with NP and MP formulations encapsulating OVA and Poly(I:C) or 
Ag and adjuvant formulated in IFA. Mice were sacrificed 7 days later to determine the 
number of Ag-specific CD8+ T cells in the spleen. Since NP 50:50 showed similar 
CD8+ T cell priming in vivo as NP 75:25 (data not shown), the ensuing in vivo studies 
comparing NP and MP were performed based on particle formulations using the same 
polymer composition (PLGA 50:50).
The in vivo vaccine potency of NP and MP formulations was analyzed in comparison to 
IFA. It is well known that plain PLGA particles have poor immune-activating properties: 
the absence of TLRL in PLGA-based vaccine protocols results in defective immune 
activation [8, 24, 54]. For that reason poly(I:C) was co-encapsulated with the Ag in our 
particles to achieve a strong activation of DC and promote the production of IL-12 [9]. 
Vaccinations with NP led to considerably higher numbers of Ag-specific CD8+ T cells 
compared to MP (p = 0.01) and IFA (p = 0.04), with almost no difference being observed 
between vaccination with MP and non-vaccinated mice (Figure 4). NP also performed 
better than IFA, suggesting that internalization of the particles may be of importance in 
inducing a stronger cellular immune response in comparison to sustained release from 




Analysis of cytokine production showed that vaccination with NP resulted in the highest 
production of IFN-γ (Supplemental Figure 5) but did not induce much IL-2 (data not 
shown). Under these conditions we also analyzed the CD8+ T cell in vivo cytotoxicity. In 
line with the relatively higher number of specific CD8+ T cells induced with NP, animals 
vaccinated with NP showed effective OVA-specific cytotoxicity in vivo (Supplemental 
Figure 6). 
Figure 4: NP vaccine shows effective CD8+ T cell priming potency. Naïve animals received 
a single s.c. vaccination with the 50 μg OVA and 20 μg poly(I:C) formulated in NP 50:50 (closed 
triangles), MP 50:50 (open squares) or in IFA (closed circles). Non-vaccinated animals were 
used as control (open triangles). Mice were sacrificed on day 7 after vaccination and the % of 
SIINFEKL-TM+ CD8+ T cells were measured by flow cytometry. Results shown are representative 
of one experiment out of two and present averages ± SEM from n = 3 - 5 mice per group, * = p 
< 0.05 and ** = p < 0.01 using an unpaired student t test in relation to the group immunized with 
NP 50:50. Each symbol represents the specific T cell response in an individual mouse.
Co-encapsulation of OVA and TLRL has previously shown to induce anti-OVA (IgG) 
humoral responses, as well as polarization of the immune response [24, 37, 55]. Blood 
samples were collected on day 21 or 35 after vaccination and titers of IgG1, IgG2a and 
IgG2b antibodies were determined. NP and IFA, but not MP, induced IgG1 production 
and low titers of IgG2a and IgG2b after single vaccination (prime) (Figure 5A & B & C). 
A second vaccination (boost) considerably enhanced the IgG1 titers for IFA and NP, but 
again not MP (Figure 5D). Significant IgG2a titers were induced after boost with NP but 
poorly by the other vaccines (Figure 5E). IgG2b titers were induced to a similar level by 
vaccinations with IFA and NP (Figure 5F). 
IgG2a is the IgG-subtype associated with TH1 responses in mice and analysis of the 
IgG1/IgG2a ratio allows one to determine the immune-polarization [56]. Vaccinations 
with NP resulted in a more balanced TH1/TH2 antibody response characterized by 
similar titers of IgG1 and IgG2a (IgG1/IgG2a ≈ 1). 
95
























































































































































































































































































































































































































































































































In contrast, vaccinations with IFA led to a predominant TH2 response (IgG1/IgG2a > 2) 
(Figure 5G), which might contribute to the differences in CD8+ T cell responses detected 
after vaccinations. A predominant humoral TH2 response will likely be accompanied by 
a weak CD8+ T cell response [57]. The higher production of IgG2a after vaccination 
is linked to the increased uptake by DC of particles encapsulating the protein and 
adjuvant [31], compared to soluble protein and poly(I:C). In addition, direct stimulation 
of B cells by the NP might also contribute better IgG2a responses compared to IFA-
based vaccine formulations [21, 58].
PLGA MP are reported to have a negative effect on protein structural integrity, leading 
to denaturation and aggregation [59]. Differences in Ag integrity of OVA in NP compared 
to OVA in MP might also play a role in the immune responses we report here, since a 
larger and deeper inner core of MP likely results in more extensive local acidification as 
compared to the much smaller NP [60]. However, release of denatured OVA from MP 
should induce at least equal but probably stronger in vivo T cell [61] and B cell responses 
[62, 63] compared to native OVA. In support of this we have shown that proteolytic 
cleavage of whole proteins into smaller peptide strands improves the activation of T 
cells by human DC [64]. Still, we cannot exclude that the inability of MPs to induce 
antibodies cross-reacting with native OVA may be due in part to a more dramatic loss 
of protein structure compared to the NP. 
4. Conclusions
Our results show that the ability of DC to internalize Ag- and TLRL-containing PLGA 
particles is a crucial factor to achieve effective MHC class I cross-presentation, prime 
CD8+ T cells and to elicit both a T and B cell response after direct vaccinations. We 
report here that NP are more efficiently internalized by DC in vitro, resulting in superior 
vaccine potency compared to MP when aiming to stimulate cellular immune responses. 
Furthermore, NP co-encapsulating Ag and TLRL outperformed IFA as an adjuvant, by 
more efficiently boosting CD8+ T cell activation and (IgG2a) antibody production. In 
conclusion, because of the superior responses induced in comparison to IFA, our data 
supports the application of biodegradable PLGA NP delivery systems as a substitute 
for mineral oil emulsions for protein vaccine-based immunotherapy.
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Supplemental Table 1: Protein concentration of sample from the last day of release study (day 
40). Protein concentration was measured by BCA assay and by fluorescence in supernatants 
(SN) and expressed as percentage of total encapsulated OVA.
Particles BCA Assay (% in SN) Fluorescence (% in SN)
NP 50:50 82 ± 14 85 ±14
NP 75:25 53 ± 10 52 ± 9
MP 50:50 48 ± 10 40 ± 3
Supplemental Table 2: Distribution of MP diameters (µm) determined by LO before (BF) and 
after filtration (AF) in terms of percentage of total number and volume. Mean values are presented 
in the last row.
% Number % Volume
Diameter (μm) BF AF BF AF
1-2 33.2 ± 6.7 39.0  ± 11.0 0.0  ± 0.0 0.0  ± 0.0
2-5 38.6 ± 7.1 16.9  ± 2.9 0.5  ± 0.3 0.0  ± 0.0
5-10 21.2 ± 3.0 10.5  ± 5.4 2.4  ± 1.4 0.1  ± 0.1
10-15 3.7 ± 2.1 4.3  ± 3.2 1.7  ± 1.2 0.1  ± 0.1
15-20 1.3 ± 1.0 4.0  ± 3.1 1.4  ± 1.1 0.4  ± 0.3
20-25 0.6 ± 0.6 4.1  ± 2.7 1.1  ± 0.8 0.8  ± 0.7
25-30 0.3 ± 0.4 3.2  ± 1.7 1.2  ± 0.9 1.2  ± 0.9
30-40 0.4 ± 0.5 4.8  ± 0.1 2.3  ± 1.4 3.2  ± 2.1
40-50 0.2 ± 0.2 3.4  ± 0.6 2.7  ± 0.9 5.0  ± 3.5
50-60 0.1 ± 0.1 2.4  ± 0.3 2.5  ± 1.4 5.9  ± 3.8
60-75 0.1 ± 0.1 2.2  ± 0.3 6.0  ± 1.9 10.6  ± 7.6
75-100 0.2 ± 0.2 2.4  ± 1.2 17.1  ± 3.7 19.3  ± 8.5
100-125 0.1 ± 0.1 1.4  ± 1.5 20.4  ± 4.3 15.3  ± 2.7
125-150 0.0 ± 0.0 0.6  ± 0.8 11.8  ± 5.7 10.0  ± 5.9
150-200 0.0 ± 0.0 0.8  ± 1.1 29.0  ± 17.1 28.2  ± 18.1
Mean diameter 5 ± 1.0 17 ± 5.0 114 ± 16.0 112 ± 26.0
B
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Supplemental Figure 1: Representative images of MP preparations analyzed by optical 
microscopy (20x magnification) before and after stirred-cell filtration. 
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Supplemental Figure 2: OVA release after filtration (AF) and before filtration (BF) of MP with 
different inner phase composition using PLGA 50:50 observed for 15 days. Hepes 50 µl (BF) 
(open diamonds) corresponds to an inner phase of 50 µl of 20 mg/ml OVA solution in 25 mM 
Hepes pH 7.4; and Water 500 µl (BF) (open triangles) to an inner phase of 500 µl of 2 mg/ml OVA 
in water. Hepes 500 µl (BF) (closed squares) and Hepes 500 µl (AF) (closed circles) correspond 
to an inner phase of 500 µl of 2 mg/ml OVA in 25 mM Hepes pH 7.4, before and after stirred-cell 
filtration, respectively. Data presented correspond to 1 batch. 
Supplemental Figure 3: Size distribution of MP before filtration (BF) and after filtration (AF) 
determined by light obscuration. A) Number distribution. B) Volume distribution. Data are 
presented as average ± standard deviation of n=3 independent batches.
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Supplemental Figure 4: Intensity-weighted size distribution of NP determined by DLS. A) NP 




Supplemental Figure 5: IFN-γ production after vaccination with NP. Animals were vaccinated 
with 50 μg OVA and 20 μg poly(I:C) formulated in NP 50:50, MP 50:50 or in IFA. A) Mice 
were sacrificed on day 7 post-vaccination, spleens harvested and single cell suspensions re-
stimulated with 1 μM SIINFEKL (OVA8). 72 h later the amount of Ag-specific IFN-γ produced was 
determined by ELISA. B) Animals vaccinated twice (day 0 and 28) were sacrificed on day 42 and 
the ex vivo IFN-γ production analyzed 72 h later. Red dotted lines indicate average background 
production of cytokines in the absence of specific stimulation. 
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Supplemental Figure 6: PLGA-OVA/poly(I:C) NP induce cytotoxic CD8+ T cells in vivo. In vivo 
cytotoxic capacity of primed OVA-specific T cells were determined in animals which received 
a single s.c. vaccinations with the 50 μg OVA and 20 μg poly(I:C) formulated in NP 50:50 
(open circles) or IFA (asterisks), and in non-vaccinated mice (open diamonds). Vaccinated mice 
received CFSE-labeled OVA8 (specific) or FLU9 (control) short peptide loaded target cells (Ly5.1. 
splenocytes) 7 days after vaccination. Animals were sacrificed 18 hr later and the % target cells 
determined flow cytometry and calculated as described in M&M. Results shown are from one 
experiment and present averages ± SEM from n = 4 mice per group.
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Protein antigen (Ag)-based immunotherapies have the advantage to induce T cells with 
a potentially broad repertoire of specificities. However, soluble protein Ag is generally 
poorly cross-presented in MHC class I molecules and not efficient in inducing robust 
cytotoxic CD8+ T cell responses. In the present study, we have applied poly(lactic-co-
glycolic acid) (PLGA) nanoparticles (NP) which strongly improve protein Ag presentation 
by dendritic cells (DC) in the absence of additional TLR ligands or targeting devices. 
Protein Ag loaded DC were used as antigen presenting cells (APC) to stimulate T 
cells in vitro and subsequently analyzed in vivo for their anti-tumor effect via adoptive 
transfer, a treatment strategy widely studied in clinical trials as a therapy against 
various malignancies. In a direct comparison with soluble protein Ag, we show that DC 
presentation of protein encapsulated in plain PLGA-NP results in efficient activation of 
CD4+ and CD8+ T cells as reflected by high numbers of activated CD69+ and CD25+, 
interferon (IFN)-γ and interleukin (IL)-2-producing T cells. Adoptive transfer of PLGA-
NP-activated CD8+ T cells in tumor-bearing mice displayed good in vivo expansion 
capacity, potent Ag-specific cytotoxicity and IFN-γ cytokine production, resulting in 
curing mice with established tumors. We conclude that delivery of protein Ag through 
encapsulation in plain PLGA-NP is a very efficient and simple procedure to stimulate 
potent anti-tumor T cells.
Keywords: PLGA, OVA, Ag cross-presentation, Adoptive immunotherapy
Précis
This paper shows that DC loaded with protein encapsulated in biodegradable and 
clinically applied polymer particles efficiently activate CD8+ T cells in vitro which upon 
adoptive transfer in vivo show potent anti-tumor immune responses.
1. Introduction
The adaptive immune system plays a major role in anti-tumor control. Induction of 
a specific immune response against tumor-associated antigen (Ag) is a potential 
approach for targeted immunotherapy of cancer. The first step in the initiation of 
an effective anti-tumor response is the uptake of tumor-associated Ag by dendritic 
cells (DC) and their subsequent presentation to naïve T cells [1,2,3]. DC are highly 
efficient antigen presenting cells (APC) and play a central role in initiating and regulating 
adaptive immunity. DC internalize and process exogenous protein Ag and present 
processed peptide epitopes in the grooves of MHC class I and II molecules to prime 
CD8+ cytotoxic T cells (CTL) and CD4+ helper T (Th) cells, respectively [4]. CTL are 
capable of direct clearance of malignant cells [5]. Th cells have shown to be vital in CTL 
priming through CD40-CD40L interactions with DC [6,7]. In addition, activated Th cells 
secrete cytokines like IL-2 important for CTL proliferation [8,9]. 
Full-length protein Ag comprise all potential naturally occurring Th and CTL epitopes 
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and can be clinically applied irrespective of the patient’s HLA haplotype. For that 
reason, protein-based tumor-associated Ag is currently being applied in a variety of 
immunotherapeutic approaches against cancer [10,11]. However, recent studies have 
indicated that cross-presentation of protein Ag is an inefficient process leading to poor 
CTL responses [12,13]. Therefore, improving cross-presentation of protein Ag by DC is 
essential to further exploit cancer immunotherapy.
Nanoparticles (NP) prepared from the polymer poly(lactic-co-glycolic acid) (PLGA) are 
promising clinical grade carriers for improving Ag delivery to DC [14,15,16]. PLGA 
polymers were originally reported for their use as sutures and implants for surgery [17] 
and since then they have been applied for the preparation of particles for drug delivery 
purposes, including the delivery of anti-cancer agents [18,19,20]. Internalization of 
protein Ag-loaded PLGA particles by DC is very efficient, resulting in adequate MHC 
class I cross-presentation and CTL proliferation in vitro [21]. Despite highly efficient 
DC uptake and cross-presentation in vitro, experimental tumor models have shown 
that the therapeutic effect of PLGA particle-based protein vaccination in vivo is strictly 
dependent on co-encapsulation of Toll like receptor ligands (TLRL) [22]. The necessity for 
the addition of TLRL for in vivo responses is most likely related to observations showing 
that PLGA-polymers on their own exhibit poor DC or macrophage stimulatory capacity 
in comparison to TLR4L [23,24]. However TLRL are dispensable for T cell activation in 
vitro, as reported by two previous studies using biodegradable polymer based artificial 
APC as a method to stimulate T cells in vitro. Applying an elegant method to formulate 
artificial APC using PLGA, T cells were stimulated in vitro with efficient proliferative and 
cytokine producing capacity [25,26]. However, the in vivo effector functions of the in 
vitro stimulated T cells were not studied in those reports. 
In the present study, the intrinsic capacity of plain protein Ag-loaded PLGA-NP to 
induce anti-tumor effector T cells with potent functionality in vivo is reported. DC, the 
immune system’s natural and most potent APC, express known and yet unknown co-
stimulatory molecules and produce various cytokines vital for optimal T cell priming 
[27,28]. Using murine DC, we performed a detailed analysis of the ability of protein 
Ag-loaded PLGA-NP, lacking any additional TLRL or targeting moiety, to induce potent 
tumor-specific effector T cells. For this analysis, we have used a murine model for 
adoptive T cell transfer therapy, a treatment modality that has been successfully tested 
in various (pre-)clinical studies against various types of cancer [29,30]. In this murine 
adoptive T cell transfer therapy model, we show that protein Ag encapsulated in PLGA 
efficiently and rapidly induces highly activated specific effector CD8+ T cells with a type 
I cytokine profile that vigorously expand in vivo in tumor-bearing mice and have the 
potency to eradicate established aggressive tumors. 
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2. Materials and Methods
2.1. Cells
D1 cells, a GM-CSF dependent immature dendritic cell line derived from spleen of  WT 
C57BL/6 (H-2b) mice, were cultured as described previously [35]. Freshly isolated DC 
(BMDC) were cultured from mouse bone marrow (BM) cells by collecting femurs from 
WT C57BL/6 strain and cultured as published previously by our group [36]. After 10 
days of culture, large numbers of typical DC were obtained which were at least 90% 
positive for murine DC marker CD11c (data not shown). B3Z CD8+ T-cell hybridoma cell 
line, specific for the H-2Kb-restricted OVA257–264 CTL epitope SIINFEKL, expressing 
a β-galactosidase construct under the regulation of the NF-AT element from the IL-2 
promoter, was cultured as described before [37] OT-IIZ, a CD4+ T-cell hybridoma cell 
line, specific for the I-Ab-restricted OVA OVA323–339 Th epitope, expressing the same 
β-galactosidase construct, was produced in house. The weakly immunogenic and 
highly aggressive OVA-transfected B16 tumor cell line (B16-OVA), syngeneic to the 
C57BL/6 strain, was cultured as described [38].
2.2. Preparation and characterization of protein Ag-loaded 
PLGA-NP
PLGA-NP were prepared using 7-17 kDa PLGA 50:50 (Resomer RG502H, Boehringer 
Ingelheim, Ingelheim, Germany) by applying a modified “water-in-oil-in-water” solvent 
evaporation method as described [39]. In brief, 50 μl of 20 mg/ml pure, endotoxin-free 
ovalbumin (OVA, Worthington LS003048) dissolved in 25 mM Hepes buffer (pH 7.4) 
was emulsified with 1 ml of dichloromethane (DCM) containing 25 mg of PLGA with an 
ultrasonic processor for 15 s at 70 W (Branson Instruments, CT, USA). The secondary 
emulsion was prepared with 2 ml of 1% (w/v) polyvinyl alcohol (PVA) in water. The 
double emulsion was then transferred into 25 ml of a 0.3% (w/v) PVA solution, and 
stirred at 37 °C for 1 h, and the resulting NP were harvested and washed twice with 
Milli-Q water by centrifugation at 8000 g for 10 min. The NP suspension was aliquoted 
in cryovials and lyophilized for 24 h. Prior to use, lyophilized NP particle size distribution 
was determined by means of dynamic light scattering (DLS) using a NanoSizer ZS 
(Malvern Instruments, Malvern UK) after resuspension of the particles in Milli-Q water. 
The zeta potential of the particles was also measured with the NanoSizer ZS by laser 
Doppler velocimetry. The OVA content of the particles was determined with a BCA 
protein assay (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions, 
and encapsulation efficiency (%EE) was determined according to equation 1. 500 µg 
lyophilized PLGA-OVA were resuspended in 350 µl sterile MQ water and endotoxin 
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content were determined with Bacterial endotoxins methode D. Chromogenic kinetic 
method’ an assay according to European Pharmacopeia 2.6.14 seventh edition. 
(1)
2.2.1. In vitro release study of PLGA-encapsulated protein
For release studies, protein-loaded PLGA NP were prepared as described, but with the 
addition of 1% (w/w total OVA) of Ovalbumin-Alexa Fluor® 488 (PLGA-OVA-Alexa488) 
(Invitrogen). Encapsulation of OVA-Alexa488 proceeds with similar efficiency as the 
regular OVA with no dye conjugated (See Table 1). 
Table 1: PLGA-OVA NP characteristics














PLGA-OVA 274 ± 19 0.18 ± 0.02 -27 ± 1 25 ± 1 62 ± 2 0.03 ± 0.00
PLGA-OVA 
Alexa
338 ± 12 0.22 ± 0.10 -27 ± 5 20 ± 1 49 ± 4 0.03 ± 0.03
PLGA empty 311 ± 52 0.14 ± 0.06 -30 ± 7 n/a n/a n/a
PLGA-OVA-Alexa488 were resuspended in 1x PBS pH 7.4 at a concentration of 10 mg 
PLGA/ml and maintained at 37oC in a water bath under constant tangential shaking 
at 100 rpm in a GFL 1086 shaking water bath (Burgwedel, Germany). At regular 
time intervals, 250 µl samples of the suspension were taken, centrifuged for 20 min 
at 18,000×g and supernatants were stored at 4ºC until fluorescence intensity, was 
determined by fluorescence spectrometry (Tecan, Infinite M 1000). Concentration of 
OVA-Alexa488 in the supernatant was assessed against a calibration curve containing 
known concentrations of OVA-Alexa488. Protein release profiles were generated for 
each NP formulation in terms of cumulative antigen release (%) over time. Release was 




2.3. Enzyme-linked Immunosorbent Assay (ELISA)
DC (100,000/well) were plated into a 96-well round bottom plate and incubated for 
24 hr with titrated amounts of Ag. Supernatants were harvested and tested for IL-12 
p40 using an ELISA assay kit (BD OptEIA™ MOUSE IL-12 Cat. Nr 555165) following 
manufacturer’s instructions.
2.4. MHC class I or class II-restricted Ag presentation and T 
cell proliferation
DC were incubated for 24 h with soluble OVA (sOVA) or OVA encapsulated in PLGA-
NP (PLGA-OVA) at the indicated concentrations. Cells were washed followed by 
overnight incubation at 37 °C in the presence of either B3Z - to measure  MHC class I 
Ag presentation of SIINFEKL (OVA257-264) in H-2Kb - or OT-IIZ cells - to assess MHC 
class II Ag presentation of ISQAVHAAHAEINEAGR (OVA323-339) in I-Ab. A colorimetric 
assay using chlorophenol red-β-D-galactopyranoside (CPRG) as substrate was used 
to detect IL-2 induced lacZ activity. OVA-specific proliferation of naïve CD8+ and CD4+ 
T cells was performed by culturing OT-I or OT-II splenocytes in the presence of DC 
loaded with titrated amounts of PLGA-OVA or sOVA. After 24 h incubated cells were 
pulsed with [3H]-thymidine and cultured further overnight. Samples were then counted 
on a TopCountTM microplate scintillation counter (Packard Instrument Co., Meridan, 
CT, USA).
2.5. Analysis of T cell phenotype and T cell cytokine 
profile
DC were loaded for 24 h with 0.25 µM OVA in PLGA (PLGA-OVA) or soluble OVA 
(sOVA), washed extensively and used as APC to stimulate spleen suspensions from 
OT-I and OT-II mice. DC and splenocytes were co-cultured for 24 h in the presence of 
7.5 µg/ml Brefeldin A. Total cells were harvested, washed twice with PBA buffer (0.01 
M sodium phosphate, 0.15 M NaCl, 1% (w/v) BSA, and 0.01% (w/v) sodium azide) 
followed by staining with PerCP rat anti-mouse CD8α monoclonal antibodies (mAb) and 
AF-conjugated rat anti-mouse CD3 mAb. To assess T cell activation, cells were stained 
with FITC-conjugated rat anti-mouse CD69 mAb or PeCy7-conjugated rat anti-mouse 
CD25 mAb. To study the T cell cytokine profile, CD8+ T cells were stained as above and 
subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to 
the manufacturer’s instructions (BD Pharmingen). Intracellular IFN-γ in the T cells was 
stained with APC-conjugated rat anti-mouse IFN-γ. Similarly, IL-2 and IL-4 were stained 
using PE-conjugated rat anti-mouse IL-2, IL-4 respectively. TNF-α was stained with 
FITC-conjugated rat anti-mouse TNF-α mAb. All antibodies were purchased from BD 
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Pharmingen. Flow cytometry analysis was performed using a LSRII flow cytometer (BD 
Pharmingen) and analyzed with FlowJo software (Treestar). 
2.6. In vivo cytotoxicity
To obtain OVA-specific effector CD8+ T cells, single cell suspensions were prepared 
from spleen and lymph nodes of OT-I mice, washed twice and resuspended in IMDM 
supplemented with 10% (v/v) FCS. Whole single cell suspensions were cultured in 
6-wells plates with Ag (0.25 µM) loaded DC for 24 h at a ratio of 25:1. DC and splenocyte 
cultures were incubated for 24 hr at 37ºC. Purified CD8+ T cells were obtained by 
a negative selection protocol using the Mouse CD8 T Cell Lymphocyte Enrichment 
Set - DM (BD Biosciences) according to the manufacturer’s instructions. This protocol 
yielded CD8+ T cell purities of at least 90% (data not shown). 2.5 x 106 Purified CD8+ 
T cells were transferred to syngeneic WT C57BL/6 animals that were rested for 24 h 
after adoptive cell transfer. To obtain OVA-specific target cells, splenocytes from naïve 
congeneic C57BL/6 Ly5.1 mice were pulsed for 1 h with 1 µM of SIINFEKL-peptide 
and co-stained with 10 µM CFSE (CFSE-high) (Molecular Probes, Eugene, OR). As a 
negative control, 1 µM of the immunodominant ASNENMETM-peptide derived from 
the influenza virus nucleoprotein co-stained with 0.5 µM CFSE (CFSE-low) was used. 
Specific and non-specific target cells were mixed 1:1 and injected intravenously (i.v.; 
10 x 106 cells of each population). Eighteen hours after cells were transferred, mice 
were sacrificed and spleen cells were harvested to prepare single cell suspensions 
that were then subjected to flow cytometric analysis. Injected cells were distinguished 
by APC-conjugated rat anti-mouse CD45.1 mAb. The percentage specific killing was 
calculated as follow: 100 - ([(% SIINFEKL-peptide pulsed in treated/% ASNENMETM-
pulsed in treated)/(% SIINFEKL-peptide pulsed in non-treated/% ASNENMETM-pulsed 
in non-treated)] x 100).
2.7. Adoptive transfer OVA-specific T cells in B16-OVA tumor 
bearing and naïve mice
WT C57BL/6 mice were injected subcutaneously (s.c.) in the right flank with 2 x 
105 B16-OVA melanoma cells. Seven days after tumor injection, when tumors were 
palpable, mice were treated by intravenous infusion of 2.5 x 106 purified effector CD8+ 
T cells derived from OT-I mice, ex vivo stimulated for 24 h in the presence of DC loaded 
with either PLGA-OVA or sOVA. Tumor growth was measured 1 - 3 times a week and 
survival was monitored daily. Tumor size (mm2) was calculated by (length) × (width). 
Mice with tumor sizes that equaled or exceeded 140 mm2 were sacrificed. Tail vein 
blood samples were collected on day 10, 17 and 31 after CD8+ T cell transfer. Blood 
samples were prepared by erythrocyte lysis, followed by 2 washing steps with PBA 
buffer. Transferred CD8+ T cells were analyzed by co-staining with APC-conjugated rat 
anti-mouse Thy1.1 mAb, FITC-conjugated anti-mouse CD8α mAb and AF-conjugated 
rat anti-mouse CD3 mAb in combination with APC-Cy7-conjugated anti-mouse CD44 
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antibody and PB-conjugated anti-mouse CD62L antibody.  OVA-specific CD8+ T cell 
mediated cytokine production was detected by overnight stimulation of peripheral 
blood cells with SIINFEKL-peptide in the presence of 7.5 µg/ml Brefeldin A. Medium 
was used as a negative control to correct for baseline cytokine production. Cytokine 
profile was analyzed by intracellular cytokine staining as described above.
2.8. Statistical analysis
Graph Pad Prism software was used for statistical analysis. Values and percentages 
of specific CD8+ T cells and secreted cytokine production were analyzed by two-tailed 
unpaired Student t test. Differences in animal survival between the different groups 
were calculated using Log-rank (Mantel-Cox) test.
3. Results
3.1. Nanoparticle characterization and protein antigen load 
and release 
We prepared several batches of PLGA-OVA NP with similar characteristics. Particles 
used in our study had an average size of 327 ± 65 nm (mean ± SD; n = 7) and a 
polydispersity index (PDI) of 0.19 ± 0.07. Encapsulation efficiency of OVA in NP was 
determined to be 59 ± 5%. Empty particles used as control particles in this study 
had a comparable size (311 ± 52 nm) and PDI (0.15 ± 0.05). Endotoxin levels were 
determined for the prepared batches and was shown to be below 0.04 IU/ml in particle 
suspensions prepared as described in material and methods. (see Table 1). Release 
kinetics of OVA from the PLGA-OVA particles were analyzed over a period of 35 days. 
The validity of using OVA-Alexa 488 fluorescence as a measure of (unlabeled) OVA 
release was confirmed by measuring the OVA content of the nanoparticles and the total 
amount released at the end of the release study by BCA assay, which gave very similar 
values as the fluorescence method (results not shown).
The NP had a burst release of the encapsulated OVA of 28.1 ± 0.2%. At the end of the 
analysis, we could detect 80.4 ± 2.2% of released OVA in suspension indicating that 
after 35 days about 20% of the originally encapsulated OVA was still associated with 
NP showing the slow release character of these NP (see Supplemental Figure 1).
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3.2. Efficient protein MHC class I and class II Ag presentation 
by DC loaded with protein encapsulated in PLGA-
NP
The efficiency of Ag (cross)-presentation of encapsulated protein Ag in comparison 
to soluble protein Ag was studied in vitro. DC were incubated for 24 h with titrated 
amounts of Ag, as indicated in µM, either encapsulated in PLGA-NP (PLGA-OVA) or in 
soluble form (sOVA). Ag presentation by MHC class I or II was assessed using the CD8+ 
(B3Z) and CD4+ (OT-IIZ) T cell hybridomas. DC loaded with PLGA-OVA very efficiently 
triggered B3Z T cells (Figure 1A). In contrast, DC pulsed with sOVA poorly stimulated 
B3Z CD8+ T cells unless very high concentrations (≥ 64 µM) of sOVA were used (data 
not shown). MHC class I cross-presentation of protein Ag was strictly dependent on 
encapsulation in PLGA-NP, as a mixture of the sOVA with empty PLGA-NP did not induce 
CD8+ T cell activation (Figure 1B). In addition, DC loaded with PLGA-OVA resulted in at 
least 100-fold enhanced activation of OT-IIZ CD4+ T cells in comparison to DC loaded 
with sOVA, indicating that also MHC class II presentation was dramatically improved by 
encapsulation (Figure 1C). Next to Ag presentation, we analyzed proliferation of naïve 
CD8+ (OT-I) and CD4+ (OT-II) T cells induced by DC loaded with PLGA-OVA or sOVA. 
Co-culture of Ag pulsed DC with either OT-I or OT-II T cells for 72 h, including overnight 
incubation in the presence of [3H]-thymidine for the last 18 h showed that PLGA-OVA 
was at least 1000-fold more efficient than sOVA in inducing OT-I T cell proliferation 
(Figure 1D) and 100-fold better than sOVA in inducing OT-II T cell proliferation (Figure 
1E). Similar to the used D1 dendritic cells, freshly isolated BMDC loaded with PLGA-
OVA were superior in comparison to sOVA-loaded BMDC in the stimulation of OT-I 
and OT-II T cells resulting in improved T cell proliferation (Supplemental Figure 2). In 
addition, we analyzed DC maturation by surface expression of CD86 and determining 
the amount of IL-12 in culture supernatants after incubation with the NP after 24 hr 
incubation. Our data show that the empty or OVA-loaded PLGA NP do not detectably 
activate and mature DC (Supplemental Figure 3) in contrast to LPS (TLR4L) or PolyI:C 
(TLR3L). This indicates that encapsulation of soluble protein antigen in plain PLGA NP 
strongly enhances antigen presentation by DC irrespective of DC maturation.
3.3. Activation of T cells by DC loaded with PLGA-NP-
encapsulated protein Ag
We analyzed whether PLGA-NP based delivery of protein Ag could induce T cell 
activation and production of pro-inflammatory cytokines. Naïve OVA-specific CD8+ (OT-
I) and CD4+ (OT-II) T cells were stimulated for 24 h in the presence of PLGA-OVA- or 
sOVA-loaded DC and analyzed for cells expressing the early activation marker CD69. 
Both CD8+ (Figure 2A) and CD4+ (Figure 2B) T cells showed strongly enhanced 
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percentages of CD69+ cells upon stimulation by PLGA-OVA pulsed DC in a dose-
dependent manner. By contrast, and in line with poor Ag presentation, stimulation with 
sOVA pulsed DC resulted in low expression of CD69 on T cells. The majority of CD8+ T 
cells stimulated with PLGA-OVA pulsed DC also expressed the interleukin-2 receptor-
alpha chain (CD25) after 24 h, whereas only a small population of sOVA induced 
CD8+ T cells showed expression of CD25 (Figure 2C). Furthermore, we analyzed the 
capacity of activated CD8+ and CD4+ T cells to produce IL-2, IFN-γ, TNF-α and IL-4 
by intracellular cytokine analysis of the T cells. Whereas hardly any cytokine-producing 
CD8+ and CD4+ T cells were observed after stimulation with sOVA pulsed DC, high 
numbers of IFN-γ- and IL-2-producing CD8+ T cells (Figure 2D) and CD4+ T cells 
(Figure 2E) were detected after stimulation with PLGA-OVA-loaded DC. The majority 
of cytokine-producing CD4+ T cells were single producers of IL-2, whereas cytokine 
producing CD8+ T cells consisted of a population of IL-2 and IFN-γ double producers, 
Figure 1: Efficient MHC class I and- class II presentation of OVA Ag incorporated in 
PLGA-NP. A) D1 cells were pulsed for 24 h with titrated amounts (μM) of OVA, either in soluble 
form sOVA or encapsulated in PLGA-NP (PLGA-OVA). MHC class I presentation was detected 
by co-culture with H-2Kb/SIINFEKL-specific B3Z CD8+ T cells; B) D1 cells were pulsed for 24 h 
with 0.25 μM OVA in PLGA-OVA, empty PLGA-NP, or a mixture of empty PLGA-NP with 0.25 μM 
sOVA, washed and co-cultured with B3Z CD8+ T cells to assess MHC class I Ag presentation; 
C) D1 cells were pulsed for 24 h with titrated amounts of PLGA-OVA or sOVA, washed, and 
co-cultured with I-Ab/ISQAVHAAHAEINEAGR-specific OT-IIZ CD4+ T cells to assess MHC 
class II Ag presentation. BMDC were loaded with titrated amounts of PLGA-OVA or sOVA. Ag 
loaded DC were subsequently used to activate naïve OT-I; D) or OT-II T (E) cells for 72 h. T cell 
proliferation was measured in triplicate by 3[H]-thymidine uptake. Data shown are means of 
triplicate measurements ± SD from one representative example out of at least three independent 
experiments.
single IFN-γ producers and a relatively smaller population of IL-2 single producers. The 
cytokines IL-4 and TNF-α could not be detected after in vitro stimulation of either CD8+ 
or CD4+ T cells with PLGA-OVA pulsed DC (data not shown).
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3.4. DC loaded PLGA-NP-encapsulated protein Ag induces 
CD8+ T cells with in vivo cytotoxic capacity 
To assess their cytotoxic capacity, CD8+ T cells stimulated in vitro by PLGA-OVA-
loaded DC were studied for their ability to lyse Ag-pulsed target cells in vivo. Following 
stimulation, the purified CD8+ T cells were transferred into recipient mice. After 24 h 
SIINFEKL-loaded target and control-target cells were injected and 18 h later mice were 
sacrificed and spleen single cell suspensions were analyzed by flow cytometry. In line 
with the observed activation status and cytokine profile, CD8+ T cells stimulated with 
PLGA-OVA-loaded DC demonstrated cytotoxicity against SIINFEKL-loaded target 
cells. In contrast, CD8+ T cells co-cultured in the presence of sOVA-loaded DC were 
not capable of killing target cells (Figure 3A and B). 
Figure 2: DC pulsed with PLGA-OVA, but not sOVA, induce strong activation of T cells. 
D1 cells were pulsed for 24 h with titrated amounts of sOVA or PLGA-OVA. Ag loaded DC 
were washed to remove excess Ag, and co-cultured for an additional 24 h with OT-I or OT-II 
splenocytes. Cells were harvested and analyzed by flow cytometry for the cell surface expression 
of A) CD69 on CD8+ T cells and B)CD4+ T cells ; C) Expression of CD25 and CD69 was analyzed 
on CD8+ T cells which were stimulated for 24 h with DC which were loaded with either PLGA-
OVA or sOVA. Immature DC without Ag served as negative control. Intracellular production of 
IL-2 and IFN-γ by D) CD8+ T cells and E) CD4+ T cells was analyzed by flow cytometry after 24 
hr stimulation with DC pulsed with titrated amounts of PLGA-OVA or sOVA. One representative 




3.5. PLGA-NP-encapsulated protein Ag induces CD8+ T cells 
with potent anti-tumor activity
To investigate the therapeutic potential of CD8+ T cells induced by DC loaded with 
PLGA-NP-encapsulated protein antigen against established tumors, mice were 
Figure 3: Enhanced in vivo cytotoxicity of ex vivo PLGA-OVA-stimulated CD8+ T cells. 
A) Mice were transferred with purified CD8+ OT-I T cells which were in vitro stimulated with D1 
cells loaded with PLGA-OVA and sOVA. Differentially CFSE-labeled SIINFEKL-peptide loaded 
and control target cells were i.v. administered. After 18 h the spleens from recipient animals 
were harvested and analyzed by flow cytometry for percentage of specific killing of target cells; 
B) Experiment was performed twice and averages  ± SEM of n = 7 mice for each condition are 
shown in bar graphs. 
inoculated s.c. with OVA-expressing B16 melanoma tumor cells. After 7 days, animals 
were treated by adoptive T cell transfer therapy by a single i.v. injection of 2.5 x 106 
purified OVA-specific CD8+ T cells stimulated for 24 h in vitro in the presence of DC 
loaded with either PLGA-OVA or sOVA. Tumor growth and animal survival in CD8+ T 
cell transferred mice were compared to those in non-treated animals. Animals were 
developing palpable tumors within 10 days after s.c. tumor inoculation. In tumor-bearing 
mice that were treated by adoptive transfer with OVA-specific CD8+ T cells stimulated in 
the presence of PLGA-OVA-loaded DC, we observed a clear therapeutic effect which 
resulted in delayed tumor growth in comparison to non-treated animals and animals 
treated with CD8+ T cells stimulated with sOVA loaded DC. We observed regression of 
tumors in the range of 2 - 4 mm2 in some animals by day 14, which were undetectable 
on day 18 after tumor challenge (insert in Figure 4A). By day 22, four animals within 
this group had tumor recurrences which eventually grew out. Nevertheless, 8 out of 12 
tumor-challenged mice treated with PLGA-OVA induced CD8+ T cells remained tumor 
free for the duration of the experiment (Figure 4A). By contrast, in tumor challenged 
animals that received sOVA induced CD8+ T cells, tumors reappeared in 11 out of 12 
mice and grew out, albeit at a decreased rate when compared to non-treated animals 
(Figure 4B). In all non-treated animals, tumors grew out fast and all mice were sacrificed 
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by day 24, because of maximum allowed tumor burden (Figure 4C). Tumors that 
did grow in animals that received PLGA-OVA induced CD8+ T cells had a significantly 
slower average growth rate when compared to tumors from mice that received sOVA 
induced CD8+ T cells. Consequently, the survival of mice treated with PLGA-OVA 
induced CD8+ T cells was significantly higher when compared to mice treated with 
CD8+ T cells stimulated in the presence of sOVA-loaded DC (Figure 4D).
3.6. CD8+ T cells stimulated with PLGA-NP-encapsulated 
protein Ag efficiently expand and produce type I cytokines 
in vivo
We measured by flow cytometry the actual numbers of OVA-specific CD8+ T cells 
(CD8+Thy1.1+ OT-I cells) in peripheral blood of tumor challenged mice up to a month 
after adoptive transfer. Ten days after adoptive transfer of equal amounts of purified 
OVA-specific CD8+ T cells, mice that had received PLGA-OVA induced cells showed 
5-fold higher levels of CD8+ T cells than animals that had received sOVA stimulated 
CD8+ T -cells (Figure 5A). The percentage of PLGA-OVA induced CD8+ T cells 
remained significantly higher at day 17 and 31 after transfer. (Figure 5B). A similar 
in vivo expansion capacity of PLGA-OVA induced CD8+ T cells was observed upon 
transfer in naïve mice, i.e. not challenged with tumors (data not shown). Furthermore, we 
analyzed the production of cytokines by CD8+ T cells in peripheral blood by intracellular 
staining. To this end, peripheral blood mononuclear cells were harvested from mice at 
day 10, 17 and 31 after adoptive transfer and stimulated overnight in the presence of 
SIINFEKL-peptide. IFN-γ-, IL-2- and TNF-α-producing CD8+ T cells were detectable 
by flow cytometry. On day 10 after adoptive transfer, we observed significantly higher 
percentages of IFN-γ-producing CD8+ T cells in mice that had received PLGA-OVA 
induced CD8+ T cells when compared to mice that had received sOVA induced CD8+ 
T cells. We were unable to detect IFN-γ-producing CD8+ T cells in tumor-bearing 
animals which were not treated using adoptive T cell transfer therapy (data not shown). 
Although, the percentage of IFN-γ producing CD8+ T cells declined at day 17 and 31 
after adoptive transfer, the IFN-γ-producing CD8+ T cells remained significantly higher 
throughout the analysis period (Figure 5C). A trend in increased levels of IL-2- and 
TNF-α-producing CD8+ T cells could be observed in mice transferred with PLGA-OVA 
but not with sOVA induced CD8+ T cells (data not shown). In addition, the phenotype 
of peripheral blood OVA-specific T cells at day 17 and 31 after adoptive transfer of 
PLGA-OVA induced CD8+ T cells was analyzed. The majority of the cells possessed a 
central memory phenotype based on high expression of CD62L (L-selectin) and CD44 
(Figure 5D) showing the superior functionality of the T cells expanded with this simple 
expansion protocol with NP encapsulated protein antigen. 
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Figure 5: PLGA-OVA stimulated CD8+ T cells expand and persist in the peripheral blood 
and have higher capacity to produce IFN-γ. A) Tumor bearing animals received a single i.v. 
injection of CD8+ T cells stimulated with PLGA-OVA-loaded DC. Tail vein blood samples were 
taken on day 10 after adoptive transfer of the CD8+ T cells and numbers of CD8+Thy1.1+ T cells 
were measured by flow cytometry; B) In vivo persistence of i.v. transferred CD8+Thy1.1+ T cells 
in tumor bearing animals was monitored for 4 weeks in blood on day 17 and 31; C) Intracellular 
IFN-γ production by CD8+ T cells was analyzed on day 10, 17 and 31 after adoptive transfer; D) 
Memory phenotype of transferred DC/PLGA-OVA in vitro stimulated CD8+Thy1.1+ T cells was 
determined by analysis of CD44 and CD62L surface expression. Results shown are averages ± 
SEM from n = 3-12 mice per group, dependent on the number of animals alive at each time-point 
post tumor challenge.  * = p < 0.05 for animals treated with DC/PLGA-OVA compared to DC/
sOVA induced CD8+ T cells using a un-paired student t test.
4. Discussion
In this study we analyzed the phenotype and in vivo functionality of T cells stimulated 
in vitro by DC loaded with plain PLGA-NP encapsulated protein Ag with no additional 
immune stimulatory agent or targeting moiety. We showed that encapsulation of 
protein Ag in plain PLGA-NP not only enhanced Ag (cross-)presentation by DC but also 
improved the functionality of the induced T cells to cure animals from  tumors upon 
adoptive T cell transfer. OVA antigen in PLGA-NP was more efficiently processed and 
presented in MHC class I and II by DC and resulted in potent activation and proliferation 
of OVA-specific CD8+ and CD4+ T cells, high production of type I cytokines and tumor 
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control  resulting in an overall survival of 75% of tumor-bearing animals.
PLGA-based particles as vaccine delivery systems were pioneered already more than 
30 years ago [14]l lactic-co-glycolic acid. Several studies have shown that efficient 
anti-tumor immune responses in vivo by PLGA-particles require not only encapsulated 
Ag, but also a co-encapsulated adjuvant such as a TLRL, surface coating of particles 
with mannan or protamine to stimulate immunity or DC targeting moieties, for example 
anti-DEC205 antibodies [22,36,37,38]. 
CD8+ T cells induced in our study were applied for adoptive T cell transfer purposes. 
Adoptive T cell transfer therapy potency in (pre)clinical setting is enhanced upon 
efficient ex vivo/in vitro stimulation/manipulation of donor T cells [30,39,40]. Using a 
similar murine model, efficient stimulation of T cells with potent effector functions was 
reported using artificial APC systems [26]. They constructed PLGA-based artificial APC 
expressing MHC class I molecules containing a specific CTL short-peptide epitope, 
which also provides T cell co-stimulation in the form of CD28 and CD3 triggering and 
releases IL-2 [41,42]. We propose that our simple approach with natural APC is equally 
efficient and has the advantage that our method is not restricted to the known MHC 
class I and II-presented T cells epitopes. In addition, the use of natural DC as APC might 
facilitate priming of T cells via more co-stimulatory pathways [43,44,45] and additional 
DC-mediated cytokines required for optimal type I pro-inflammatory T cell activation, 
for example IL-12 [46], and avoids sub-optimal formation of the immunological synapse 
as has been described for other bead-based artificial APC systems [47]. 
Adoptive T cell therapy has yielded promising results as a cancer immunotherapy in 
the last decade [30,48]. Standard adoptive transfer protocols mandate that T cells 
are cultured for 2 – 14 days in the presence of specific Ag and exogenous cytokines 
[39,49,50,51] for optimal stimulation and expansion. In contrast, we opted for a short 
24 h stimulation of T cells without addition of any exogenous cytokines. We favor short 
incubation with DC loaded with PLGA-OVA, which potently activates T cells, because 
longer incubation periods might tip the balance to activation induced cell death (AICD) 
[52,53]. In addition, our protocol allowed us to transfer T cells that were not skewed 
based on the cytokines added to the cultures [54,55] nor negatively affected by the 
added cytokines [42,56,57]. 
In our culture systems we used two types of DC: D1 cells, a well characterized murine 
splenic DC cell line, originally isolated from WT C57BL/6 animals [58] and bone marrow 
derived DC. Both CD11c+ myeloid types of DC were cultured as immature cells in GM-
CSF containing media. D1 DC do not exhibit substantial functional differences with 
BMDC, they possess equal capacity to prime T cells and upon transfer to recipient 
animals show similar efficiency to induce protective anti-tumor immunity [32]. We 
compared CD4+ and CD8+ T cell proliferation by PLGA-NP encapsulated protein Ag 
and we observed similar observations using either D1 cells or WT BMDC as APC. 
Therefore, easily cultured myeloid types of DC are well suited for the T cell activation 
protocol with NP encapsulated Ag we describe here.
In this study splenocytes from OT-I mice, which contain high numbers of OVA-specific 
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T cells, were used to activate and adoptively transfer into recipient animals. We are 
aware that in clinical settings, majority of patients which were treated with adoptive 
T cell transfer therapy exhibit lower precursor frequencies of TAA-specific T cells that 
require stimulation and expansion to yield sufficient numbers for adoptive transfer. 
Our system still works by DC/PLGA-OVA stimulation of cell cultures containing lower 
amounts (between 1 - 10%) of OVA-specific T cells regarding T cell activation and 
cytokine production (data not shown). On the other hand, higher precursor frequencies 
of both CD4+ and CD8+ Ag-specific T cells have been observed in draining lymph 
nodes of cervical cancer patients [59,60]. These cells were able to produce type I 
pro-inflammatory cytokines and proliferate upon specific stimulation suggesting that 
these cells might be suitable for future adoptive T cell transfer protocols. Indeed, in 
a melanoma patient case report, it was shown that CD4+ T cells isolated in relatively 
higher precursor frequencies could be successfully stimulated and transferred to the 
recipient back to the patient resulting in a clinical response [61].
The PLGA-OVA particles used in our study are devoid of any additional TLRL or 
immunostimulatory agents. We observed no differences in T-cell proliferation by 
MyD88 KO BMDC loaded with PLGA-OVA (data not shown), it is therefore unlikely 
that any unanticipated TLR-stimulation plays a role in our system. The enhanced 
T cell proliferation and activation is most likely the result of enhanced uptake of Ag 
available for efficient processing and MHC presentation.  Uptake of particulate matter 
proceeds via phagocytosis [62,63] of protein Ag-loaded PLGA particles by DC resulting 
in adequate MHC class I cross-presentation to CTL [64]. DC internalize particles and 
maintain these intracellularly for up to 72 hr [65]. Prolonged presence of Ag inside 
cells has been shown to result in sustained MHC class I Ag presentation and efficient 
priming of CD8+ T cells [66]. 
Transferred DC/PLGA-OVA stimulated CD8+ T cells were still detectable 31 days 
post adoptive transfer and the majority of these cells possessed a central memory 
phenotype correlating with tumor control. Numbers of specific T cells in vivo have 
been shown to directly correlate with tumor-regression [67]. Efficient tumor killing is 
achieved upon efficient CD8+ T cell activation accompanied with high production of 
type I pro-inflammatory associated cytokines which is dependent on the method of 
in vitro activation [68,69]. Our data are in line with these reports as peripheral CD8+ T 
cells from mice which received DC/PLGA-OVA stimulated CD8+ T cells were capable of 
producing type I pro-inflammatory cytokines upon specific peptide stimulation. Indeed, 
expansion of IFN-γ producing T cells correlates with clinical effect in patients with 
human papillomavirus type 16 induced vulvar intraepithelial neoplasia [70]. 
Numbers of cytokine-producing cells decreased with time in all treated animal groups 
The decrease in numbers of cytokine-producing OVA-specific CD8+ T cells in time 
might be related to lack of sufficient OVA-specific CD4+ T cells. Co-transfer of DC/
PLGA-OVA in vitro stimulated CD4+ T cells may prolong and sustain higher numbers of 
cytokine producing effector CD8+ T cells [71]. 
We conclude that protein Ag delivery by PLGA-NP might be an attractive and simple 
strategy to improve ex vivo tumor-specific T cell stimulation for clinical adoptive 
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T transfer therapy. Apparently, the intrinsic characteristics of PLGA-Ag NP to be 
efficiently internalized and processed by DC is sufficient to induce effector T cells in 
vitro with expansion capacity in vivo, and with strong therapeutic effectiveness. So, 
encapsulation of tumor associated protein Ag in PLGA-NP may serve as a clinically 
feasible strategy to generate T cells with optimal effector quality for adoptive transfer-
based immunotherapy of cancer.
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6. Supplemental Material 
Supplemental Figure 1. Encapsulated OVA is released gradually from PLGA-NP. 
PLGA-OVA-Alexa488 with an average OVA content of 14.11 ± 2.89 µg OVA/mg PLGA were 
re-suspended at a concentration of 10 mg/mL of PBS and incubated at 37ºC under constant 
shaking. At indicated time points 250 µl samples were collected, centrifuged for 20 min at 
18,000xg and the amount of OVA-Alexa488 in the supernatant determined by fluorescence, as 
described in the material and methods. Average results of two independent release studies with 
four different batches of PLGA-OVA are shown, mean ± SD.
Supplemental figure 2. Improved CD4+ and CD8+ T cell proliferation by BMDC loaded 
with PLGA-OVA in comparison to sOVA-loaded BMDC. WT C57BL/6 BMDC were 
incubated with titrated amounts of PLGA-OVA or sOVA. Ag loaded BMDC were subsequently 
used as APC in a co-culture with naïve OT-I (A) or OT-II T (B) cells for 72 h. T cell proliferation 
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a synthetic long peptide in PLGA 
nanoparticles: low burst release is crucial 
for efficient CD8+ T cell activation
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Jaap Oostendorp, Wim Jiskoot




Overlapping synthetic long peptides (SLP) hold great promise for immunotherapy of 
cancer. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) are being developed as 
delivery systems to improve the potency of peptide-based therapeutic cancer vaccines. 
Our aim was to optimize PLGA NP for SLP delivery with respect to encapsulation 
and release, using OVA24, a 24-residue long synthetic antigenic peptide covering a 
CTL epitope of ovalbumin (SIINFEKL), as a model antigen. Peptide-loaded PLGA NP 
were prepared by a double emulsion/solvent evaporation technique. Using standard 
conditions (acidic inner aqueous phase), we observed that either encapsulation was 
very low (1 – 30%), or burst release extremely high (> 70%) upon resuspension of NP in 
physiological buffers. By adjusting formulation and process parameters, we uncovered 
that the pH of the first emulsion was critical to efficient encapsulation and controlled 
release. In particular, an alkaline inner aqueous phase resulted in circa 330 nm sized NP 
with approximately 40% encapsulation efficiency and low (< 10%) burst release. These 
NP showed enhanced MHC class I restricted T cell activation in vitro when compared 
to high-burst releasing NP and soluble OVA24, proving that efficient entrapment of the 
antigen is crucial to induce a potent cellular immune response. 
Keywords: Peptide antigen, CTL epitope, PLGA nanoparticles, cancer immunotherapy, 
cellular immune response
1. Introduction
In recent years there is an increased interest in the application of therapeutic vaccination 
for treatment of cancer [65]. Therapeutic cancer vaccines aim to induce a strong cellular 
response against tumor associated antigens [66]. Dendritic cells (DC) are professional 
antigen presenting cells (APCs) that play a major role in the initiation of such an 
immune response, by continuously sampling the environment for foreign antigens and 
establishing the communication between the innate and adaptive immune system [67, 
68]. Only appropriately activated DC are capable of inducing a robust cytotoxic T cell 
(CTL) response, which is required for effective immunotherapy of established tumors 
[3, 69-71]. For this purpose, DC are the major target cells for cancer immunotherapy 
vaccines [3, 66]. 
Therapeutic vaccination with overlapping synthetic long peptides (SLP), covering the 
entire amino acid sequence of tumor associated protein antigens and thus containing 
all possible MHC class I and II epitopes, has been successfully applied in murine 
models and clinical therapeutic vaccination trials [66, 72-75]. Moreover, vaccination of 
patients suffering from human papillomavirus 16 (HPV16) induced premalignant vulvar 
intraepithelial neoplasia with an HPV16-based SLP vaccine resulted in complete clinical 
regression of the lesions in some cases [66, 74, 75].
So far, Montanide-based water-in-oil (w/o) emulsions have been applied to formulate 
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SLP in the majority of clinical therapeutic cancer vaccination trials [74-80]. The use 
of Montanide-based formulations has some important limitations, including non-
biodegradability, causing significant local side effects, poorly controlled antigen 
release rates and limited scalability because of lack of long-term stability [81-83]. 
Biodegradable delivery systems based on poly(lactic-co-glycolic acid) (PLGA) offer a 
promising alternative strategy for peptide-based cancer vaccines. PLGA is well suited 
for the preparation of micro- and nanoparticles (NP) [54, 84-86], which can protect 
antigen from proteolytic enzymatic degradation and rapid clearance [87-90], allow co-
encapsulation and simultaneous delivery of both antigen and adjuvants, and facilitate 
antigen uptake by DC [8, 91-93]. PLGA has a long safety record and is Food and 
Drug Administration (FDA) approved as an excipient, owing to its biodegradability 
and biocompatibility, with several slow-release formulations currently on the market 
[92, 94]. PLGA undergoes hydrolysis in the body to produce the original monomers, 
lactic acid and glycolic acid, which are natural by-products of metabolic pathways. 
Antigen release can be regulated e.g. by varying the lactic acid/glycolic acid ratio [95-
97]. PLGA-based particulate systems can be manufactured reproducibly according 
to Good Manufacturing Practice conditions and have been studied extensively for 
the delivery of a wide variety of antigens [54, 94, 98-100]. Antigens encapsulated in 
PLGA microparticles have shown to induce immune responses comparable to those of 
antigens adjuvanted with Montanide 51 [17, 97]. PLGA is also known to have several 
disadvantages regarding instability of protein antigens, e.g., due to the hydrophobicity 
of the polymer and the local acidification of the microenvironment that occurs during 
degradation of the polymer at physiological pH [101-103]. However, for synthetic 
peptides, which do not possess a tertiary structure, this is less problematic and several 
peptides in PLGA microspheres have been successfully launched on the market [94, 
100, 103]. 
The aim of this study was the pharmaceutical characterization of PLGA NP as a 
suitable delivery system for encapsulation of SLP for cancer immunotherapy. OVA24, a 
24-residue long synthetic antigenic peptide covering a CTL epitope of ovalbumin (OVA; 
SIINFEKL), was studied as a model SLP, because of its proven capability to induce 
CTL responses in vitro and in vivo [104]. Efficient entrapment of OVA24 SLP in the 
polymeric matrix was obtained by exploring and fine tuning of formulation and process 
parameters. OVA24-loaded PLGA NP were characterized for antigen encapsulation 
efficiency, antigen burst release, particle size and zeta-potential, and the obtained 
formulations were immunologically evaluated in vitro for their potency to induce CD8+ 
T cell activation. 
2. Materials and methods
2.1. Materials
Synthetic long peptide 24-mer OVA24 (DEVSGLEQLESIINFEKLAAAAAK) [105], 
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covering the cytotoxic T lymphocyte (CTL) epitope SIINFEKL of ovalbumin (OVA) 
was synthesized at the interdepartmental GMP facility of the Department of Clinical 
Pharmacy and Toxicology of Leiden University Medical Center as described previously 
[73]. Poly(D,L-lactic-co-glycolic acid) [PLGA], Resomer® RG 502H was purchased 
from Boehringer Ingelheim (Ingelheim, Germany). 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES), sodium cholate, dichloromethane (DCM), dimethyl 
sulfoxide (DMSO), and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Acetonitrile (ACN) and methanol (MeOH) were obtained from 
Biosolve BV (Valkenswaard, the Netherlands), Polyvinil alcohol (PVA) 4-88 (31 kDa) was 
purchased from Fluka (Steinheim, Germany). Tween 20 was purchased from Merck 
Schuchardt (Hohenbrunn, Germany). Sodium hydroxide was purchased from Boom 
(Meppel, Netherlands). Reversed phase HPLC column ReproSil-Pur C18-AQ 3 µm 
(150x4 mm) was purchased from Dr. Maisch HPLC GmbH (Ammerbuch-Entringen, 
Germany). Phosphate-buffered saline (NaCl 8.2 g/L; Na2HPO4.12 H2O 3.1 g/L; 
NaH2PO4.2H2O 0.3 g/L) (PBS) was purchased from B. Braun (Melsungen, Germany). 
Iscove’s Modified Dulbecco’s Medium (IMDM) was purchased from Lonza (Walkersville, 
USA). All other chemicals were of analytical grade and all aqueous solutions were 
prepared with milli Q water.
2.2. Nanoparticle preparation
2.2.1. General particle preparation process
Nanoparticles loaded with OVA24 were prepared using a double emulsion with solvent 
evaporation method [37]. In brief, 50 mg of PLGA dissolved in 1 ml of dichloromethane 
was emulsified under sonication (30 s, 20 W) with a solution containing 1.4 mg OVA24 
(for solution compositions, see results). To this first emulsion (w1/o), 2 ml of an aqueous 
surfactant solution (for surfactant types, see results) were added immediately, and the 
mixture was emulsified again by sonication (30 s, 20 W), creating a double emulsion 
(w1/o/w2). The emulsion was then added dropwise to 25 ml of extraction medium 
(0.3% w/v surfactant) previously heated to 40°C under agitation, to allow quick solvent 
evaporation, while stirring, which was continued for 1 h. The particles were then 
collected by centrifugation for 15 min at 15000 g at 10°C, washed, and resuspended 
in deionized water, aliquoted and freeze-dried at -55oC in a Christ Alpha 1-2 freeze-
drier (Osterode am Harz, Germany) for 12 hours.
As starting conditions, the method described by Slütter et al. [37] was used, with 1% 
v/v Tween 20 in 25 mM Hepes pH 7.4 as the aqueous phase for second emulsion, with 
the following modifications: DMSO used as inner phase instead of PBS pH 7.4 and 5% 
(w/v) PLGA was used instead of 2.5% . 
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2.2.2. Optimization of formulation parameters
In order to achieve an optimum formulation, the following parameters involved in the 
particle preparation were varied, and their effect on peptide encapsulation efficiency 
was investigated.
a) Surfactant type: investigated by dissolving different surfactant types (PVA; 
Tween 20; sodium cholate) in the second aqueous phase (w2) during the 
second emulsion step.
b) Inner solvent: investigated by dissolving the peptide in different solutions (w1), 
i.e. DMSO; 50% ACN + 0.1% TFA; 50% ACN in 25 mM NaOH; and 50% ACN 
in 0.25 mM NaOH + 400 µL Hepes pH 8.0 at different concentrations).
c) Volume ratio (w1/o): investigated by varying the volume of the inner aqueous 
phase w1 (50 µL, 100 µL; 500 µL).
2.3. Nanoparticle characterization
2.3.1. Dynamic light scattering and zeta-potential
The Z-average size and polydispersity index (PDI) of NP were measured by dynamic 
light scattering, using a Zetasizer (Nano ZS, Malvern Ltd., United Kingdom). The zeta-
potential was measured by laser Doppler electrophoresis, using the same device. For 
that purpose, NP were diluted to 2.5 mg/ml in 1 mM Hepes pH 7.4. 
2.3.2. Antigen content and encapsulation efficiency 
Peptide encapsulation efficiency was determined by measuring the peptide content of 
digested particles by reversed phase HPLC. For that purpose, 200 µL NP suspension 
(containing 10 mg NP) was freeze-dried overnight. The lyophilizate was then dissolved 
in 250 µL DMSO and the solution was agitated at 50°C for 30 min. Next, 750 µL 
50% ACN with 0.1% TFA were added and the mixture was agitated at 50°C for an 
extra 60 min, to allow dissolution of the peptide and degradation/precipitation of PLGA, 
which was then  eliminated by centrifugation for 10 min at 18000 g. The supernatant 
containing the peptide was collected and 50 µL were injected into a HPLC system 
equipped with a C18 column (Dr. Maisch Reprosil-Pur C18-AQ, 3 mg, 150 x 4.6 mm) 
and an ultraviolet detector (Waters 486). Mobile phases applied were 5% ACN in 
water with 0.1% TFA (solvent A), and 95% ACN in water with 0.085% TFA (solvent B). 
Separation was performed by applying a linear gradient from 0% to 78% solvent B over 
20 min, at a flow rate of 1 ml/min, and peptide detection was performed by absorbance 
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at 220 nm. Peptide concentration in each sample was calculated using a calibration 
curve created with known concentrations of OVA24. 
2.4. In vitro release studies
To determine burst release (BR) at time zero (t0), freeze-dried NP were resuspended in 
1x PBS, 1x IMDM cell culture medium, or 5% w/v glucose solution at a concentration of 
10 mg PLGA NP/mL and the mixture was vortexed for 30 seconds at room temperature 
to allow complete resuspension of the particles. Then particles were centrifuged for 10 
min at 18000 g, the supernatant recovered and the pellet resuspended. Both fractions 
were freeze-dried overnight, and extraction was performed as described previously, 
before being analyzed by HPLC for peptide quantification. 
For longer release studies, peptide-loaded PLGA NP were prepared as described, 
resuspended in 1x PBS pH 7.4 at a concentration of 10 mg and maintained at 37oC in 
a water bath under constant tangential shaking at 100/min in a GFL 1086 shaking water 
bath (Burgwedel, Germany). At regular time intervals, 250 µl samples of the suspension 
were taken, centrifuged for 10 min at 18000 g, and the supernatant recovered. To 
eliminate undesirable PLGA degradation products affecting detection by HPLC, the 
supernatant was freeze-dried over night, and extraction was performed as described, 
with the final supernatant being analyzed by HPLC for peptide quantification. Peptide 
release profiles were generated for each NP formulation in terms of cumulative antigen 
release (%) over time. 
2.5. In vitro antigen presentation
D1 cells, a long term growth factor-dependent immature splenic DC line derived from 
C57BL/6 (H-2Kb) mice, were cultured as described previously [106]. B3Z, cultured as 
described before, is a CD8+ T-cell hybridoma cell line, specific for the H-2Kb–restricted 
ovalbumin derived CTL epitope  SIINFEKL, that expresses a β-galactosidase construct 
under the regulation of the NF-AT element from the IL-2 promoter [107]. DC were 
incubated for 2.5 h with soluble OVA24 (sOVA24) or OVA24 encapsulated in PLGA 
NP at the indicated concentrations. Cells were washed three times with medium 
before the T-cell hybridoma B3Z cells were added followed by overnight incubation 
at 37 °C.  MHC class I Ag presentation of SIINFEKL (OVA257–264) in H-2Kb was 
detected by activation of SIINFEKL-specific CD8+ B3Z T cells. Upon T-cell receptor 
(TCR) ligation, lacZ protein is produced under the control of the IL-2 promoter thus 
allowing measurement of the IL-2 production indirectly by a colorimetric assay using 
chlorophenol red-β-d-galactopyranoside (CPRG) as substrate to detect lacZ activity in 
cell lysates. Color conversion is determined by measuring absorbance (optical density, 
OD) at 590 nm.
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2.6. Statistical analysis
Graph Pad Prism software was used for statistical analysis. Burst release in different 
physiological media and the effect of inner solvent and emulsion volume on burst 
release between different formulations in PBS were analyzed by two-tailed unpaired 
Student’s t-test. CD8+ T cell activation of SIINFEKL-specific CD8+ T cells by a two-
tailed paired Student’s t-test. Effect of the inner phase composition on apparent pH and 
the effect of Hepes concentration in the inner phase on release were analyzed using 
two-way ANOVA.
3. Results
3.1. Antigen encapsulation and burst release in PLGA 
NP
In this study, a 24-mer SLP covering a well-known CTL epitope (SIINFEKL) of ovalbumin, 
here designated as OVA24, was used as a model antigen to study the encapsulation 
of SLP in PLGA NP by a double emulsion with solvent evaporation method, as function 
of formulation and process parameters. As starting point, a slightly modified version 
of the standard double emulsion method described by Slütter et al. [37] was applied 
(see section 2.2.1), in which OVA24 was dissolved in DMSO and Tween 20 used as 
surfactant in the outer phase (Table 1, formulation 1). Since this method led to very 
low encapsulation efficiencies (ca. 1%), DMSO as inner phase was replaced by 50% 
ACN/0.1% TFA, which resulted in a marginal improvement (see Table 1, formulation 
2). Attempts to dissolve OVA24 in the PLGA-containing dichloromethane phase failed 
(results not shown). Therefore, several process parameters were investigated in order 
to increase the encapsulation efficiency of OVA24 in PLGA NP. First, commonly used 
surfactants for making NP, sodium cholate and PVA [37, 85], were tested in replacement 
of Tween 20 (Table 1, formulations 3-7). The type of surfactant used to stabilize the 
second emulsion had a dramatic positive effect on the encapsulation efficiency. Using 
50% ACN/0.1% TFA (with an apparent pH of 2.0) as first emulsion medium and PVA as 
surfactant in the second emulsion step resulted in the highest encapsulation efficiency 
(EE) (up to about 30%, see Table 1, formulations 4-7). PVA concentrations of 1% 
and 2% (w/v) PVA yielded comparable EE and particle size (Table 1, formulations 6 
and 7). PVA concentrations below 1% led to a lower encapsulation efficiency and a 
larger particle size (Table 1, formulations 4 and 5). For our further studies, OVA24-
loaded PLGA NP prepared with 50% ACN/0.1% TFA as inner solvent and 1% PVA as 
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Formulation 6 was tested for burst release of the peptide in PBS and IMDM (cell culture 
medium), which are commonly used for in vitro and in vivo applications. Directly upon 
resuspension (t=0) in either PBS or IMDM, OVA24-loaded PLGA NP showed a very 
high release, ranging from 80 to 90% (Figure 1), indicating that initial encapsulation 
results were misleading. In contrast, a release study in isotonic 5% glucose solution 
(Figure 1), did not induce substantial peptide release.
With the purpose to decrease the very high burst release, new solutions were tested 
as inner phase (w1) in the NP preparation process, where the effect of pH was studied. 
Instead of using pHs below the isoelectric point (pI) of the peptide (pI = 4.3), we decided 
to use pHs above it, which would change the charge distribution in the peptide and 
thereby could affect encapsulation, as well as inner phase volume, which might affect 
the peptide’s distribution between the inner and outer aqueous phases present during 
formation of the double emulsion. Therefore, instead of 50% ACN/0.1% TFA (apparent 
pH 2.0), OVA24 was dissolved in 50% ACN/25 mM NaOH (apparent pH 12.5).
Figure 1: Burst release of OVA24 in different physiological media (PBS, IMDM cell culture 
medium, 5% glucose) from PLGA NP (Table 1, formulation 6). Data are presented as average 
± standard deviation of n=3 independent batches. Data was analyzed by two-tailed unpaired 
Student’s t-test. P values are presented as non-significant (ns) = P > 0.05; * = P < 0.05; ** = P < 
0.01; *** = P < 0.0001.
Improvement was observed in neither encapsulation efficiency nor burst release when 
using an inner alkaline phase volume of 100 µL (Table 1, formulation 9; Figure 2a). 
However, a concomitant increase of inner emulsion volume, by using an inner phase 
volume of 500 µL (Table 1, formulation 11), drastically reduced burst release from circa 
90% to less than 10%, while improving encapsulation efficiency. Still, when at acidic pH, 
a higher inner emulsion volume (Table 1, formulation 10) did not affect encapsulation 
efficiency or burst release compared to previous values, confirming the central effect 
of pH in the matter. Indeed we observed that the peptide was very acidic, most likely 
due to remaining TFA from synthesis, drastically decreasing pH of solutions upon 
dissolution, with only the higher volumes containing enough base/buffer molecules to
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neutralize the acid contained in the peptide (Figure 2b), and keep the pH above 7.
The size and zeta-potential of the prepared OVA24-loaded NP was measured in 1 mM 
Hepes pH 7.4. Irrespective of the preparation method, the particles were negatively 
charged, with zeta-potentials ranging from -10 to -15 mV (see Table 1), when prepared 
using 1% PVA as surfactant. Though the inner emulsion ratio is generally thought to 
influence final particle size, with a larger ratio typically yielding bigger particles [84], we 
did not observe significant differences in average size (Table 1), with final particle sizes 
ranging from 300 to 400 nm for higher inner phase volumes and polydispersity indices 
below 0.3. 
Since it is well known that extreme pHs may harm peptide structure and stability, we 
decided to lower the working pH. Therefore, NaOH concentrations were decreased 
from 25 mM (apparent pH 12.5) to 0.25 mM NaOH (yielding an apparent pH of 10.5), 
and after dissolving the peptide in 50% ACN 0.25 mM NaOH, pH was adjusted by 
diluting 5 fold in Hepes buffer pH 8.0 at different Hepes concentrations (Table 1, 
formulations 12-16). We observed that a buffer concentration of at least 50 mM was 
necessary to maintain a basic pH in presence of peptide (Figure 2b), with the final pH 
having a direct effect on burst release (Figure 2c). Since the formulation with a relatively 
mild inner phase with an apparent pH of 8.0 (see Table 1, formulation 16) showed a 
comparable EE and burst release as the formulation with an apparent inner phase pH 
of 10.5 (Table 1, formulation 11), formulation 16 was adopted for further functional 
studies. With this formulation we obtained particles with an encapsulation efficiency of 
38%, with an average size of 328 nm, and zeta potencial of -13.6 mV.
3.2. Release kinetics
Since the particles are meant to be delivered to DC and taken up by DC rapidly after 
administration, short term release properties of the peptide-loaded particles (Table 
1, formulation 16) were assessed for 24 h. It can be observed that after 1 h OVA24 
shows approximately 30% release in PBS at 37ºC under shaking 100/min (Figure 
3). Over the next 24 h, no further release was observed. The slight decline in initial 
concentration of OVA24 was due to aggregation and, hence, partial precipitation during 
the centrifugation step. Indeed, free OVA24 dissolved in PBS at 37°C under agitation 
aggregated over time, as detected by DLS (results not shown). Adding Tween 80 (0.1 
% w/v) to the release medium did not help. We did not further study this phenomenon, 
but it obviously limited the duration of the release study.
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Figure 2: A) Effect of inner solvent and emulsion volume on burst release of OVA24 in PLGA 
NP, assessed at to upon resuspension in PBS (Formulations 8-11). B) Effect of the inner phase 
composition on apparent pH before and after the addition of OVA24 (P<0.0001) (formulations 
8, 11- 16). C) Effect of Hepes concentration in the inner phase on release, assessed at t0 (burst 
release) and 1 h after resuspension (P<0.0001) (formulations 12-16). Data are presented as 
average ± standard deviation of n=3 independent batches. Formulation numbers are according 
to Table 1. P values are presented as non-significant (ns) = P > 0.05; * = P < 0.05; ** = P < 0.01; 
*** = P < 0.0001.
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Figure 3: Release kinetics of OVA24 from PLGA NP (Table 1, formulation 16) in PBS at 37oC 
under shaking 100/min. Data are presented as average ± standard deviation of n=3 independent 
batches.
3.3. In vitro antigen presentation of SLP antigen encapsulated 
in NP
The effect of encapsulation of OVA24 on the efficiency of DC uptake and processing into 
MCH class I for antigen cross-presentation resulting into activation of CD8+ T cells was 
tested in vitro (Figure 4). For that purpose, the different formulations were incubated 
with DC for 2.5 h, washed to remove excess unbound antigen, followed by co-culture 
in the presence of OVA-specific B3Z CD8+ T cells. OVA24-containing PLGA NP with 
low (<10%) burst release (Table 1, formulation 16) were compared with those exhibiting 
high (>75%) burst release (Table 1, formulation 9), against soluble OVA24, empty 
particles, and a mixture of soluble OVA24 and empty particles. Encapsulation of OVA24 
in PLGA-NP resulted in significantly enhanced activation of B3Z CD8+ T cells compared 
to soluble OVA24. Although both tested NP formulations enhanced MHC class I antigen 
cross-presentation, we observed that delivery of OVA24 via encapsulation in PLGA NP 
with low (<10%) burst release resulted in improved T cell responses in comparison to 
OVA24-containing PLGA NP with high (ca. 75%) burst release. The addition of empty 
NP to soluble OVA24 did not show an effect on T cell activation in comparison to 
soluble OVA24 alone, indicating the strict necessity of peptide encapsulation in NP for 
enhanced processing in MHC class I antigen presentation pathways. Taken together, 
these data demonstrate that effective entrapment of antigen in PLGA with low burst 
release is crucial for efficient antigen cross-presentation by DC.
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Figure 4: Normalized CD8+ T cell activation of SIINFEKL-specific CD8+ T cells (B3Z) after 
co-culturing with DC incubated for 2.5 hours with titrated amounts of different OVA24 SLP 
formulations:  low-burst releasing (LBR) PLGA NP loaded with OVA24 (Table 1, formulation 16), 
high-burst releasing (HBR) PLGA NP loaded with OVA24 (Table 1, formulation 9), soluble OVA24 
mixed with empty NP (sOVA24 + Empty NP), empty NP, and soluble OVA24 (sOVA24). Data are 
presented as average ± SD of triplicate measurements. Representative results from one out of 3 
experiments are shown.  Graphs depict normalized T cell activation data based on the maximal 
OD 590 nm value/T cell activation measured upon incubation of DC with 1 µM of the minimal 
H2-Kb epitope OVA8/SIINFEKL-peptide (OD 590 nm value of 0.918 = 100%) as positive control. 
P values are presented as * = P < 0.05; ** = P < 0.01.
4. Discussion
The aim of this study was to develop a method to efficiently encapsulate OVA24 in 
PLGA, and perform a full characterization of the obtained formulation. This approach 
may result in antigen-bearing biodegradable particles that can be actively taken up by 
DC, generating specific T cell immunity and improving the efficacy of synthetic peptide-
based cancer vaccines. 
Whereas hydrophilic and hydrophobic peptides have been successfully encapsulated 
in PLGA NP and/or microparticles in the past [85, 97, 100, 108], efficient entrapment of 
the moderately hydrophobic OVA24 proved to be challenging. OVA24 does not readily 
dissolve in aqueous solutions and is insoluble in solvents like DCM or chloroform. 
However, it can be dissolved in a suitable matrix such as 50% v/v ACN in water, as 
well as in the commonly used solvent DMSO, prior to dilution in aqueous solutions. 
Standard encapsulation procedures generally used for encapsulation of hydrophilic 
or hydrophobic antigens led to low encapsulation efficiencies and high burst release 
once NP were resuspended in isotonic solutions at physiological pH. Therefore, 
150
Chapter 5
several formulation parameters, particularly inner and outer emulsion compositions, 
were studied in order to increase encapsulation. The positive effect of using PVA in 
the outer aqueous phase on EE may be due to fact that it is not a classical surfactant 
with a distinct hydrophobic tail and hydrophilic headgroup, but a polymer that coats 
the surface, stabilizing the emulsion. In contrast, both Tween 20 and cholate are able 
to form micelles at concentrations above their critical micelle concentrations (0.07 and 
0.6% w/v for Tween 20 and cholate, respectively), that may capture and solubilize 
the peptide during the emulsification process and thereby favor its extraction in the 
external water phase. A measurable difference between NP formulated with Tween 20 
or sodium cholate (Table 1, formulations 1-3) and those formulated with PVA (Table 1, 
formulations 5-16) was that the negative zeta-potential of the former formulations was 
significantly higher. While the relatively high zeta-potential values obtained with cholate 
can be explained by the negative charge of the surfactant, we can only speculate that 
the nonionic surfactant Tween 20, due to its lower molecular size, does not shield the 
negative charge of the PLGA as much as PVA coating does. 
The observed high burst release in the formulations with acidic inner phase led us to 
the notion that the majority of the OVA24 molecules might not be encapsulated in 
the NP’s polymeric matrix, but instead were adsorbed to their surface, masking real 
encapsulation efficiencies. This would explain the rapid release of peptide from the NP 
in presence of salt by disruption of electrostatic interactions between the peptide and 
the PLGA surface, due to the presence of counter ions that may shield the charges, 
and/or alter the peptide’s solubility. Indeed, the high burst release is highly consistent 
with observed release profiles for a tumor necrosis factor alpha blocking peptide 
adsorbed to PLGA NP [99], occurring once exposed to salt-based isotonic solutions 
at physiological pH. Increasing particle hydrophobicity by using different types of PLGA 
with higher molecular weights and lactic acid/glycolic acid ratio (PLGA 75:25), as well 
as using DMSO as solvent, creating an oil-in-water emulsion, instead of water-in-oil-
in-water to reduce porosity [109, 110], did not result in a decrease of the burst release 
(data not shown), concurring with the adsorption hypothesis, in opposition to diffusion 
due to high porosity. Moreover, resuspension in either water or isotonic 5% (w/v) 
glucose solution did not lead to substantial burst release (Figure 1), which provides 
further evidence that the instant release was not due to high particle porosity and 
peptide diffusion due to osmosis.
A clear correlation between burst release and pH of the inner phase was observed 
(Figure 2), confirming that the pH of the inner phase is of primary importance for efficient 
peptide encapsulation. The effect of the higher inner phase volume on the burst release 
is mainly pH related, by providing a higher number of base/buffer molecules able to 
neutralize the acidic peptide and maintain an alkaline pH, whereas a higher acidic inner 
volume showed no effect (Table 1, formulation 10). 
In order to better understand the physicochemical characteristics of the peptide and the 
effect of pH of the inner (w1) phase on the observed encapsulation efficiency and burst 
release, the sequence of the peptide was analyzed using ProtParam, the online protein 
identification and analysis software that is available through the ExPASy World Wide 
Web server [111] Using this tool, the theoretical isoelectric point of the OVA24 peptide 
151
Optimization of encapsulation of a SLP in PLGA NPs
5
was determined as 4.3, and the grand average of hydropathicity (GRAVY) as 0.087 
[112]. According to this index, amino acids are separated into hydrophilic (negative 
GRVAY value) and hydrophobic (positive GRAVY value). The amino acids with GRAVY 
values closer to zero correspond to the least hydrophobic and hydrophilic ones, which 
are respectively alanine (1.8) and glycine (-0.4). The slightly positive value of the OVA24 
peptide confirms its slight hydrophobic nature. 
Hydrophobic protein domains have shown to adsorb to polymer surfaces by 
electrostatic and/or hydrophobic interactions, and particle surface properties can 
influence adsorption [113]. Though for the OVA24/PLGA system the mechanism of 
encapsulation versus surface localization is still not clear, we hypothesize that efficient 
encapsulation at a higher pH of the inner phase may result from a more favorable 
partitioning of the peptide between internal/external aqueous phases and interfaces. 
A closer look at the peptide sequence and position of its charged residues (D-E-
VSGLE-QLE-SIIN-FE-K+LAAAAAK+) allows us to divide it into two sections, with 
distinct characteristics. At low pHs, below the peptide’s pI, the DEVSGLEQLESIINFE 
part should be mostly neutral, with the exception of the N-terminal amine group, and 
therefore rather hydrophobic. On the other hand, the K+LAAAAAK+ sequence might 
act as a charged headgroup, thereby rendering the molecule surface active and prone 
to migrate to the surface. Free peptide in the external phase may also adsorb to the 
particles through electrostatic interactions between positively charged residues and 
negatively charged PLGA NP surfaces. Once exposed to saline solutions at higher 
pHs, the ’hydrophobic tail’ will become negatively charged, hence more hydrophilic, 
by which the molecule may loose its surface activity, as well as repel from negatively 
charged PLGA, whereas the electrostatic interactions between the positively charged 
residues and PLGA may also be displaced by the presence of counter ions, which 
could explain the release in PBS pH 7.4, but not in water (i.e., during washing of the 
particles during preparation) or isotonic glucose solutions with acidic pHs. 
Previous studies with the short synthetic peptide SIINFEKL in PLGA microparticles 
showed nearly total release of the peptide within 24 hours in PBS [54]. Studies with 
longer peptides (13 to 43 amino acids) or recombinant human growth hormone in 
microparticles showed 20-70% release over the first 24 h [114-117], whereas insulin 
also shows 30-40% release from PLGA NP within 24 h [118]. With our method we 
were able to encapsulate OVA24 with nearly 40% EE in NP showing minimal burst 
release and a total peptide release of circa 30% over 24 h. The better retention of 
SLP will allow delivery of encapsulated peptide to DC, which is a great improvement 
compared to release over the same period of time of high releasing formulations. This is 
especially important if we consider subsequent development of this particulate system 
for delivery of SLP, which may include co-encapsulation of adjuvants, such as Toll-
like receptor ligands (TLRL), or even surface modification with targeting moieties that 
require covalent binding to the particles at controlled pH such as described by Cruz et 
al. [85] without losing most of the antigen during the manufacturing process or shortly 
after administration.
The effect of OVA24 encapsulation on antigen cross-presentation to activate CD8+ T 
cells was tested in vitro with conclusive results. OVA24-containing PLGA NP with low 
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burst release showed significantly higher capacity of CD8+ T cell activation comparing 
to those with high burst release (Figure 4). Likewise, soluble peptide mixed with empty 
particles did not show any improvement when compared to soluble peptide, further 
proving the need of effective entrapment of antigen in PLGA to increase antigen cross 
presentation by DC. Furthermore, we showed that not only encapsulation of OVA24 in 
PLGA NP is required, but also the release characteristics are of vital importance, with 
low burst release being fundamental to induce a potent cellular immune response. This 
is probably due to enhanced uptake and/or processing by DC of particulate antigen. 
When incubated with low-burst releasing particles, DC may efficiently uptake the antigen 
cargo still encapsulated in PLGA particles, whereas with high-burst releasing particles, 
DC will take up less encapsulated peptide, thereby lowering the overall efficiency by 
which the peptide is internalized and routed into MHC class I antigen presentation 
pathways. The improved MHC class I antigen presentation observed with low-burst 
releasing particles is indicative of sustained release of the peptide inside the DC, similar 
to other antigen delivery systems to DC [119].
5.  Conclusion
In this study we described a method for efficient encapsulation of a model SLP in PLGA 
NP, resulting in a particle delivery system able to enhance CD8+ T cell activation in vitro. 
This encapsulation method, employing an apparent inner phase pH above the pI of the 
encapsulated SLP, may be a promising approach for encapsulation of peptides with 
amphiphilic and/or hydrophilic properties, and may be considered as a firm basis for the 
development of NP formulations for SLP-based immunotherapy of cancer. Preliminary 
studies showed that the method is applicable to other SLP as well (unpublished 
results). Additionally, this study shows the importance of thorough characterization 
of peptide encapsulation process in PLGA NP to achieve a successful formulation. 
In conclusion, this study has shown that encapsulation and release characteristics 
are strongly dependent on the pH of the first emulsion, whereas a direct comparison 
between NP with similar physicochemical characteristics in terms of charge, size and 
antigen loading, but different release profiles, uncovered the importance of low burst 
release to induce a potent cellular immune response. 
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We previously reported the succesfull incorporation of synthetic long peptides (SLPs) 
in poly(lactic- co-glycolic acid) (PLGA) nanoparticles (NP) as a vaccine delivery vehicle. 
We showed that a low burst release of the encapsulated SLP was crucial to improve 
MHC class I presentation and CD8+ T cell activation in comparison to soluble SLP 
(sSLP) in vitro. Using SLP-OVA24aa as vaccine antigen (Ag) and toll-like receptor (TLR) 
2 ligand Pam3CSK4 as an adjuvant encapsulated in PLGA-NP (PLGA-SLP and PLGA-
SLP/TLR2L), we show in this report that TLR 2 stimulation enhances MHC class I 
presentation of PLGA-SLP by dendritic cells (DCs), however co-encapsulation of 
the TLR ligand was not required for this effect. DC loaded with PLGA-SLP(/TLR2L) 
internalized NP into endo-lysosomal compartments and not the cytosol as occurs 
with sSLP. Moreover, PLGA-NP encapsulated SLP could be detected for prolonged 
periods inside endo-lysosomal compartments. Prolonged presence of NP inside DC 
resulted in MHC class I presentation of encapsulated SLP for up to 96 hr, which led 
to sustained CD8+ T cell proliferation in in vivo adoptive transfer of PLGA-SLP loaded 
DC. These findings explain the in vivo effectiveness of nanoparticle vaccination and 
shows that PLGA-SLP is a promising delivery vehicle for clinical application as a cancer 
immunotherapy. 
Keywords: Peptide antigen, synthetic long peptides, CTL epitope, PLGA nanopar-
ticles, TLRL, cancer immunotherapy, cellular immune response
1. Introduction
Cancer immunotherapy is a promising treatment modality to enhance the tumor asso-
ciated antigen (Ag) specific T cell responses in cancer patients. Efficient MHC class I Ag 
presentation and subsequent CD8+ T cell priming are pre-requisites for optimal clinical 
efficacy of a cancer immunotherapy vaccine [1, 2]. We recently reported that synthetic 
long peptides (SLP) considerably facilitate MHC class I presentation in comparison to 
protein, which was related to faster uptake and processing of SLP by dendritic cells 
(DC) compared to that of protein Ag [3]. 
SLP-vaccines emulsified in Montanide(-ISA51) water-in-oil-in-water emulsion have 
been studied in the clinic against various forms of cancer [4, 5] and other immuno-
logical diseases [6, 7]. However, the use of Montanide is associated with considerable 
adverse effects [8-11]. In addition, montanide has poorly defined adjuvant properties 
and the release kinetics of the emulsified vaccine-Ag cannot be controlled. Alternative 
vaccine delivery systems and adjuvants for SLP, being at least as efficient as but hav-
ing less side effects than Montanide, are therefore highly required like well-defined Toll 
like receptor ligands (TLRL). In light of this we have previously reported the succesful 
application of nanoparticles (NP) formulated with the fully biocompatible polymer, poly-
(lactic-co-glycolic-acid) (PLGA) as delivery vehicle for SLP vaccines. Encapsulating SLP 
in PLGA led to a significant enhancement of MHC class I Ag presentation and CD8+ 
165
Prolonged Ag presentation of SLP encapsulated in PLGA NPs
6
T cell activation compared to soluble SLP [10]P. However, PLGA-NP have low immu-
nostimulatory properties by itself but allows controled co-encapsulation and release of 
TLRL [12, 13].  
The aim of the present paper was to study 1) how PLGA-NP encapsulated SLP is 
routed and processed into MHC class I molecules and 2) how a defined adjuvant co-
encapsulated in NP affects the efficiency and duration of CD8+ T cell activation by DC. 
For this purpose, NP were formulated together with a  TLR2L (Pam3CSK4) as adjuvant, 
which effectively boosted vaccine-Ag specific immune responseswhen covalently con-
jugated to SLP [14, 15]. 
We show here that co-encapsulating TLR2L with SLP in PLGA-NP further enhanc-
es the efficiency of MHC class I cross-presentation of SLP by DC compared to plain 
PLGA-SLP. In addition, loading of DC using PLGA-NP results in sustained MHC class 
I presentation of SLP compared to soluble SLP. However, the effect of sustained MHC 
clas I presentation was not related to TLR2L-mediated DC maturation but likely be-
cause of the prolonged presence of PLGA-NP encapsulated SLP inside endo-lyso-
somal compartments upon uptake by DC. These organels are similar to the storage 
compartments in DC we have described for other antigen targeting system like FcR-
mediated uptake [16].
Finally, we show that adoptive transfer of DC loaded with PLGA-SLP/TLR2L stimulated 
CD8+ T cells over a sustained period of time whereas soluble SLP loaded DC failed to 
do so. Therefore, this study presents additional evidence for the use of PLGA-NP as a 
clinically suitable vaccine delivery systems to enhance direct MHC class I Ag presenta-
tion and T cell activation but also maintain CD8+ T cell responses over a prolonged time 
period. 
2. Material and methods
2.1. Mice
WT C57BL/6 (CD45.2/Thy1.2; H2-Kb) mice were obtained from Charles River 
Laboratories (France). TAP1 KO mice (C57BL/6 CD45.2/Thy1.2; H2-Kb) were 
purchased from the Jackson laboratory (Bar Harbor, ME). All mice were used at 8–12 
weeks of age in accordance with national legislation and under supervision of the 




The synthetic long peptide DEVSGLEQLESIINFEKLAAAAAK (SLP-OVA24) [17], cover-
ing the H2-Kb restricted CD8+ T cell epitope SIINFEKL of ovalbumin (OVA) and SLP-
OVA24-Bodipy-FL (Bp) were synthesized at the interdepartmental GMP facility of the 
Department of Clinical Pharmacy and Toxicology of Leiden University Medical Center as 
described previously [10]. Poly(D,L-lactic-co-glycolic acid) [PLGA], Resomer® RG 502H 
was purchased from Boehringer Ingelheim (Ingelheim, Germany). 4-(2-hydroxyethyl)-
1-piperazine-ethanesulfonic acid (HEPES), dichloromethane (DCM), dimethyl sulfoxide 
(DMSO), and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (Steinheim, 
Germany). Acetonitrile (ACN) and methanol (MeOH) were obtained from Biosolve BV 
(Valkenswaard, the Netherlands), Polyvinyl alcohol (PVA) 4-88 (31 kDa) was purchased 
from Fluka (Steinheim, Germany). Reversed phase HPLC column ReproSil-Pur C18-
AQ 3 µm (150x4 mm) was purchased from Dr. Maisch HPLC GmbH (Ammerbuch-
Entringen, Germany). Pam3CSK4 and Pam3CSK4-Rhodamine were purchased from 
Invivogen (San Diego, USA). Iscove’s Modified Dulbecco’s Medium (IMDM) was pur-
chased from Lonza (Walkersville, USA). All other chemicals were of analytical grade and 
all aqueous solutions were prepared with milli Q water.
2.3. Nanoparticle preparation and characterization
Nanoparticles loaded with SLP-OVA24 were prepared using a double emulsion with 
solvent evaporation method as previously described [10]. In brief, 1.4 mg SLP-OVA24 
were dissolved in 100 μL 50% ACN in 0.25 mM NaOH and then added to 400 μL 50 
mM Hepes, pH 8.0. This solution was then added to 50 mg of PLGA in 1 ml of di-
chloromethane and the mixture was emulsified under sonication (30 s, 20 W). To this 
first emulsion (w1/o), 2 ml of an aqueous surfactant solution (for surfactant types, see 
results) were added immediately, and the mixture was emulsified again by sonication 
(30 s, 20 W), creating a double emulsion (w1/o/w2). The emulsion was then added 
drop-wise to 25 ml of extraction medium (0.3% w/v surfactant) previously heated to 
40°C under agitation, to allow quick solvent evaporation, and left stirring for 1 h. The 
particles were then collected by centrifugation for 15 min at 15000 g at 10°C, washed, 
resuspended in Milli Q water, aliquoted and freeze-dried at -55°C in a Christ Alpha 1-2 
freeze-drier (Osterode am Harz, Germany) overnight. For particles co-encapsulating 
SLP-OVA24 and Pam3CSK4, 250 μg of Pam3CSK4 were dissolved in DCM together 
with PLGA, and for particles containing SLP-OVA24-Bp-FL, circa 10% labeled peptide 
was added to the peptide solution.
Particle characterization was performed as described [10]. NP were diluted to 2.5 
mg/ml in 1 mM Hepes pH 7.4. Size and polydispersity index (PDI) of NP were mea-
sured by dynamic light scattering, and zeta-potential was measured by laser Doppler 
electrophoresis, using a Zetasizer (Nano ZS, Malvern Ltd., United Kingdom). The en-
capsulation efficiency (EE) was calculated according to equation 1 and drug loading 
(DL) by equation 2. EE of OVA24 was determined by measuring the peptide content 
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of digested particles by reversed phase HPLC as described [10]. EE of Pam3CSK4-
Rhodamine was determined by measuring fluorescence detected in the supernatant 




Freshly isolated murine DCs were cultured from mouse bone marrow (BM) cells, as 
described before [18]. The D1 cell line, an immature primary splenic DC line (C57BL/6-
derived), was cultured as described elsewhere [19]. B3Z CD8+ T cells (H2-kb/SIINFEKL) 
are hybridoma cell lines expressing a β-galactosidase construct which upon T-cell ac-
tivation can be measured by a colorimetric assay [3].
2.5. Murine MHC class I Ag presentation assays
C57BL/6 BMDCs or D1 cells (1*105 cells/well) were plated out in triplicate using 96-
well plates (Greiner #655101) and incubated for 2.5 hr with the Ag at the indicated con-
centrations. Cells were washed 3x with complete medium to remove excess Ag before 
the B3Z CD8+ T cells were added to assess MHC class I cross-presentation. T cells 
were cultured in the presence of Ag-loaded DC for 2.5 at 37 °C. In some experiments, 
BMDC or D1 cells were pre-incubated with epoxomicin (324800, Merck) or bafilomycin 
A1 (196000, Merck) followed by Ag-incubation as described above in the presence of 
the compounds. D1 cells were pre-incubated with bafilomycin A1 (196000, Merck) and 
MHC class I Ag presentation determined as described above. To study sustained MHC 
class I Ag presentation, 2*106 immature D1 cells were incubated for 2.5 hr with 4 μM 
SLP in different formulations. After incubation, cells were harvested and transferred to 
50 ml Falcon tubes, resuspended in complete medium and centrifuged . This proce-
dure was performed 3x to wash away unbound Ag. Cells were either used directly as 
Ag presentating cells (APC) (“direct condition”) or plated out again in petri dishes and 
further cultured for 96 hr (“chase condition”). Ag loaded D1 cells were then harvested 
and plated out in 96-wells plates (5*104 cells/well) and used as APC in co-culture with 
B3Z CD8+ T cells to detect capacity to cross-present SLP in MHC class I molecules 
using a colorometric assay as described before [3].
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2.6. Adoptive transfer of Ag loaded DC 
C57BL/6 BMDC cells (10*106 cells/petri dish, Corning # 430589) were loaded with 
4 μM PLGA-SLP, PLGA-SLP/TLR2L and sSLP on t = - 96 hr and t = -2.5 hr. Cells 
were washed to remove unbound Ag and either used directly or further cultures in the 
absence of Ag. On t = - 1 day, splenocytes from Thy1.1+ OT-I mice were harvested and 
transferred i.v. to recipient animals (10*106 splenocytes/mouse). On t = 0, OVA-specific 
T cells enriched mice received i.v. 1*106 DC loaded with PLGA-SLP, PLGA-SLP/TLR2L. 
Tail vein bloodsamples were collected on t = day 3 post-transfer of DC and analyzed 
for the percentages of Thy1.1+ CD8+ T cells using rat anti-mouse CD90.1-APC, CD3-
AF800 and CD8-FITC antibodies (Biolegend). Samples were measured using an LSRII 
flow cytometer (BD) and analyzed with FlowJo software (Treestar). 
2.7. Confocal microscopy
DCs were incubated for 24 hr with 10 µM SLP-OVA24-Bodipy-FL in different formula-
tions at 37°C. Specific murine DC used is described in the figure legends. After incuba-
tion cells were washed 3 times to remove excess and unbound Ag, resuspended at a 
concentration of 2x105 cells in 200 µl complete medium and plated into poly-d-lysine 
coated glass-bottom dishes (MatTek) followed by mild centrifugation to allow the cells 
to adhere. Adhered cells were then fixed with 0.2% paraformaldehyde. All imaging 
experiments were carried out on a Leica TCS SP5 confocal microscope (HCX PL APO 
63×/1.4 NA oil-immersion objective, 12 bit resolution, 1024×1024 pixels, pinhole 2.1 
Airy discs, zoom factor 1 or 7). Imaging was performed using the 488 nm line from an 
Argon laser collecting emission between 500 and 600 nm. Dual color images were 
acquired by sequential scanning, with only one laser per scan to avoid cross talk. The 
images were analyzed using the Leica software program (LAS AF).
2.8. Analysis of cytokine production by DC using Enzyme-
linked Immunosorbent Assay (ELISA)
BMDC were incubated for 24 hr with NP. Supernatants were harvested and tested 
for IL-12 p70 (BD OptEIA™ MOUSE IL-12 Cat. Nr 555256) following manufacturer’s 
instructions.
169
Prolonged Ag presentation of SLP encapsulated in PLGA NPs
6
2.9. Statistics
Graphpad prism was used as the main statistical software. Statistical analyses applied 
to determine the significance of differences are described in the figure legends.
3. Results 
3.1. Characterization of formulated PLGA-SLP and PLGA-
SLP/TLR2L NP
PLGA-NP were formulated using a modified double emulsion method and solvent evap-
oration technique with SLP-OVA24 as described before, PLGA-SLP [10]. This formula-
tion was adapted by adding the TLR2 ligand (TLR2L) Pam3CSK4 in the organic phase 
to yield PLGA-NP co-encapsulating SLP and adjuvant, PLGA-SLP/TLR2L. For visual-
ization purposes selected batches were formulated with 10 % SLP-OVA24-Bodipy-FL 
(SLP-Bp). Fluorescent SLP was added during formulation. Particle characteristics are 
described in Table 1. 
Co-encapsulation of TLR2L and/or SLP-Bp did not affect the physical properties of 
the formulated NP, with several batches showing very similar characteristics (Table 1).











PLGA-SLP* 1.06 ± 0.15 39 ± 6 n/a n/a 322 ± 44 0.19 ± 0.04 -12 ± 1
PLGA-SLP/
TLR2L*
1.02 ± 0.17 38 ± 6 0.32 ± 0.05 67 ± 10 293 ± 19 0.18 ± 0.04 -13 ±1
PLGA-SLP-Bp** 1.01 37 n/a n/a 312 0.23 -16
PLGA-SLP/
TLR2L-BP**
0.95 35 0.16 33 304 0.20 -13
DL = drug loading; EE = encapsulation efficiency; PDI = poly dispersity index; variance, an arbitrary measure 
for the degree of dispersity in particle size within one batch of particles suspension, PDI values below 0.3 was 
considered monodisperse and accepted for follow up studies [20].ZP = zeta potential; The magnitude of the 
zeta potential is predictive of the colloidal stability. Nanoparticles with Zeta Potential values greater than +25 
mV or less than -25 mV typically have high degrees of stability. Dispersions with a low zeta potential value will 
eventually aggregate due to Van der Waal inter-particle attractions.
ºSLP-OVA24 (DEVSGLEQLESIINFEKLAAAAAK).
*Values represent average ±SD of > 4 independently prepared batches.
**Values obtained from 1 batch.
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3.2. Enhanced cross-presentation of PLGA-NP encapsulated 
SLP in the presence of TLR2L
DC loaded with PLGA-SLP cross-presented SLP in the context of MHC class I mol-
ecules with higher efficiency compared to sSLP, as published previously [20]. TLR-
stimulation is known to improve proteasome activity and thus enhance MHC class I 
Ag cross-presentation. Indeed, the presence of TLR2L during Ag-loading enhanced 
MHC class I cross-presentation of all SLP-formulations tested compared to DC loaded 
in the absence of TLR2L (Figure 1A). PLGA-SLP/TLR2L resulted in better CD8+ T cell 
activation than PLGA-SLP. However, co-encapsulation of TLR2L was dispensable to 
enhance MHC class I presentation of PLGA-encapsulated SLP in vitro as mixtures of 
PLGA-SLP + soluble TLR2L (sTLR2L) showed similar potency to PLGA-SLP/TLR2L. 
 TLR2 stimulation failed to improve the cross-presentation of sSLP to comparable lev-
els as observed with PLGA-encapsulated SLP (Figure 1A). This observation stresses 
the importance of an optimal delivery method to achieve high levels of Ag intracellularly 
and to improve MHC class I Ag processing.
In summary, combining TLR2L stimulation with PLGA-NP delivery of SLP significantly 
improves MHC class I presentation compared to Ag loading in the absence of TLR2L. 
The positive effect of TLR2L was irrespective of co-encapsulation in PLGA-NP. 
3.3. Ag-delivery via PLGA-NP results in prolonged MHC class 
I Ag cross-presentation
The duration of MHC class I presentation and TCR recognition/binding is an important 
factor determining CD8+ T cell priming. Short TCR-stimulation leads to sub-optimal 
T cell priming which is associated in impaired effector functions anergy [21, 22]. The 
long term effects on MHC class I cross-presentation of SLP was studied by stimulating 
B3Z CD8+ T cells with 96 hr rested Ag-loaded DC. DC were incubated for 2.5 hr in 
the presence of 4 μM SLP in either soluble or particulate form with or without TLR2L. 
As a positive control, DC were incubated with SLP-TLR2L conjugates which induce 
the formation of Ag-storage compartments upon internalization. These compartments 
facilitate prolonged MHC class I presentation and sustained CD8+ T cell priming as we 
have previously reported [14, 18]. DC loaded with sSLP failed to activate CD8+ T cells 
96 hr post Ag-incubation (Figure 1B). Only DC incubated with PLGA-encapsulated Ag 
and the SLP-TLR2L conjugate were capable of MHC class I SLP cross-presentation 
after 96 hr (Figure 1B). 
TLR-stimulation has been shown to slow down the decay of MHC class I molecules 
thereby prolonging cell-surface expression of MHC class I molecule/peptide complexes 
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Figure 1. TLR2 stimulation improves MHC class I cross-presentation of PLGA-NP 
encapsulated SLP. D1 cells were incubated for 2.5 h with titrated amounts of SLP-OVA24 
in different formulations with our without Pam3CSK4 (TLR2L) and co-cultured overnight in the 
presence of (A) B3Z CD8+ T cells. T-cell activation was determined as described in Materials 
and methods. (B) D1 cells were incubated with 4 μM Ag for 2.5 hr on t = -96 hr (chase) and 
on t = -2.5 hr (direct). “Chase” and “direct” Ag loaded DC were harvested at t = 0 hr and their 
APC capacity to activate B3Z CD8+ T cells compared. Data are shown as mean + SD of three 
samples from one representative experiment representative of four (A) and three (B) experiments 
performed. *** P < 0.001 using a two-way ANOVA and Bonferroni posttests.
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[23]. In our system however, prolonged presence of MHC class I molecules/peptide 
complexes is unlikely to be the main mechanism facilitating sustained CD8+ T cell 
activation by PLGA-SLP as plain particles in the absence of additional adjuvants poorly 
matured DC. PLGA-SLP had no phenotypical (Figure 2A) nor functional DC maturating 
effects (Figure 2B) on DC. Addition of Pam3CSK4 to PLGA-SLP formulations, to 
obtain PLGA-SLP/TLR2L, very efficiciently matured DC (Figure 2). However, TLR2L 
stimulation did not further MHC class I Ag cross-presentation by DC loaded with 
PLGA-SLP or sSLP loaded DC and then rested for 96 hr in culture in the absence of 
Ag. Therefore, TLR2-stimulation by itself cannot explain our observations of prolonged 
Ag presentation by DC pulsed by PLGA-SLP.
In conclusion, Ag delivery via PLGA-NP results in prolonged MHC class I presentation 
in vitro and sustained CD8+ T cell activation. Prolonged MHC class I presentation of 
SLP was not dependent on DC maturation.
Figure 2. Addition of TLR2L to plain PLGA-SLP and sSLP improves adjuvanticity and 
results in DC maturation. D1 cells were incubated in the presence of titrated amounts of SLP 
formulations with or without Pam3CSK4 (Invivogen, tlrl-pms), and soluble LPS (TLR4L) (Sigma 
L4130, Escherichia coli 0111:B4). After 24 hr supernatants were collected, DC harvested and 
stained for MHC class II and CD86 and their expression analyzed by FACS (A). Percentages 
indicate the numbers of double positive cells. Supernatants were analyzed via ELISA for IL-2 
levels (B). Data shown are representative of three independent experiments. 
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3.4. DC loaded with SLP encapsulated in NP are capable of 
sustained in vivo priming after adoptive transfer
The in vitro observations were confirmed in vivo by transferring DC which were loaded 
with Ag on t = -96 hr into recipient mice enriched with OT-I CD8+ T cells on day before 
adoptive transfer. The extent of CD8+ T cell expansion was compared to mice receiving 
DC loaded with Ag (-2.5 hr, “direct”).
Only DC which were loaded with PLGA-SLP or PLGA-SLP/TLR2L induced significant 
OT-I CD8+ T expansion using freshly Ag-loaded DC (Figure 3). DC loaded with sSLP 
performed poorly as APC at the concentrations of sSLP tested. Poor priming of OT-I 
CD8+ T cells can be related to the lower MHC class I presentation of sSLP compared 
to PLGA-SLP but is most likely a result of sub-optimal activation of naive OT-I CD8+ T 
cells, which are co-stimulation dependent, by sSLP loaded DC which have a immature 
phenotype (Figure 2). PLGA-SLP and even PLGA-NP in general, do not mature DC. 
However NP-based Ag delivery is very efficient leading to high density of Ag-epitope 
loaded MHC class I molecules on the cell-surface leading to sufficient triggering of OT-I 
CD8+ T cells for them to proliferate in vivo. PLGA-SLP with co-encapsulated TLR2L 
results in significant OT-I expansion even after 96 hrs incubation indicating sustained 
antigen storage of the particle-delivered antigen by DC.
Figure 3. PLGA-SLP loaded DC possesses APC capacity and stimulated CD8+ T cells 
96 hr after Ag-loading. Ag loaded BMDC (C57BL/6) were tested for their capacity to expand 
specific CD8+ T cells in vivo. WT C57BL/6 animals received 10*106 OVA-specific Thy1.1+ OT-I 
splenocytes i.v. on t = day -1. On t = 0, OVA-specific T cell enriched mice received i.v. 1*106 DC 
loaded with PLGA-SLP, PLGA-SLP/TLR2L and sSLP on t = -96 hr and t = -2.5 hr. Blood samples 
were taken on t = day 3 post-transfer of DC and analyzed for the percentages of Thy1.1+CD8+ T 
cells. DC loaded with SIINFEKL and 10 μg/ml LPS and antigen naïve DC were used as positive 
(pos) and negative (neg) control. Percentages determined for each individual mice are displayed 




3.5. Re-routing and prolonged presence of SLP into the 
endosomes by encapsulation in PLGA-NP
We analyzed if the intracellular localisation of PLGA-SLP after uptake by DC might play 
a role in the observed MHC class I presentation. For this purpose DC were incubated 
with sSLP, PLGA-SLP and PLGA-SLP/TLR2L and analyzed directly by confocal micro-
scope. D1 dendritic cells and BMDC were highly capable to internalizing Bp-labeled 
SLP in the tested formulations (green fluorescence, Figures 4 & 5). 
Figure 4. Rerouting of SLP into endo-lysosomal compartments upon encapsulation of 
in PLGA-NP. BMDC were incubated with 20 μM sSLP-Bp, 20 μM PLGA-SLP-Bp (10% SLP-
Bodipy-FL) or 20 μM PLGA-SLP-Bp/TLR2L (10% SLP-Bodipy-FL) (excitation- 488nm, visualized 
as the green signal) for 2.5 hr and co-stained with Lysotracker red for visualization of the endo-
lysosomes (red signal) and visualized by confocal microscopy. (A) 1st column shows images 
depicting green signal as the fluorescence of Bodipy-FL (488nm). 2nd column shows images 
depicting red signal as the fluoresence of the lysotracker red/endo-lysosomes (625nm). 3rd 
column depicts overlay images of red/green. Yellow-overlay signal marks co-localization. Images 
were analyzed using Leica software. BMDC were incubated at 4°C and 37°C with (B) titrated 
amounts of PLGA-SLP, PLGA-SLP/TLR2L and PLGA-SLP + sTLR2L (10% SLP-Bodipy-FL). (C) 
Alternatively, DC were incubated with with 2.5 μM of PLGA-SLP and PLGA-SLP/TLR2L (10% 
SLP-Bodipy-FL). Ag uptake was quantified by flow cytometry and data shown are absolute 
values (% NP+ DC at 37°C - % NP+ DC at 4°C) and represent Avg + SEM of 3 independent 
experiments (A) and Avg + SD of 2 independent experiments.
175
Prolonged Ag presentation of SLP encapsulated in PLGA NPs
6
Figure 5. Sustained presence of PLGA-NP encapsulated SLP in endo-lysosomes. D1 
cells were incubated with 20 μM sSLP-Bp, 20 μM PLGA-SLP-Bp (10% SLP-Bodipy-FL) or 20 
μM PLGA-SLP-Bp/TLR2L (10% SLP-Bodipy-FL) (488nm) for 2.5 hr on t = - 2.5 h (A) and t = - 
96 h (B) and co-stained with Lysotracker red for visualization of the endo-lysosomes on t = - 15 
min. Live cell imaging were performed at t = 0. 1st column shows images depicting green signal 
as the fluorescence of Bodipy-FL (488nm). 2nd column shows images depicting red signal as 
the fluoresence of the lysotracker red/endo-lysosomes (625nm). 3rd column depicts overlay 
images of red/green. White arrow indicates hotspots (yellow) within a cell were green and red 
co-localize. Closed circles show cells containing green-flourescent signal (and red fluorescent 




sSLP internalized by DC was present for a large part outside the endo-lysomes as we 
showed before [20] whereas PLGA-encapsulated SLP showed high co-localization, 
with endo-lysomes, suggested by the formation of bright yellow spots, marked in the 
Figures 4 & 5 by the arrows. DC which took up NP tend to have larger endo-lysosomal 
compartments (bright red spots, Figures 4 & 5) compared to DC which internalized 
sSLP which might suggest formation of phagolysosomes. The results indicate that en-
capsulation of SLP inside PLGA-SLP modulates intracellular trafficking of SLP by keep-
ing the Ag inside endosomal compartments, thereby directing it away from the cytosol.
Brighter yellow spots were observed when BMDC internalized PLGA-SLP in compari-
son to sSLP. This suggest that DC take up much higher amounts of SLP on a single cell 
basis when it is encapsulated in PLGA-NP, pointing to the more efficient uptake by DC 
of SLP when encapsulated (Figure 4). Interestingly, encapsulation of TLR2L in PLGA-
NP (PLGA-SLP/TLR2L) even further enhanced the efficiency (Figure 4B) and rapidity 
of NP internalization  (Figure 4C) by BMDC suggesting an additional role for TLR2 in 
the internalization of NP. 
DC are known to preserve internalized PLGA-(micro)spheres inside endo-lysosomal 
compartments for up to 48 hr [25] which suggests that intracellular hydrolysis of PLGA 
particles to be a slow process. In our study, sustained MHC class I cross-presentation 
of PLGA-encapsulated SLP could be detected even after 96 hr. We therefore analyzed 
D1 cells loaded with sSLP, PLGA-SLP, PLGA-SLP/TLR2L directly after loading (Figure 
5A) or after 96 hr rest (Figure 5B). sSLP-loaded D1 cells analyzed after 96 hr rest 
showed clear differences with DC analyzed directly after Ag-loading. Fluorescent signal 
of SLP was largely undetectable in DC cultured with sSLP whereas labeled SLP origi-
nated from the PLGA-SLP or PLGA-SLP/TLR2L could be clearly detected still inside 
endosomal compartments (Figure 5). 
It is known that internalized soluble proteins are also routed into endosomal compart-
ments [24-26]. However, endosomal presence of an Ag does not guarantee preserva-
tion as soluble protein was not detected inside DC after 96 hr (Supplemental Figure 
1). This observation fits with our previous reports showing that soluble proteins do not 
lead to sustained Ag presentation [18]. 
3.6. Processing of PLGA-NP encapsulated SLP can be 
blocked by inhibitors of endo-lysosomal acidification, 
proteasome and TAP
Exogenous Ag routed towards the MHC class I cross-presentation pathway can follow 
two pathways I) the classical cytosolic pathway or II) the endosomal pathway [27-29]. 
The endosomal pathway is dependent on the pH inside the endo-lysosomes but the 
cytosolic pathway is (mostly) independent of the pH gradient inside endo-lysosomes 
[29]. We observed that CD8+ T cell activation by DC loaded with PLGA-SLP and PLGA-
SLP/TLR2L can be completely blocked (Figure 6) in a dose dependent manner 
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using the lysotropic agent, bafilomycin A (Baf A). MHC class I cross-presentation of 
sSLP was slightly decreased as observed before [3] but CD8+ T cell activation could 
still be detected at the highest concentration of the compound tested in this study. The 
presentation of the minimal MHC class I binding peptide (OVA8) was unaffected over 
the whole range of concentrations used. PLGA-SLP MHC class I cross-presentation 
was reduced in the presence of a proteasome inhibitor (Figure 6B & C). MHC class I 
processing of PLGA-SLP was significantly impaired in the absence of functional TAP 
(Figure 6B & E) or when when endo-lysozomal acidification is blocked (Figure 6B & 
D). 
4. Discussion
In this study, we analyzed the effects on MHC class I presentation of co-encapsulating 
a TLR2L with SLP in PLGA-NP. SLP and PLGA-NP are inert synthetic materials with 
poor immunestimulating properties. The therapeutic effectivity of cancer vaccines is 
largely based on its potency to activate DCs, which have superiour capacity to induce 
robust anti-tumor T cell responses.
We previously reported the succesful formulation of PLGA-SLP using a novel double 
emulsion and solvent-evaporation technique. Applying PLGA-NP as a vaccine delivery 
system, the efficacy of MHC class I Ag presentation and subsequent CD8+ T cell 
activation by DCs was significantly enhanced [10] compared to sSLP. We have also 
shown recently that plain PLGA-NP have poor DC activating properties compared to 
TLRL [12]. With the purpose of further increasing the vaccine potency of PLGA-SLP, we 
have included a TLR2L, Pam3CSK4; an adjuvant which has led to promising pre-clinical 
results when covalently coupled to SLP. To this end, TLR2L was co-encapsulated in 
PLGA-NP with the goal to achieve asubstantial DC activation leadingleads to better 
CD8+ T cell activation in comparison to particles which are not adjuvanted. 
In light of our recent findings showing that sSLP are efficiently cross-presented because 
of a rapid translocation into the cytosol facilatating proteasome dependent processing; 
the intracellular location of PLGA-SLP was studied to elucidate if PLGA-NP further 
enhances translocation of SLP, after release from the NP, to the cytosol or if different 
mechanisms are involved in the handling of PLGA-encapsulated SLP in comparison to 
the sSLP.
We show here that the addition of Pam3CSK4 to PLGA-NP encapsulating SLP strongly 
promotes DC maturation and CD8+ T cell activation. The difference on Ag uptake and 
MHC class I cross-presentation of PLGA-SLP versus PLGA-SLP/TLR2L was was max 
3-fold. Lower than we expected given our previous studies using SLP-TLR2L [14]. This 
moderate enhancement can be explained considering the already very efficient uptake, 
processing and presentation of plain PLGA-SLP (NP) by DC which perhaps is already 
close to maximum levels.
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Moreover, Pam3CSK4 was not to required to be encapsulated inside particles for it 
to exert its positive effects on MHC class I presentation of SLP. Mixing sTLR2L with 
plain PLGA-SLP led to similar results as using PLGA-SLP/TLR2L. Thus Pam3CSK4 
has a different effect on the potency of SLP when co-encapsulated in NP compared 
to covalently coupling the compound to a peptide, which results in very strong 
enhancement of CD8+ T cell activation compared to mixtures of SLP and Pam3CSK4 
[14]. 
Pam3CSK4 has a lipidic nature and contains positively charged lysine residues which 
direct adsorbtion to to the negatively charged PLGA-NP surface due to hydrophobic 
and (or) electrostatic interactions [3]. The adsorbtion of Pam3CSK4 to PLGA-SLP when 
mixed might lead to similar NP-characteristics as PLGA-SLP/TLR2L. This effect could 
explain why both the mixing or co-encapsulation will result in an similar participation 
of Pam3CSK4 in MHC class I presentation. In conclusion, we show that addition of 
a Pam3CSK4, whether co-encapsulated or not, further improves MHC class I cross-
presentation of SLP and improves CD8+ T cell activation compared to plain PLGA-SLP. 
sSLP present in the cytosol are degraded via ubiquitin proteasome system (UPS) [30], 
whereas the Ag present inside endo-lysosomal compartments can be protected from 
rapid degradation by the UPS. Upon internalization of PLGA-NP by DC, a majority of 
the Ag could be detected inside the endo-lysosomes where hydrolysis of the polymer 
takes place releasing the encapsulated SLP [31]. Thus, the PLGA-NP encapsulated 
Ag inside endo-lysosomal compartments (Figure 4) serves as an intracellular reservoir 
which gradually releases the SLP for processing via the classical proteasome-TAP 
dependent MHC class I processing pathways. Baf A clearly interferes with MHC 
class I Ag presentation of PLGA-SLP. One possibility is that the compound blocks the 
transportation of SLP from the endo-lysosomes to the cytosol [32]. Another possibility 
is that Baf A modulates the activity of endo-lysosomal cathepsins [31]. Cathepsin S 
has been shown to have a role in MHC class I cross-presentation [27]. Using BMDC 
generated from Cathepsin S KO mice, we did not observe differences in MHC class 
I cross-presentation of PLGA-SLP compared to WT BMDC (data not shown). Taken 
our results using proteasome inhibitors and TAP-deficient BMDC we show that SLP 
encapsulated in PLGA-NP is cross-presented via the classical MHC class I processing 
pathway but we cannot exclude that the endo-lysosomal environment and other pH 
dependent proteases still play a role in the observed MHC class I Ag cross-presentation 
[28, 29].
The most important observation of this study was that encapsulation of sSLP in PLGA-
NP results in sustained presence of the Ag inside DC upon internalization. More over, 
DC loaded with PLGA-SLP or PLGA-SLP/TLR2L showed prolonged MHC class I 
presentation in comparison to DC loaded with sSLP. Prolonged Ag presentation was 
not dependent on TLR2L stimulation but the addition of Pam3CSK4 does improve 
and sustain CD8+ T cell activation over a longer time period in vivo. Others observed 
similar results using PLGA-particles encapsulating proteins [33]. However, in contrast 
to our results, it has been reported that PLGA-particles induce membrane rupture and 
rapid endo-lysosomal [34] followed by “leakage” of the PLGA-encapsulated Ag inside 
the cytosol; so called endosomal escape [33]. Membrane rupture by particulate Ag is 
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associated with inflammasome activation and secretion of IL-1β by APC [35]. In our 
system, however we could not detect IL-1β in culture supernatants using ELISA after 
24 hr incubations of DC with PLGA-SLP nor PLGA-SLP/TLR2L (data not shown). As 
mentioned before, we could detect green-fluorescent signal of the SLP-OVA24-Bodipy-
FL and CD8+ T cell activation even after 96 hr indicating that in our study the majority of 
PLGA-encapsulated SLP was not directly tranported to the cytosol after DC internalized 
the NP. Thus, internalized PLGA-NP show functional similarities with intracullar storage 
compartments as reported for other targeted vaccine delivery systems [14, 18]. 
Therefore, we postulate that the efficient and prolonged MHC class I presentation 
observed using PLGA-SLP and PLGA-SLP/TLR2L is related to preservation of the 
Ag inside intact intracellular compartments. We show here based on the intracellular 
localization of internalized PLGA-NP and functional studies that these particles also 
end up in Ag storage compartments [18]. 
Finally, direct s.c. vaccinations with PLGA-SLP/TLR2L but not PLGA-SLP induces 
endogenous Ag-specific CD8+ T cells capable of target cell lysis (Supplemental Figure 
2). In conclusion, the study reported here supports a mechanism that CD8+ T cell 
responses is enhanced when the Ag is cross-presented in MHC class I molecules in a 
sustained manner. We show that the co-encapsulation of a TLR2L further boosts these 
effects and thus supports the use of PLGA-NP co-encapsulating long peptide vaccines 
and adjuvants as an anti-cancer vaccine. Cancer cells are notorious for providing very 
few “danger signals”, which is one of the causes why the immune system sometimes 
fails to clear cancers. However, if one vaccinates with PLGA-SLP/TLR2L, encoding 
tumor associated Ag (TAA), for example the sustained release of Ag and adjuvant will 
lead to strong DC maturation, enhanced and prolonged MHC class I presentation and 
efficient priming of cytotoxic CD8+ T cells. Indeed, vaccination with PLGA-NP based 
vaccines results in robust anti-tumor responses with the capacity to significantly control 
tumor out growth [36-39].
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6. Supplemental Figures
Supplemental Figure 1. Endosomal localisation of whole protein after internalization 
does not lead to prolonged Ag presence. D1 cells were incubated with 20 μM ovalbumin-
Alexa488 (excitation- 488nm, visualized as the green signal) for 2.5 hr and either directly analyzed 
(upper panels) or further cultured in the absence of additional Ag or stimuli for 96 hr (lower 
panels). Co-staining with Lysotracker red was performed for visualization of the endo-lysosomes 
(red signal) and visualized by confocal microscopy. 1st column shows images depicting green 
signal as the fluorescence of the dye (488nm). 2nd column shows images depicting red signal 
as the fluoresence of the lysotracker red/endo-lysosomes (625nm). 3rd column depicts overlay 
images of red/green. Yellow-overlay signal marks co-localization. Images were analyzed using 
Leica software. 
Supplemental Figure 2. Vaccinations with PLGA-SLP/TLR2L but not PLGA-SLP induces 
CD8+ T cells with in vivo cytotoxic capacity. Priming efficacy of endogenous cytotoxic CD8+ 
T cells by PLGA-SLP formulations, mice were vaccinated with 20 nmol SLP encapsulated in 
PLGA with or without Pam3CSK4 co-encapsulated. On day 7 post-vaccination, SIINFEKL-
loaded (OVA-specific) target and control-target cells were injected. To obtain OVA-specific target 
cells, splenocytes from naïve congeneic C57BL/6 Ly5.1 mice were pulsed for 1 h with 1 µM of 
SIINFEKL-peptide and co-stained with 10 µM CFSE (CFSE-high) (Molecular Probes, Eugene, 
OR). As a negative control, 1 µM of the immunodominant ASNENMETM-peptide derived from 
the influenza virus nucleoprotein co-stained with 0.5 µM CFSE (CFSE-low) was used. Specific 
and non-specific target cells were mixed 1:1 and injected intravenously (i.v.; 10 x 106 cells 
of each population). 18 hr after cells were transferred, mice were sacrificed and spleen cells 
were harvested to prepare single cell suspensions that were then subjected to flow cytometric 
analysis. Injected cells were distinguished by APC-conjugated rat anti-mouse CD45.1 mAb. 
The percentage specific killing was calculated as follow: 100 - ([(% SIINFEKL-peptide pulsed 
in treated/% ASNENMETM-pulsed in treated)/(% SIINFEKL-peptide pulsed in non-treated/% 
ASNENMETM-pulsed in non-treated)] x 100).
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The potential of synthetic long peptide (SLP)-cancer vaccines, based on TLR ligand-
adjuvanted liposomes and PLGA nanoparticles (NPs) to induce a cell-mediated immune 
response, as potential alternatives to clinically used Montanide ISA-51- and squalene-
based emulsions is investigated in this study.  The liposomal and PLGA NP formulations 
were successfully loaded with up to four different compounds and were able to enhance 
antigen uptake by DCs and subsequent activation of T cells in vitro. Subcutaneous 
vaccination of mice showed that the efficiency of the SLP-loaded liposomes and PLGA 
NPs to induce functional antigen-T cells in vivo was as good as or even better than that 
of the emulsions, with liposomes outperforming PLGA NPs. Moreover, after adoptive 
transfer of target cells in mice, liposomes showed the highest killing capacity. These 
findings, considering also the inadequate safety profile of the currently clinically used 
adjuvant Montanide ISA-51, make these two particulate delivery systems promising 
candidates as a delivery platform for SLP-based immunotherapy of cancer.
Keywords: cellular immune response, synthetic long peptides, TLR ligands, cationic 
liposomes, PLGA nanoparticles
1. Introduction
Peptide-based vaccine formulations offer several advantages over protein-based 
vaccines, as peptides can be easily synthesized and characterized, and are generally 
more stable [1] and better processed [2] than whole proteins. Synthetic peptides 
derived from tumor associated antigens (TAAs) have attracted considerable interest 
as a basis for cancer vaccines, and vaccination with synthetic long peptides (SLPs), 
containing all the CTL and Th epitopes of a TAA, has been applied in mouse models 
with superior efficacy to protein antigen [3] or minimal MHC class I restricted epitopes 
[4, 5]. In contrast to short peptides, SLPs cannot bind directly to MHC molecules, 
but have to be taken up and processed by DCs like regular pathogens, inducing a 
stronger immune response, owing to the activation of both CD4+ and CD8+ T cells [5-
7]. However, peptides alone are poorly immunogenic and need to be combined with 
adjuvants such as immune modulators and/or delivery systems in order to properly 
activate the innate and adaptive arms of the immune system [1]. 
Over the past few years, delivery systems that elicit strong immune responses, such 
as nano-emulsions and particulate delivery systems, have been extensively studied. 
These include MF59 (Novartis) and AS03™ (GlaxoSmithKline), squalene-based oil-in-
water emulsions, which have been approved in Europe for use in the Fluad® and 
Pandemrix™ influenza vaccines, respectively [8]. Despite the efficacy of these emulsions 
as influenza vaccine adjuvants, and though some degree of  Th1 responses have been 
observed, still they lack the ability to stimulate strong T cell responses [9].  Montanide 
(ISA-51, Seppic) water-in-oil (w/o) emulsions have shown to elicit CTL responses in 
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clinical studies, and have been applied to formulate SLPs in several clinical therapeutic 
cancer vaccination trials [10-16]. However, the use of Montanide has some important 
limitations, such as non-biodegradability, limited long-term stability, poorly defined 
release properties, suboptimal efficacy, and in some cases induction of local adverse 
side effects [17, 18]. Therefore, alternative delivery systems for SLP-based vaccines 
are highly needed. 
Studies have shown that peptide-based vaccines may benefit from particulate delivery 
systems that mimic the size and structure of a pathogen, facilitating uptake by DCs 
and increasing cross-presentation of the peptide [19-21]. Importantly, they can harbor 
multiple vaccine components and be actively or passively targeted to DCs, also shaping 
the induced immune response via specific receptors, such as toll-like receptors (TLRs), 
by incorporation of TLR ligands (TLRLs). Among several particulate delivery systems, 
both liposomes and polymeric particles have been widely studied.
We have previously studied the application of poly-(lactic-co-glycolic-acid) (PLGA) NPs 
[22] and cationic liposomes composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) [23] for the 
encapsulation of a 24-amino acid-long SLP (referred to as OVA24)  harboring the CTL 
epitope SIINFEKL of ovalbumin (OVA). Encapsulation of SLP in PLGA NPs led to a 
significant enhancement of MHC class I Ag presentation and CD8+ T cell activation 
compared to soluble SLP (sSLP) in vitro [24]. The SLP-specific CD8+ T cell frequency 
induced in vivo by a liposomal SLP formulation containing poly(I:C), showed a 25 fold 
increase compared to poly(I:C)-adjuvanted soluble SLP. Furthermore, intradermal 
immunization of mice with 5 nmol SLP-liposomes combined with poly(I:C) led to a 
strong cytotoxic activity, in contrast to vaccination with a mixture of soluble SLP and 
poly(I:C) [23].
In this study, we investigated the potential of PLGA NPs and cationic liposomes as 
delivery systems for SLP-based vaccine candidates for the induction of a cell-mediated 
immunity. For that purpose, we studied the co-delivery of two SLPs containing the 
CTL (OVA24) and the T helper (Th, OVA17) epitopes of OVA together with poly(I:C) and 
Pam3CSK4, a TLR3 and TLR2/1 ligand, respectively, in comparison to the adjuvants 
Montanide ISA-51 and SWE, a squalene oil-in-water emulsion. OVA24/OVA17-loaded 
PLGA NPs and liposomes with or without the TLR-ligands were characterized for 
particle size, zeta-potential and for peptide and TLR loading efficiencies. The obtained 
formulations were assessed in vitro and in vivo for their potency to induce CD8+ and 
CD4+ T cell immune responses. The observed T cell immune responses induced by 
our particulate formulations were superior to the ones observed with the emulsions 
(Montanide ISA-51 or SWE), with the liposomal formulation outperforming PLGA NPs. 
These findings reinforce that particulate systems are promising delivery vehicles for 
clinical application in cancer immunotherapy. 
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2. Materials and Methods
2.1. Materials
The ovalbumin-derived SLP OVA24 [DEVSGLEQLESIINFEKLAAAAAK], including 
the CTL epitope SIINFEKL, and the short peptide OVA8 [SIINFEKL] were produced 
and purified at the GMP facility of the Clinical Pharmacy and Toxicology Department 
at the Leiden University Medical Center [6]. The ovalbumin-derived SLP OVA17 
[ISQAVHAAHAEINEAGR], including the helper Th-epitope AAHAEINEA, was produced 
in the Immunohematology and Blood Transfusion Department of the Leiden University 
Medical Centre. The lipids DOPC and DOTAP were purchased from Avanti Polar 
Lipids (Alabaster, Alabama, USA) and the TLR ligands (poly(I:C) and Pam3CSK4) with 
their labeled analogues (rhodamine and fluorescein) were obtained from InvivoGen 
(Toulouse, France). Resomer® RG 502H was purchased from Boehringer Ingelheim 
(Ingelheim, Germany). 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), 
dichloromethane (DCM), dimethyl sulfoxide (DMSO), and trifluoroacetic acid (TFA) 
were purchased from Sigma-Aldrich (Steinheim, Germany). Acetonitrile (ACN) was 
obtained from Biosolve BV (Valkenswaard, the Netherlands), PVA 4-88 (31 kDa) was 
purchased from Fluka (Steinheim, Germany). Sodium hydroxide was purchased from 
Boom (Meppel, Netherlands). Carboxyfluorescein succinimidyl ester (CFSE) was 
purchased from Invitrogen (Eugene, Oregon, USA). Acetonitrile (ACN), chloroform, 
and methanol were obtained from Biosolve BV (Valkenswaard, the Netherlands) 
and Vivaspin 2 centrifuge membrane concentrators were purchased from Sartorius 
Stedim Biotech GmbH (Goettingen, Germany). Iscove’s modified Dulbecco’s medium 
(IMDM; Lonza Verniers, Belgium ) was supplemented with 8 % (v/v) foetal calf serum 
(Greiner Bioscience, Alphen a/d Rijn, the Netherlands), 50 µM 2-mercaptoethanol 
(Sigma-Aldrich, Zwijndrecht, Netherlands), 100 IU/mL penicillin and 2 mM glutamine 
(Life Technologies, Bleiswijk, the Netherlands). Deionized water with a resistivity of 18 
MΩ.cm was produced by a Millipore water purification system (MQ water). Montanide 
ISA-51 was purchased from Seppic SA (Paris, France). Squalene oil-in-water emulsion 
(SWE) contained 3.9% (w/v) squalene, 0.5% (w/v) Tween 80 and 0.5% (w/v) Span 85 
in 10 mM citrate buffer pH 6.5 and it was manufactured by the Vaccine Formulation 
Laboratory of the University of Lausanne. Phosphate buffer was composed of 7.7 mM 
Na2HPO4.2H2O and 2.3 mM NaH2PO4.2H2O, pH 7.4 (10 mM PB, pH 7.4). MQ water 
and 10 mM PB, pH 7.4, were filtered through a 0.22-µm Millex GP PES-filter (Millipore, 
Ireland) before use. Phosphate-buffered saline, which was used for all the in vitro and in 
vivo assays was purchased from B.Braun (Meslungen, Germany). All other chemicals 
were of analytical grade and all aqueous solutions were prepared with milli Q water. 
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2.2. Mice 
Female C57BL/6 (H-2b) mice were purchased from Charles River (L’Arbresle, France) 
and congenic CD45.1 (Ly5.1) mice were bred at the Leiden University Medical Centre 
animal facility and used at 8-14 weeks of age according to the Dutch Experiments 
on Animal Act, which serves the implementation of “Guidelines on the protection of 
experimental animals” by the Council of Europe. 
2.3. Liposome preparation
Cationic liposomes loaded with SLPs were prepared by using the thin film dehydration-
rehydration method, as described previously [23]. Briefly, DOTAP and DOPC (1:1 molar 
ratio) in chloroform were mixed in a round-bottomed flask to reach a concentration 
of 10 mg total lipid per mL of final liposome dispersion. The formed dry film was 
rehydrated with 2 mL of 1 mg/mL OVA24 and/or OVA17 in ACN/H2O 1:1 (v/v); for 
the liposomes loaded with both OVA24 and OVA17, the aqueous solution of the SLPs 
was first adjusted to pH 8.5. For poly(I:C)-loaded liposomes, the ligand (including 
0.5% fluorescently-labeled equivalent) in a total concentration of 200 µg/mL was 
added dropwisely to the dispersion, while for the Pam3CSK4-loaded liposomes, the 
TLR ligand was dissolved in chloroform together with the lipids, before the dry film 
formation. After the lipid film hydration, the liposome dispersion was snap-frozen in 
liquid nitrogen, followed by overnight freeze-drying. Dehydrated-rehydrated liposomes 
were generated by gradually adding 10 mM PB, pH 7.4, to the freeze-dried lipid cake. 
Liposomes were down-sized by high-pressure extrusion at room temperature using 
a Lipex extruder (Northen Lipids Inc., Canada) and concentration of peptide-loaded 
liposomes was performed by using a VivaSpin 2 centrifugation concentrator (PES 
membrane, molecular weight cut-off (MWCO) 300 kDa) as described previously [23].
2.4. PLGA NPs preparation 
Nanoparticles loaded with OVA24 and/or OVA17 and/or TLRLs were prepared by 
using a double emulsion with solvent evaporation method [22]. In brief, 50 mg of PLGA 
dissolved in 1 ml of dichloromethane, with or without 0.25 mg Pam3CSK4 (and 0.1% 
Pam3CSK4 Rhodamine-labeled), were emulsified under sonication (30 s, 20 W) with 
1.4 mg OVA24, 1 mg OVA17, 1 mg poly(I:C) (and 0.1% Poly(I:C) fluorescein-labeled 
,dissolved in 50% ACN in 0.25 mM NaOH + 400 µL Hepes pH 8.0). To this first emulsion 
(w1/o), 2 ml of 1% PVA solution were added immediately, and the mixture was emulsified 
again by sonication (30 s, 20 W), creating a double emulsion (w1/o/w2). The emulsion 
was then added dropwise to 10 ml of extraction medium (0.3% w/v PVA) previously 
heated to 40°C under agitation, to allow quick solvent evaporation, while stirring, which 
was continued for 1 h. The particles were then collected by centrifugation for 15 min at 
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15000 g at 10°C, washed, resuspended in deionized water, aliquoted and freeze-dried 
at -55oC in a Christ Alpha 1-2 freeze-dryer (Osterode am Harz, Germany) for 12 hours.
2.5. Liposome and PLGA NP characterization
Average diameter (Zave) and polydispersity index (PDI) of the formulations were 
determined by dynamic light scattering (DLS) using a Zetasizer (NanoZS, Malvern Ltd. 
UK). The same instrument was used for zeta-potential determination by laser Doppler 
electrophoresis. For these measurements, liposome samples were diluted 100-fold 
in PB, pH 7.4. Peptide loading efficiency was determined by extracting OVA24 and 
OVA17 from the liposomes using a modified Bligh-Dyer method and applying a UPLC 
method, as described previously [23]. 
For the PLGA NPs, the Z-average size, polydispersity index and zeta-potential were 
measured after the freeze-dried NP were resuspended in 1 mM Hepes pH 7.4 to a 
final concentration of 10 mg PLGA/ml. Peptides’ loading efficiency was determined 
by measuring the peptide content of digested particles by reversed phase HPLC, as 
described previously [24]. 
Loading efficiency of poly(I:C) and Pam3CSK4 was calculated by fluorescence detected 
with a Infinite® M 1000 Pro (Tecan, Switzerland) microplate reader (excitation/emission 
wavelengths:  492 nm/518 nm for fluorescein and 549 nm/566 nm for rhodamine).
2.6. Montanide ISA-51 and SWE emulsions preparation and 
characterization 
Preparation of Montanide ISA-51 emulsion was performed by diluting the SLPs, 
Pam3CSK4 and poly(I:C) in PBS and mixing with Montanide ISA-51 water-in- oil for 
30  min in a 1:1 (v/v) ratio, using a vortex mixer. The squalene-based formulation, 
SWE, was prepared as previously described [25, 26]. For the loading of the SLPs and 
adjuvants, the SWE was diluted with vaccine medium to 2% (v/v) squalene to the same 
ratio and mixed gently for 10s prior to immunization.
2.7. In vitro MHC class I antigen presentation 
Immature D1 cells were incubated in 96-well flat-bottomed plates at 37ºC in 
supplemented IMDM with SLP-loaded formulations or plain sSLP (with or without TLR-
ligands) in PBS (sOVA24+sOVA17) at different concentrations. After 2.5 hours T cell 
reporter hybridoma B3Z cells (50x105/well) were added and the mixture was incubated 
overnight at 37ºC. Chlorophenol red-β-galactopyranoside (CPRG) was used as lacZ 
substrate in cell lysates and color conversion was measured by detecting absorbance 
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at 590 nm.
2.8. Immunization of mice
Mice were immunized with SLP-loaded formulations or soluble peptides, sOVA24 and 
sOVA17 (with or without TLR-ligands), by subcutaneous injection in the tail base. All 
formulations were prepared on the day of injection. Vaccination dose was based on the 
OVA24 SLP concentration, 1 nmol (2.5 µg) of peptide in a total volume of 100 µl, and 
immunizations were performed on day 0 (prime immunization) and on day 14 (boost 
injection). Vaccinations with adjuvanted vaccines included a dose of 0.5 – 1.0 µg of a 
TLR ligand. During the in vivo studies, blood samples were obtained from the tail vein 
at different time points. 
2.9. Analysis of antigen-specific CD8+ and CD4+ T-cell 
responses by flow cytometry
Staining of the cell surface was performed on blood samples after red blood cell 
lysis. Cells were stained in staining buffer for 30 min with allophycocyanin labeled 
tetramer-OVA8 (TM-SIINFEKL) and fluorescently labeled antibodies specific for mouse 
CD3 (BD Biosciences), CD4, CD8 and the killer cell-lectin-like receptor G1 (KLRG1) 
(eBiosciences). 7-Aminoactinomycin D (Life Technologies) was used for the exclusion 
of dead cells.
Overnight intracellular cytokine analysis of PBMCs was performed after incubating the 
cells with 2 µM of OVA8 and 2 µM of OVA17, in presence of brefeldin A (7.5 µg/mL) (BD 
Biosciences, Breda, the Netherlands). After the overnight cells incubation the assay 
was developed as previously described [23].
2.10. In vivo cytotoxicity assay
Splenocytes from naive congenic CD45.1+ mice were lysed and split into two equal parts. 
Cells were labeled with CFSE and adoptively transferred intravenously in previously 
immunized recipient C57BL/6 mice in a volume of 200 µl in PBS as described [23]. 
Two days after the cell transfer (day 24), mice were sacrificed, spleens were isolated 
and single cell suspensions were analyzed by flow cytometry. Specific killing (SK) was 





3.1. Characterization of adjuvanted SLP-loaded liposomes 
and PLGA NPs
We have previously shown that effective tumor vaccines require the inclusion of both 
CTL and Th epitopes [6, 27]. In this study, a 24-mer SLP covering a CTL epitope and 
a 17-mer covering a T helper epitope of ovalbumin, designated as OVA24 and OVA17, 
respectively, were used as model antigens to study the effect of co-encapsulation 
of these SLP adjuvanted with poly(I:C) and Pam3CSK4 (TLR3- and TLR2-ligands 
respectively) in liposomes and PLGA nanoparticles (NPs). Our main objective was 
the direct comparison of the immunogenicity of the different systems, relative to that 
of a squalene- oil-in-water emulsion (SWE) used at preclinical stage studies and the 
clinically Phase I/II used Montanide ISA-51 water-in-oil emulsion.
SLP-loaded liposomes were prepared by adjusting the dehydration-rehydration method 
so that the highest loading of both SLPs in the liposomes was achieved, as previously 
described [23].
The obtained SLP-liposomes had an average diameter that ranged from 147 nm 
(only SLPs-loaded liposomes) to 180 nm (OVA24/Pam/poly(I:C)-loaded liposomes). 
Liposomes with poly(I:C) or poly(I:C) combined with Pam3CSK4 were larger and less 
monodisperse (PDI > 0.2). The positive zeta-potential was about 26 mV, independent 
of the formulation (Table 1).The loading efficiency (LE) of OVA24 and OVA17 in 
unadjuvanted liposomes was about 46 % and 20%, respectively, and practically 
independent of the co-encapsulation of poly(I:C) and Pam3CSK4 (Table 1), suggesting 
that there is no competition between the TLRLs and the two peptides.
PLGA NPs were prepared by a double emulsion with solvent evaporation method 
described by Silva et al. [22]. Irrespective of the type of the loading, PLGA NPs were 
negatively charged, with a zeta-potential ranging from -11 to -14 mV (Table 1), with 
a final particle size varying from 260 to 360 nm and a PDI below 0.3. The loading 
efficiency varied between 21 - 30% for OVA24, 31 – 36% for OVA17, 65 – 75% for 
Pam3CSK4 and 53 – 73% for poly(I:C). We have previously shown the importance of 
pH for the effective encapsulation of peptides in PLGA NPs and how crucial low burst 
release is in order to induce a cellular response [22]. Therefore, both OVA24 and OVA17 
SLP were formulated at pH 8.0 for optimal encapsulation and showed a relatively low 
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burst release from NPs of circa 30% after 24 h (data not shown). 










Pam3CSK4   Poly(I:C)
OVA24/Pam/
poly(I:C)-liposomes
180±10 0.29±0.03 26 ± 3 56 ± 5 NA 40 ± 5       60 ± 6
OVA24/
OVA17-liposomes
147±10 0.21±0.02 25 ± 2 46 ± 7 20 ± 5 NA
OVA24/OVA17/Pam/
poly(I:C)-liposomes
175±20 0.27±0.05 26 ± 2 46 ± 5 20 ± 5 40 ± 5       55 ± 8
OVA24/OVA17/
poly(I:C)-liposomes
173±20 0.28±0.05 27 ± 2  42 ± 10 20 ± 3 NA 60 ± 4
OVA24/Pam/
poly(I:C)-PLGA
 260 ± 19 0.19± 0.02 -14 ± 1 26 ± 3 NA 67 ± 7 60 ± 2
OVA24/OVA17-PLGA  355 ± 13 0.24± 0.02 -14 ±1  30 ± 10 36 ± 6 NA
OVA24/OVA17/Pam/
poly(I:C)-PLGA
 357 ± 45 0.22± 0.02 -14 ± 2 21 ± 8  31 ± 5 65 ± 7 73 ± 5
OVA24/OVA17/
poly(I:C)-PLGA
350±23 0.22±0.02 -14 ± 3 29 ± 10 35 ± 6 NA 70 ± 8
OVA24/OVA17/Pam/
poly(I:C)-ISA-51




 136 ± 15 0.15±0.00 -20 ± 3 NA NA NA
Data are averages ± SD of at least 3 independent batches. Zave average: particle diameter; PDI: polydispersity 
index; ZP: zeta-potential; LE: loading efficiency; NA: not applicable
Altogether, the data presented in Table 1 shows that the model SLPs, OVA24 and 
OVA17, can be efficiently and reproducibly loaded in liposomes and PLGA NPs, also in 
presence of up to two TLR-ligands.
3.2. In vitro SLP cross-presentation
The immunogenicity of the SLP formulations was first tested in vitro, based on their 
efficiency to activate immature DCs and cross-present the processed SIINFEKL-
harboring peptide (OVA24) to the CD8+ antigen-specific T cells leading to their activation. 
Immature DCs were incubated with liposomes and PLGA NPs including both 
SLPs and both TLR-ligands. Improved concentration-dependent activation of 
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CD8+ T cells was observed when particles were used compared to free peptides 
(sOVA24+sOVA17+Pam+poly(I:C)). Moreover, although PLGA NPs plots consistently 
show a larger dose-response effect, liposomes seem to be more effective in antigen 
presentation at lower concentrations (Figure 1).
Figure 1: SIINFEKL-specific B3Z CD8+ T cell activation after overnight co-culture with DCs and 
titrated amounts (4.0-0.0625 μM, 2-fold dilution series) of SLPs/TLR ligands-loaded formulations. 
Graphs show T cell activation based on the optical density (OD) at 590 nm after color conversion 
of cell lysates after addition of CPRG (lacZ substrate). *p<0.05, evaluated with one-way ANOVA 
with Tukey’s post hoc test and calculated with Mann-Whitney non-parametric test. Pam = 
Pam3CSK4; pIC = poly(I:C)
Furthermore, the B3Z assay suggests efficient processing and presentation of OVA24 
SLP by the DCs, irrespective of the presence of the OVA17 SLP (Figure 1). In addition to 
that, the incorporation of the TLR-ligands poly(I:C) and Pam3CSK4 did not significantly 
affect the in vitro T cell activation by the SLP-loaded particle formulations, as expected 
(Figure 1). 
3.3. In vivo induction of CD8+ T cells
We evaluated the capacity of our particulate formulations to induce cell-mediated 
immune responses in vivo after subcutaneous vaccination at the tailbase of mice, an 
administration route that appeared to enhance drainage to the lymphatic system in a 
more efficient way compared to subcutaneous delivery in the flank (unpublished data). 
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The in vivo vaccine potency of liposomes and PLGA NPs was directly compared with 
that of the Montanide ISA-51 and SWE adjuvants.
Figure 2: OVA24-specific CD8+ T cell responses in blood (Day 21) and in splenocytes (Day 24) 
following s.c. immunization with 1 nmol of SLPs on day 0 and 14 (A). Representative gating 
strategy for detection of SIINFEKL-specific CD8+ T cells by flow cytometry using specific MHC 
class I tetramers (B). * p<0.05, ** p<0.01 calculated with by one-tailed Mann-Whitney test. 
ISA51= Montanide; Pam = Pam3CSK4; pIC = poly(I:C).
In blood of mice immunized twice with SLP(s)-loaded liposome or PLGA NP formulations, 
on day 21 a high percentage of antigen-specific CD8+ T cells (above 1% of the total 
CD8+ T cell population) was detected in most groups, whereas in the Montanide ISA-
51 or SWE groups this percentage remained below 0.5% (Figure 2A). In detail, it 
appeared that the OVA24/Pam/poly(I:C)-liposomes were more potent than the OVA24/
Pam/poly(I:C)-PLGA NPs, expanding the percentages of antigen-specific CD8+ T cells 




Incorporation of the Th epitope-SLP (OVA17) did not seem to improve the CD8+ T cell 
proliferation induced by the PLGA NP formulations, while the addition of at least one 
TLR-ligand, such as poly(I:C), seemed to be essential for T cell activation. 
On the other hand, incorporation of the two SLPs in the liposomes (OVA24+OVA17) 
seemed to be sufficient for the induction of the highest frequency of CD8+ T cells (> 5 
%) in blood of vaccinated mice, compared to all other liposomal groups (Figure 2A). 
Interestingly, incorporation of poly(I:C) to the formulation with the two SLPs did not seem 
to further increase the number of the induced T cells in blood, while co-encapsulation 
of the lipophilic Pam3CSK4 seemed to result in lower numbers of antigen-specific T 
cells. On day 24 in the analyzed splenocytes of vaccinated mice, the ex vivo (non-
restimulated) T cell responses in most groups were comparably low, except for the 
OVA24/OVA17-liposomes group, which showed a CD8+ T cell frequency of about 1% 
(Figure 2A).
3.4. In vivo cytokine and cytotoxicity induction
Next to the T cell expansion potency of the vaccine formulations also the cytokine-
producing functionality of the induced T cells was analyzed. Thus, blood samples 
from the immunized mice were re-stimulated with MHC class I and class II binding 
peptides (short SIINFEKL and OVA17) ex vivo and the percentages of CD8+ and CD4+ 
T cells producing interferon gamma (IFN-γ) or IFN-γ and TNF-α simultaneously (data not 
shown), were assessed by intracellular cytokine staining. 
In re-stimulated blood samples from mice immunized with PLGA NPs loaded with 
OVA24, Pam3CSK4 and poly(I:C) (OVA24/Pam/polyI:C-PLGA) a higher percentage of 
cytokine-producing CD8+ T cells was detected (0.7%) in comparison to the Montanide 
ISA-51 formulation (0.3%). This frequency did not increase after loading of OVA17 in 
the formulation, while all PLGA NPs showed a stronger induction of IFN-γ-producing 
CD4+ T-cells (~ 0.8 %) in comparison with the Montanide ISA-51 and SWE emulsions 
(~0.1 %) (Figure 3B).
Mice vaccinated with liposomes loaded with both SLPs, with or without the two TLR-
ligands (OVA24/OVA17/Pam/poly(I:C)-liposomes and OVA24/OVA17-liposomes, 
respectively) showed an at least eight-fold higher efficiency to induce functional IFN-γ-
producing CD8+ T cells, as compared to the Montanide ISA-51- and SWE formulations 
(Figure 3A). As also observed in the SIINFEKL-specific CD8+ T cell induction analysis 
(Figure 2), incorporation of poly(I:C) and Pam3CSK4 into liposomes did not increase 
the number of induced T cells, although still much higher than the soluble SLP and 
TLR ligands. Although Pam3CK4 is known to improve SLP vaccination by itself [27], its 
incorporation into the liposomes seems to have a inhibitory effect on the vaccination 
efficacy of the cationic liposomes, suggesting a possible change in the liposomes 
properties which influences the particles targeting.
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Altogether, all liposomal formulations appeared to be significantly more efficient than any 
of the PLGA formulation tested (Figure 3). Furthermore, apart from CD8+, functional 
CD4+ T cells were detected in all groups treated with OVA17-containing liposomal 
formulations as well as PLGA NPs, indicating that OVA17 retains its functionality when 
co-encapsulated with OVA24 (Figure 3) and pointing out the importance of poly(I:C) 
presence for induction of antigen-specific CD4+ T cells.
Figure 4: In vivo cytotoxicity against SIINFEKL-presenting target cells. The mean 
percentage of the killing activity of each SLP formulation is presented based on the frequency of 
the transferred CD45.1+ cells that could be detected in splenocytes of mice immunized twice with 
the different formulations containing 1 nmol of OVA24. Bar graphs show the mean percentages 
(+SEM) of killed cells on day 24 (A).Representative histograms of CSFE-labeled positive target 
cells (right peak=SLP pulsed and left peak=negative control) (B). * p<0.05 calculated with by one-
tailed Mann-Whitney test. ISA51= Montanide; Pam = Pam3CSK4; pIC = poly(I:C)
Finally, to test the effectiveness of our particulate vaccines to induce a strong functional 
cell-mediated immune response, the cytotoxic capacity of the induced CD8+ T cells 
was tested in an in vivo cytotoxicity immunoassay, based on the killing of SIINFEKL-
loaded target cells which were injected intravenously on day 22 in immunized mice 
(Figure 4). 
Incorporation of poly(I:C) into PLGA NPs including both SLPs (and not Pam3CSK4) 
appeared to be crucial for activation of CD8+ T cells with a cytotoxic activity up to 40% 
, four times as high compared to the emulsions (Figure 4). In splenocytes of all mice 
vaccinated with liposomes a high killing capacity above 60 % was detected. Mice 
immunized with liposomes containing both SLPs (OVA24/OVA17-liposomes) showed 
maximal in vivo cytotoxicity with or without poly(I:C). 
According to the functional data of both the intracellular cytokine production and 
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cytotoxicity assay, we can conclude that liposomal formulations loaded with the SLPs 
are superior to both PLGA NPs and Montanide ISA-51 or squalene-SLP-contained 
emulsions, when a rather low dose of SLPs (≤ 1 μg of SLPs) is used like in the current 
study. Moreover, it appeared that the inclusion of an adjuvant (Pam3CSK4 or poly(I:C)) 
in the liposomal formulation might not be necessary for the priming of a T cell-based 
immune response, since solely the presence of the Th epitope seems to facilitate a Th1-
based proinflammatory immune reaction essential for effective therapeutic vaccines,  to 
maintain a robust and long-lasting anti-tumor CD8+ T cell response.
4. Discussion
There is a growing interest in therapeutic vaccination against cancer. The identification 
of tumor associated antigens (TAAs) has allowed the development of novel therapeutic 
strategies resulting in tumor regression. However, fine-tuned vaccines are required to 
reach the optimal potency and eventually replace the suboptimal formulations currently 
used. A major advantage of using particulate vaccines, such as liposomes and PLGA 
NPs, is their modularity. By tuning their physicochemical properties like size, charge and 
hydrophobicity, not only the stability of the particles and their antigen release pattern 
can be improved, but also the amount of antigen uptake by DCs, and priming of DCs 
towards cross-presentation, resulting in a more effective Th1 type CTL response, 
required for cancer immunotherapy.
In this study we showed the successful co-encapsulation of two SLPs (OVA24 and 
OVA17) and two TLR-ligands (poly(I:C) and Pam3CSK4) in two different particulate 
delivery systems. The SLP-loaded and adjuvanted PLGA NPs and cationic liposomes 
were rather different in size and surface charge, since PLGA NPs are negatively 
charged and liposomes are positively charged, while their different chemical nature 
is expected to influence the SLPs/TLR-ligands localization and their in vivo release 
profiles. Considering all possible differences, their potential for the induction of a cell-
mediated immunity was investigated in comparison with two other systems, Montanide 
ISA-51, a water-in-oil emulsion, and SWE, a squalene-based oil-in-water emulsion.
As we showed here, co-delivery of a Th antigen with a CTL epitope increases the 
expression of effector cytokines. This is most likely due to the stimulation of the MHC 
molecules displayed by DCs: CD40/CD40L ligation plays an important role in the 
activation of DCs and is a crucial stimulus for CD4+ Th-based CD8+ T cell priming [28, 
29]. In addition, incorporation of a TLR ligand to the formulation, such as poly(I:C), can 
promote the active targeting and shape the immune response towards a more CTL-
restricted manner. It has been shown that poly(I:C) stimulation of CD8a+ DCs in mice 
led to successful cross-priming of CD8+ T cells [30], improved the survival of CD4+ T 
cells and produced functional CD8+ memory even in the absence of CD4+ T cells [31]. 
These findings are in line with our data which presented an improved functionality of 
the activated T cells by formulations where poly(I:C) is present. In contrast, inclusion of 
Pam3CSK4 in the formulations did not further improve the induced immune response. 
This may be due to its lipophilic nature, resulting in localization of the Pam3CSK4 
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lipopeptide in the lipid bilayer of the liposomes, or the polymeric matrix of the PLGA 
NPs, which might negatively affect the functionality of the TLR-ligand, and thereby its 
immunogenicity. With regard to the PLGA NPs, unadjuvanted PLGA NPs are considered 
to have very low immune-stimulating properties [32, 33]. The formulation including both 
SLPs and poly(I:C), but not Pam3CSK4, was the most promising for the induction of 
functional and cytotoxic T cells. Although the effect of the Pam3CSK4 on the induced 
immune response in PLGA NPs was not as pronounced as in liposomes, a negative 
influence by its presence was also observed, suggesting a change in the PLGA NPs 
which leads to a less efficient formulation or a different targeting that does not favor the 
induction of a T cell-based immune response.
In this study we showed that for SLPs-based vaccines, cationic liposomes appeared 
to be the most potent delivery system, followed by PLGA NPs. The size of particulate 
adjuvants is crucial for their adjuvant activity and the immunogenicity difference 
observed in this study between liposomes and PLGA NPs may be partly attributed 
to the different particle sizes. In general, APCs are able to take up different particles 
ranging from the size of viruses (20-300 nm), bacteria (0.5-2 μm) up to whole cells, 
which can be bigger than 10 μm. Upon vaccination, small particles (10-150 nm) can 
easily penetrate the extra-cellular matrix (ECM) and be quickly transported into the 
lymph nodes [34] where they will interact with lymph node resident DCs [35]. Moreover, 
particulate systems with a size below 200 nm, such as the liposomes used in this 
study, will likely be taken up by DCs more efficiently than bigger particles [36], which 
are more prone to be recognized  by macrophages and other scavenger immune cells, 
leading to a poorer T cell activation capacity [33, 37]. In addition, it was suggested that 
smaller particles (20-150 nm) are naturally taken up by endocytosis, resulting in cellular 
immune response, while larger particles, such as PLGA NPs used here, are more likely 
to be phagocytosed, leading to a predominantly humoral immune response [38]. 
Furthermore, the particles’ size combined with the most efficient administration 
route has also an impact on antigen uptake and therefore can affect the efficacy of 
immunotherapy. Particles larger than 150 nm cannot be efficiently transported via the 
lymphatic system as mentioned above, and a percentage of the administered particles 
will be trapped in the tissue, creating a depot. Subcutaneous vaccination at the tailbase 
of mice, as the administration route selected for the in vivo studies presented in this 
study, appeared to enhance the drainage to the lymphatic system in a faster and more 
efficient way compared to subcutaneous delivery in the flank. With regard to Montanide 
ISA-51, although the exact adjuvant mechanism is not well understood, it is believed 
that such a water-in-oil emulsion creates a sustained release from the local antigen 
depot. However, a longer retention time of larger particles does not necessarily correlate 
with better antigen uptake and a stronger induced immune response [2]. Considering 
that, our data suggest that the internalization of particles, such as PLGA or liposomes, 
may be more important for the induction of an efficient cellular immune response than 
the formation of a depot.
Surface charge is another variable parameter between the particulate systems 
investigated in this study, since the PLGA NPs were negatively charged and the 
liposomes positively charged. However, it is not clear whether positively, negatively 
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or neutrally charged particles are the best choice to induce effective Th1-type cellular 
immune response. Investigations so far have revealed contradictive results. For instance, 
anionic PLGA NPs induced antibody responses as well as strong CTL responses and 
Th1-biased cytokine release in mice and macaques [39]. Anionic PLGA particles also 
showed a higher accumulation in the lymph node compared to PEGylated particles 
of the same size [40]. However, anionic liposomes interacted with a limited fraction 
of human and murine DC populations [41], setting cationic liposomal formulations in 
favor. This outcome is in line with published research data where cationic liposomes 
were considered to be a very potent choice for immunotherapy [42] and we have 
recently reported efficient cellular response induction in vivo with DOTAP based cationic 
liposomes carrying synthetic long peptides antigens [23]. It was suggested that the 
positive charge promotes electrostatic interactions with the negatively charged cell 
surface, thus interacting more efficiently with DCs and other APCs [41]. Positively 
charged liposomes showed the induction of a superior antigen specific cellular immune 
response, in comparison with negative or neutral liposomes [43]. Moreover, cationic 
particles are thought to have an adjuvant effect themselves [44]. It was found that 
cationic liposomes, but not anionic or neutral ones, can stimulate the expression of DC 
maturation markers such as CD80 and CD86, depending on the lipid structure, but 
did not lead to pro-inflammatory cytokine- or enhanced NF-κB expression, suggesting 
that they act independently of this pathway [45]. The partially contradicting results 
could be due to different formulation procedures, immunization protocols and antigen 
characteristics used in reported studies. The latter may result in a charge-dependent 
entrapment efficiency and antigen release pattern.
To sum up, the reason why liposomes appeared to be a more potent delivery system 
for the induction of a T cell-based immune response upon therapeutic vaccination than 
PLGA NPs is not yet fully clear, but is likely due to differences in size, zeta potential 
and/or surface chemistry. Further research is required to elucidate how these and other 
properties affect the functionality of particle types as vaccine delivery system, which 
should help to further improve their properties for effective immunotherapy of cancer.
5. Conclusions
In this study we successfully co-encapsulated four compounds (two antigenic SLPs 
and two TLR-ligands) in two different delivery systems, cationic DOTAP-based 
liposomes and PLGA NPs. In a comparative study, we compared the immunogenicity 
of the particulate formulations with that of two emulsion-based adjuvants, Montanide 
ISA-51 and squalene SWE. The capacity of the particulate systems of inducing 
functional antigen-specific T cells was at least as good (PLGA NPs) or better (cationic 
liposomes) than that of the emulsion-based formulations. This, while also considering 
the unfavorable safety profile of the currently used adjuvant Montanide ISA-51, makes 
these particulate delivery systems attractive candidates as a delivery platform for SLP-
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In recent years, there has been a growing interest in therapeutic vaccination as a 
treatment modality against diseases such as cancer [1]. In particular, synthetic long 
peptides (SLPs) have been studied as well-defined antigens for immunotherapy of 
cancer. So far, SLPs have been formulated in Montanide ISA 51-based water-in-oil (w/o) 
emulsions in (pre-)clinical trials. However, the use of Montanide has some important 
limitations, such as suboptimal efficacy and side effects, so alternative formulations for 
peptide-based cancer vaccines are highly needed. The field of cancer immunotherapy, 
the current status of peptide-based cancer vaccines, their lack of efficacy and the need 
for new adjuvants are introduced in Chapter 1. Poly(lactic-co-glycolic acid) (PLGA) 
biodegradable particulate delivery systems are particularly interesting because they 
are biocompatible; can protect soluble antigens from degradation and rapid clearance 
once administered; allow for co-encapsulation of (multiple) antigens and adjuvants; and 
mimic the size and structure of a pathogen, being more efficiently taken up by DCs than 
soluble antigen [2, 3]. In Chapter 2 we provide a detailed overview of the use of PLGA 
particulate delivery systems for the delivery of protein- and peptide-based vaccines. 
This chapter discusses formulation parameters influencing the adjuvanticity of these 
systems, such as size, charge, antigen localization, release profile, and the co-delivery 
of immune modulators, such as Toll-like receptor ligands (TLRLs), and/or specific 
targeting molecules, such as antibodies. It further outlines how these characteristics 
affect uptake, processing and antigen presentation by dendritic cells (DCs) and the 
ensuing immune response. It also provides a summary of the PLGA formulations that 
have been studied for the delivery of synthetic peptide-based vaccines.
The principal aim of the research described in this thesis was to investigate how PLGA-
based particulate systems can act as an adjuvant for SLP-based cancer vaccines in 
a pre-clinical setting in order to gain insight into how to improve the immunogenicity, 
clinical efficacy and safety of SLP-based vaccines for cancer immunotherapy, to be 
used as a safer and more effective alternative to Montanide. The main objectives of this 
research included:
• Determination of the best size range of PLGA particles for subcutaneous vaccine 
delivery
• Development of SLP-loaded PLGA NP formulations 
• Development of formulations based on PLGA NPs co-encapsulating SLPs and 
TLRLs
The first objective was achieved in Chapter 3, where the role of particle size to induce 
an immune response was studied. For that purpose, we performed a comparative 
study between NPs versus MPs containing equivalent amounts of a model antigen, 
ovalbumin (OVA), and a TLRL, poly(I:C), with comparable release kinetics, and studied 
how their ability to be internalized by DCs affects MHC class I antigen presentation in 
vitro and the ensuing immune responses in vivo, in comparison to sustained release 
from a local subcutaneous depot. Particles were formulated to obtain NPs that could 
be efficiently internalized by DCs, forming intracellular depots, versus MPs with a size (> 
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20 μm) too large to be taken up, thus functioning exclusively as an extracellular depot, 
similarly to Montanide. We showed that efficient particle uptake is crucial to induce 
an immune response: NPs were efficiently taken up by DCs upon in vitro incubation, 
whereas MPs were not, resulting in increased MHC class I antigen presentation in vitro 
for NPs but not MPs. Moreover, upon subcutaneous vaccination in mice, significantly 
higher numbers of antigen-specific CD8+ T were obtained with NPs compared to 
MPs or OVA emulsified in incomplete Freund’s adjuvant (IFA). In addition, NP led to 
better antibody responses compared to MP, and induced a more balanced TH1/TH2-
type antibody response than IFA. We concluded that particulate vaccines should be 
formulated in a nano-size range that allows efficient uptake, significant MHC class I 
cross-presentation and effective T and B cell responses. 
Having determined the optimal size range of PLGA particles for protein-based vaccines, 
in Chapter 4 we describe the application of these PLGA NPs as a delivery vehicle for ex 
vivo loading of DCs, in order to stimulate antigen-specific CD8+ T cells to be used for 
adoptive T cell immunotherapy. For that purpose, DCs previously incubated with PLGA 
NPs encapsulating model antigen OVA or the soluble protein were used to stimulate 
CD8+ T cells, which were then transferred to mice. Ex vivo stimulation of CTLs by 
DCs incubated with PLGA NPs, as compared to soluble protein, resulted in a superior 
capacity to lyse target cells in vivo after adoptive transfer. Furthermore, administration 
of CTLs stimulated by PLGA NP-loaded DCs resulted in more efficient tumor control 
leading to prolonged survival of tumor bearing animals, showing that protein antigens 
benefit from encapsulation in PLGA-NPs, clearly enhancing MHC class I presentation 
and CTL activation. 
As we showed that protein antigen delivery through encapsulation in PLGA NPs is 
an efficient way to stimulate potent anti-tumor T cells, in Chapter 5 we studied the 
feasibility of the application of encapsulation in PLGA NPs to SLPs, achieving the 
second objective. Using OVA24, a 24-residue long synthetic antigenic peptide covering 
a CTL epitope of OVA (SIINFEKL), as a model antigen, our aim was to define the 
formulation parameters required to successfully encapsulate an SLP in PLGA NPs, 
and to optimize PLGA NPs for SLP delivery with respect to encapsulation and release 
kinetics, to improve the efficacy of SLP cross-presentation by DCs. When using the 
standard “double emulsion with solvent evaporation” encapsulation techniques, we 
observed that either encapsulation was very low (< 30%), or burst release extremely 
high (> 70%). By adjusting formulation and process parameters, we uncovered that the 
pH of the first emulsion was critical to efficient encapsulation and sustained release. 
By using an alkaline inner aqueous phase rather than an acidic one, we were able not 
only to optimize the encapsulation of the SLP but also to reduce its burst release, finally 
obtaining stable NPs of approximately 330 nm, with an encapsulation efficiency of 
circa 40% and a burst release lower than 10%. Encapsulation of OVA24 in PLGA NP 
resulted in enhanced MHC class I restricted T cell activation in vitro when compared 
to high-burst releasing NP and soluble OVA24, revealing the importance of low burst 
release to induce a potent cellular immune response. This encapsulation method 
may be a promising approach for encapsulation of peptides with amphiphilic and/or 
hydrophilic properties, and has been successfully applied to other SLPs as well. This 
study underscores the importance of optimizing the encapsulation process for the 
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development of an effective and stable delivery system, and may be considered as a 
basis for the development of NP formulations for SLP-based immunotherapy of cancer. 
Subsequently, the third objective was addressed in Chapter 6, where we studied the 
co-encapsulation of SLP OVA24 and TLR2L Pam3CSK4 in PLGA NPs, which were 
used to characterize the intracellular mechanisms via which DC process PLGA-SLP 
NPs and to determine the study the immunological effects the combination of SLPs with 
an adjuvant. We showed that TLR 2 stimulation enhanced MHC class I presentation 
of SLP by DCs in vitro. DCs loaded with PLGA-SLP(/TLR2L) NPs internalized them 
into endolysosomal compartments and not the cytosol as occurs with soluble 
SLP. Moreover, encapsulated SLP could be detected for long periods inside DCs 
endolysosomal compartments, resulting in prolonged MHC class I presentation for 
up to 96 h. PLGA-SLP NPs and especially PLGA-SLP/TLR2L NPs induced sustained 
CD8+ T cell proliferation in vivo after adoptive transfer of PLGA-SLP(/TLR2L) NP-loaded 
DCs. These findings demonstrate that CD8+ T cell response is enhanced when the 
antigen is cross-presented in MHC class I molecules in a sustained manner, and that 
co-encapsulation of a TLRL further boosts these effects, and thus supports the use of 
PLGA NPs co-encapsulating SLPs and TLRLs as anti-cancer vaccines.
Finally, in Chapter 7 we investigated the potential of PLGA NPs and cationic liposomes 
as delivery systems for SLP-based vaccines for the induction of cell-mediated 
immunity. For that purpose, we studied the co-delivery of two SLPs containing the 
CTL (OVA24) and the Th (OVA17) epitopes of OVA together with TLRLs Pam3CSK4 
and/or poly(I:C) in a direct comparison to the clinically used adjuvants Montanide (a 
water-in-oil emulsion) and a squalene-based oil-in-water emulsion analog to MF59. 
The obtained formulations were assessed in vitro and in vivo for their potency to induce 
CD8+ and CD4+ T cell immune responses. The liposomal and PLGA NP formulations 
were able to enhance antigen uptake by DCs and subsequent activation of T cells in 
vitro. Subcutaneous vaccination of mice showed that the efficiency of the SLP-loaded 
liposomes and PLGA NPs to induce functional antigen-specific T cells in vivo, was at 
least as good (PLGA NPs) or better (cationic liposomes) than that of the emulsion-
based formulations, while liposomes induced T cells with the highest killing capacity of 
transferred target cells in mice, outperforming PLGA NPs. Considering the questionable 
safety profile of the currently clinically used adjuvant Montanide, these findings indicate 
that both particulate systems are promising biodegradable delivery vehicles for clinical 
application of SLP-based cancer immunotherapy.
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2. Discussion & Perspectives
At the Leiden University Medical Center (LUMC), several (pre-)clinical studies have been 
conducted, showing that SLP-based vaccines efficiently induce the immune system 
against cancer [4-6]. In a clinical setting, a vaccine consisting of 13 overlapping SLPs 
covering the entire sequence of the E6 and E7 oncogenic proteins of high-risk human 
papillomavirus 16 (HPV16) emulsified in Montanide ISA 51 was administered to women 
suffering from HPV16-induced (pre-)malignant vulvar intraepithelial neoplasia, resulting 
in robust immunogenicity in end-stage cervical cancer patients, and complete regression 
of pre-malignant lesions in 9 of 20 women [4-6]. However, Montanide, a clinical grade 
version of IFA, has some important limitations: it shows poor control of the antigen 
release rate, lacks specific DC-activating capacity, and the mineral oil component, 
which is non-biodegradable, has been associated with significant local side effects 
[4, 7, 8]. Moreover, though SLP-vaccines showed potent therapeutic efficacy against 
pre-malignant lesions, they failed to achieve durable clinical responses in late-stage 
cancer patients, underlining the necessity for better SLP-vaccine formulations that 
could enhance their therapeutic efficacy. This was the starting point for designing the 
PhD project described in this thesis, aimed at optimizing the efficacy of SLP vaccines 
via the encapsulation in poly-(lactic-co-glycolic acid) (PLGA) particles, while reducing 
the side effects associated with the current (pre-)clinical administration of SLP vaccines 
emulsified in water-in-oil preparations.
This thesis describes the research toward the optimization of PLGA particulate systems 
for the delivery of synthetic long peptide (SLP)-based vaccines for immunotherapy of 
cancer as an alternative to Montanide. For this purpose we explored the use of PLGA 
particles as delivery systems for SLPs from the pharmaceutical formulation to the 
immunological evaluation.
Two main approaches have been used to target DCs in cancer immunotherapy: 
administration of ex vivo TAA-loaded DCs and in vivo delivery of TAAs. In Chapter 4 we 
showed the superior ability of particulate delivery systems compared to soluble antigen 
to activate DCs in vitro, resulting in better CD8+ T cell priming and increased tumor 
protection in vivo. However, though ex vivo-loaded DC-based cancer vaccines have 
been successfully used in therapeutic settings, each vaccine needs to be specifically 
prepared for each individual, requiring the harvest and in vitro culture of their own DCs, 
which is time-consuming and requires extensive logistics, thus making these vaccines 
extremely expensive [9]. By using in vivo delivery of tumor associated antigens (TAAs) 
and adjuvant together to DCs, cancer vaccines could be widely applied to cancer 
patients. Therefore, our aim was to study formulations to be applied in vivo.
Several aspects concerning particulate vaccine formulations have been studied in this 
thesis, in particular the characterization of the formulations and their immunological 
effects in vitro and in vivo. Depending on their physicochemical characteristics, delivery 
systems can modulate the immune response, mainly due to direct influence in the 
following mechanisms: facilitated uptake by DCs, regulation of the internalization and 
presentation pathways, and interaction with specific receptors that mediate the immune 
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response towards humoral or cellular bias. 
One of the most important factors playing a crucial role in vaccine efficacy is size. 
While smaller particles tend to be more easily taken up by DCs, larger particles can 
form stable extracellular depots from where the antigen can be slowly released [1]. 
In Chapter 3, we studied the role of particle size to induce an immune response by 
comparing NPs that could be internalized by DCs with MPs that could not. Although 
previous studies had investigated the role of size in particle uptake and ensuing immune 
response, the extreme differences in antigen release kinetics observed between the 
formulations would most likely have affected the results [10]. By comparing NPs and 
MPs with similar sustained release profiles, we were able to get better insight on 
the actual differences between antigen release from intracellular versus extracellular 
depots at a similar rate. Indeed, NPs were effectively taken up by DCs, inducing more 
potent immune responses than MPs, and more importantly than IFA, pointing to the 
importance of efficient particle uptake by DCs.
While MPs and IFA allow the formation of a depot that can trigger inflammation and 
the local recruitment of immune cells to the site of injection, to which the antigen and 
TLRL can be delivered extracellularly in soluble form, the findings in Chapter 6 show 
that the mechanisms of uptake and processing soluble or particulate antigen by DCs 
do differ. DCs internalized NPs into the endolysosomal compartments and not the 
cytosol, as occurs with soluble SLPs. Encapsulated SLPs could be detected for long 
periods inside DCs’ endolysosomal compartments, resulting in prolonged MHC class 
I presentation in comparison to soluble SLPs. Indeed, these observations concur 
with the results described in Chapter 4, where ex vivo PLGA NP-loaded DCs more 
effectively primed CD8+ T cells to confer tumor protection after adoptive transfer in vivo. 
Moreover, they are also in line with the observations in Chapter 5, where we compared 
NP with similar physicochemical characteristics in terms of charge, size and antigen 
loading, but different release profiles, having determined that a low-burst release, with 
the majority of antigen being delivered to DCs still encapsulated in PLGA NPs. was 
crucial to enhance MHC class I presentation.
The importance of release kinetics and especially the burst release points to the 
importance of thorough characterization and optimization of SLPs encapsulation in 
PLGA NPs in order to obtain a successful vaccine formulation. In Chapter 5, we studied 
the encapsulation of OVA24 SLP in PLGA NP as function of formulation and process 
parameters. Whereas hydrophilic and hydrophobic peptides have been successfully 
encapsulated in PLGA NP and/or microparticles in the past [11-13], efficient entrapment 
of the moderately hydrophobic OVA24 proved to be challenging. The observed high 
burst release indicated that most of the OVA24 molecules might not be encapsulated 
in the NP’s polymeric matrix, but instead were adsorbed to their surface, being quickly 
released when resuspended in physiological buffers. Efficient entrapment of OVA24 
SLP in the polymeric matrix was obtained by exploring and fine-tuning of formulation 
and process parameters, in particular the composition of the inner aqueous phase, as 
encapsulation and release characteristics were strongly dependent on the pH of the 
first emulsion. Our novel PLGA NP formulation method allowed us to achieve up to 
40% encapsulation efficiency of OVA24, exhibiting minimal burst release. Moreover, 
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this novel method was also successfully applied to encapsulate OVA17, encoding the T 
helper epitope of OVA, and gp100, encoding an immunodominant CTL epitope present 
in melanoma. These encouraging results illustrate the applicability of our encapsulation 
process to different SLPs, and the possibility to be applied in the future to encapsulate 
the 13 overlapping SLPs encoding the HPV16 E6 and E7 oncoproteins in PLGA NPs 
to be tested in pre-clinical models and eventually in the clinic.
The formulation method developed in Chapter 5 was also applied to co-encapsulate 
OVA24 SLP with TRL2L agonist Pam3CSK4 in the PLGA NPs studied in Chapter 6. 
The prolonged CD8+ T cell activation observed indicates that the internalized NPs slowly 
release the encapsulated SLPs inside the endolysosomal compartments. The released 
antigen is then gradually processed in the cytosol, after escape from the endosome, 
where it is continuously transferred to the proteasome and degraded into smaller 
peptides to be loaded on MHC class I molecules, resulting in sustained MHC class I 
Ag presentation. The enhanced MHC class I presentation observed is likely related to 
the protection from the rapid degradation that occurs with soluble SLPs in the cytosol, 
which were barely detectable after 24 h, whereas encapsulated SLPs were detected up 
to 72 h after antigen loading. Co-encapsulation of Pam3CSK4 significantly enhanced 
the capacity for DCs to prolong MHC class I Ag presentation and CD8+ T cell activation 
in vivo. TLR stimulation is critically involved in the uptake and processing of antigens by 
DCs, and can trigger cross-presentation [14, 15]. TLR activation induces the secretion 
of proinflammatory cytokines and type I interferon, and leads to upregulation of CD40, 
CD80 and CD86 costimulatory molecules on the surface of APCs, as well as release of 
Th1 cytokines leading to T cell activation [16]. Moreover it increases the half-life of MHC 
class I-peptide complexes on the cell surface [17], which together with the prolonged 
presence of encapsulated antigen inside endolysomal compartments can account for 
the sustained CD8+ T cell activation we described using PLGA-SLP/TLR2L NPs.
For successful implementation of PLGA NPs as delivery systems for SLP-based 
vaccines in a clinical setting, PLGA NPs should be applicable to co-encapsulate 
multiple SLPs with different physicochemical properties, such as the 13 overlapping 
long peptides encoding the HPV16 E6 and E7 oncoproteins. Furthermore, as most 
pathogens present multiple TLR agonists to APCs, the combination of multiple TLRLs 
can result in a synergistic effect in order to induce strong immune responses [15]. In 
Chapter 7 we studied the potential of liposomes and PLGA NPs, co-encapsulating 
two SLPs containing the CTL (OVA24) and the Th (OVA17) epitopes of OVA together 
with TLRLs Pam3CSK4 and/or poly(I:C), as alternatives to clinically used Montanide- 
and squalene-based emulsions in a direct comparison. Both liposomal and PLGA 
NP formulations were able to enhance antigen uptake by DCs and subsequent 
activation of T cells in vitro, and induce functional antigen-specific T cells in vivo, with 
at least equivalent or even better efficacy than the emulsion-based formulations after 
subcutaneous vaccination in mice. Liposomes outperformed PLGA NPs, showing the 
highest killing capacity after transfer of target cells in mice. The differences observed 
between liposomes and PLGA NPs may be attributed to the combination of two main 
factors, particle size and surface charge. The size of particulate adjuvants is crucial 
for their adjuvant activity and the immunogenicity, as small particles (10-150 nm) 
can easily penetrate the extra-cellular matrix and be transported via the lymphatic 
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system into the lymph nodes where they come in contact with resident DCs [18], 
while particles smaller than 200 nm, such as the liposomes used in this study, but 
not the PLGA NPs, will likely be taken up by DCs more efficiently than bigger particles 
[19]. Furthermore, as immune cells are negatively charged, cationic particles are more 
efficiently uptaken due to electrostatic interactions [20], while polycations can also aid 
in phagosomal/endosomal escape after being internalized by APCs [2], potentially 
influencing the antigen presentation pathway and type of immune response. Therefore 
cationic liposomes are in advantage in comparison with PLGA NPs, which are both 
bigger and negatively charged. Making smaller PLGA NPs similar to liposomes and/
or coating them with cationic surfactants may be a way to increase their adjuvanticity. 
Still, both liposomes and PLGA NPs were used successfully to co-encapsulate up to 
four components, showing their ability to deliver (multiple) SLPs and TLRLs together to 
DC, and outperforming both clinically used Montanide and squalene-based emulsions.
For successful implementation of PLGA NPs as a delivery vehicle for SLP-based 
vaccines to human use, the pharmaceutical formulation should be straightforward, 
reproducible, stable, and meet GMP quality requirements and regulations. Important 
factors influencing vaccine efficacy include size; release kinetics; surface characteristics; 
concomitant delivery of antigen and immunostimulants, allowing DCs to associate 
danger signals with the antigen, while co-encapsulation of multiple TLRLs may result 
in a synergistic effect; coating or coupling of DC-specific targeting moieties, increasing 
DC uptake and enhancing antigen presentation to T cells. Future developments in 
vaccine delivery will likely involve the combination of (multiple) TLRLs with delivery 
vehicles modified with DC-specific targeting ligands/antibodies to significantly enhance 
the delivery of SLP-vaccines to DCs.
Taking into consideration particle size, antigen release kinetics, adjuvanticity and in 
vivo uptake, the findings described in this thesis indicate that robust cellular immune 
responses can be obtained by using small NPs rather than MPs, with low-burst 
sustained release, positively charged and co-encapsulating (multiple) antigens and 
TLRLs (Chapters 3, 5, 6 and 7). 
In conclusion, the results described in this thesis present evidence that PLGA NPs may 
be successfully used as a delivery system for SLP-vaccines as a suitable replacement 
for emulsions-based formulations for cancer immunotherapy.
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In de laatste jaren is er een toenemende interesse in therapeutische vaccinatie als 
behandelingsmethode tegen ziektes zoals kanker [1]. In het bijzonder zijn synthetische 
lange peptiden (SLPs) bestudeerd als goed gedefinieerde antigenen voor kanker-
immunotherapie. Tot dusver zijn in (pre-)klinische studies SLPs geformuleerd in 
Montanide ISA 51, een water-in-olie (w/o) emulsie. Het gebruik van Montanide heeft 
echter belangrijke beperkingen, zoals een suboptimale effectiviteit en bijwerkingen. Er is 
dus een grote behoefte aan alternatieve formuleringen voor SLP-vaccins tegen  kanker. 
Het domein van kanker-immunotherapie, de huidige status van peptidevaccins tegen 
kanker, hun gebrek aan voldoende effectiviteit en de behoefte aan nieuwe adjuvantia 
worden geïntroduceerd in Hoofdstuk 1. In het bijzonder zijn biologisch afbreekbare 
afgiftesystemen op basis van een polymeer van melk- en glycolzuur (poly(lactic-co-
glycolic acid; PLGA)) interessant omdat ze biologisch compatibel zijn; vrije  antigenen 
na toediening kunnen beschermen tegen afbraak en snelle uitscheiding; co-inkapseling 
van (meerdere) antigenen en adjuvantia toelaten; en de grootte en structuur van een 
pathogeen imiteren. Bovendien worden ze efficiënter opgenomen door dendritische 
cellen (DCs) dan vrije antigenen [2, 3]. 
In Hoofdstuk 2 wordt een gedetailleerd overzicht gegeven van het gebruik van PLGA-
deeltjes voor de afgifte van eiwit- en peptidevaccins. Dit hoofdstuk bespreekt de 
formuleringsparameters die de adjuvanticiteit van deze systemen beïnvloeden, zoals 
grootte (nanodeeltjes (NDs) versus microdeeltjes (MDs), lading, antigeenlokalisatie, 
afgifteprofiel, en het includeren van immuunmodulatoren, zoals Toll-like receptor ligands 
(TLRLs), en/of moleculen met specifieke sturing, zoals antilichamen. Verder schetst 
dit hoofdstuk hoe de formuleringsparameters opname, verwerking en presentatie 
van antigenen door DCs en de daarop volgende immuunrespons beïnvloeden. Dit 
hoofdstuk geeft ook een samenvatting van PLGA-formuleringen die in de literatuur 
bestudeerd zijn voor de afgifte van synthetische peptidevaccins.
Het voornaamste doel van het in dit proefschrift beschreven onderzoek was het 
bestuderen hoe PLGA-deeltjes kunnen dienen als adjuvans in peptidevaccins tegen 
kanker, als een veiliger en effectiever alternatief voor Montanide. De belangrijkste 
doelstellingen van dit onderzoek waren:
• Het bepalen van de beste grootte van PLGA-deeltjes voor subcutaan toegediende 
vaccins;
• Ontwikkeling van PLGA-ND-formuleringen die beladen zijn met SLPs;





Het eerste doel werd bereikt in Hoofdstuk 3, waarin de rol van de deeltjesgrootte 
bij het opwekken van een immuunrespons werd bestudeerd. Hiervoor voerden we 
een vergelijkende studie uit tussen NDs en MDs die equivalente hoeveelheden van 
het modelantigeen ovalbumine (OVA), en een TLRL, poly(I:C), met vergelijkbare 
afgiftekinetiek bevatten. We bestudeerden hoe de mate van internalisering door 
DCs de MHC-I klasse antigeenpresentatie in vitro beïnvloedt, en de daaropvolgende 
immuunrespons in vivo, vergeleken met afgifte van een lokaal subcutaan depot. Hiertoe 
werd enerzijds PLGA geformuleerd als NDs die efficiënt door DCs geïnternaliseerd 
konden worden, waarbij intracellulaire depots gevormd worden. Anderzijds werd PLGA 
verwerkt tot MDs die te groot (> 20 µm) zijn om opgenomen te worden, om zo enkel te 
functioneren als een extracellulair depot, vergelijkbaar met Montanide. We toonden aan 
dat efficiënte opname van deeltjes cruciaal is om een immuunrespons op te wekken. 
NDs werden efficiënt opgenomen door DCs na in vitro incubatie, terwijl dit bij MDs 
niet gebeurde. Dit resulteerde bij het gebruik van NDs, in tegenstelling tot MDs, in 
verhoogde MHC- I klasse antigeenpresentatie in vitro. Bovendien werd bij subcutane 
vaccinatie bij muizen een significant groter aantal antigeenspecifieke CD8+ T-cellen 
verkregen met NDs in vergelijking met MDs of OVA geëmulgeerd in incomplete Freund’s 
adjuvant (IFA). Bovendien leidde de ND-formulering tot een betere antilichaamrespons 
in vergelijking met de MD-formulering. Bovendien induceerde de ND-formulering een 
meer evenwichtige TH1/TH2-type antilichaamrespons dan de IFA-formulering. We 
concludeerden dat vaccins geformuleerd zouden moeten worden in nanodeeltjes ter 
bewerkstelliging van efficiënte opname en significante MHC-I klasse cross-presentatie 
van het antigeen, maar ook voor effectieve T- en B-celresponsen. 
Na het bepalen van de optimale grootte van PLGA-deeltjes voor eiwitvaccins, 
beschrijven we in Hoofdstuk 4 de toepassing van deze PLGA-NDs als afgiftesysteem 
voor het beladen van DCs ex vivo, om antigeen-specifieke CD8+ T-cellen te stimuleren 
om gebruikt te worden voor adoptieve T-celimmuuntherapie. Daarvoor werden DCs, 
die voorheen geïncubeerd werden met PLGA-NDs met daarin ingekapseld het 
modelantigeen OVA of met het vrije eiwit geformuleerd in fysiologische zoutoplosing, 
gebruikt om CD8+ T-cellen te stimuleren, die vervolgens wereden toegediend aan 
muizen. DCs geïncubeerd met PLGA-NDs stimuleerden cytotoxische T-lymfocyten 
(CTLs) ex vivo efficiënter dan niet verpakt eiwit. Bovendien leidde het toedienen van 
CTLs gestimuleerd met PLGA-NDs beladen DCs tot een betere lyse van de doelcellen in 
vivo en een efficiëntere tumorcontrole, waardoor muizen met agressieve tumoren langer 
konden overleven. Met deze studie is aangetoond dat de effectiviteit van eiwitantigenen 
voor vaccinatie tegen kanker verbeterd kan worden door ze te verpakken in PLGA-
NDs. 
Aangezien uit bovenstaande studie gebleken was dat de afgifte van eiwitantigeen via 
inkapseling in PLGA-NDs een efficiënte manier is om krachtige anti-tumor T-cellen 
te induceren, bestudeerden we in Hoofdstuk 5 de toepassing van inkapseling van 
SLPs in PLGA-NDs, om zo het tweede doel te bereiken. Met gebruikmaking van het 
modelantigeen OVA24, een 24-residu lang synthetisch peptide met daarin een CTL-
epitoop van OVA (SIINFEKL), was ons doel de formuleringsparameters te bepalen die 
nodig zijn om een SLP succesvol in PLGA-NDs in te kapselen. Daarnaast werden 
PLGA-NDs geoptimaliseerd wat betreft de SLP-inkapseling en -afgiftekinetiek, om 
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daarmee de efficiëntie van SLP cross-presentatie door DCs te verbeteren. Wanneer de 
standaard inkapselingstechnieken gebruikt werden (een dubbele emulsie, waarbij het 
oplosmiddel wordt verdampt), was de inkapseling erg laag (< 30%), of de directe afgifte 
(burst release) erg hoog (> 70%). Door de formulerings- en procesparameters aan te 
passen, ontdekten we dat de pH van de eerste emulsie van kritiek belang is voor efficiënte 
inkapseling en constante afgifte. Door in de binnenste fase een alkalische, in plaats van 
een zure, omgeving te creëren, waren we in staat om niet alleen de inkapseling van 
het SLP te optimaliseren, maar ook de burst release te reduceren, waarbij uiteindelijk 
stabiele NDs van ongeveer 330 nm werden verkregen met een inkapselingsefficiëntie 
van ongeveer 40% en een burst release van minder dan 10%. Inkapseling van OVA24 
in deze PLGA-NDs gaf sterkere  MHC-I klasse gemedieerde T-celactivatie in vitro ten 
opzichte van NDs met een hoge burst release en vrij (niet verpakt) OVA24. Dit toont 
aan dat een lage burst release van belang is voor het opwekken van een krachtige 
cellulaire immuunrespons. Deze inkapselingsmethode kan een veelbelovende aanpak 
zijn voor het formuleren van peptiden met amfifiele en/of hydrofiele eigenschappen, en 
is ook succesvol toegepast op andere SLPs. Deze studie onderschrijft het belang van 
het optimaliseren van het inkapselingsproces bij het ontwikkelen van een effectief en 
stabiel vaccinafgiftesysteem, en kan gezien worden als een basis voor de ontwikkeling 
van ND-formuleringen met SLPs voor kanker-immunotherapie. 
Vervolgens werd de derde doelstelling onderzocht in Hoofdstuk 6, waarbij de 
inkapseling van een SLP (OVA24) samen met een TLRL (Pam3CSK4) in PLGA-
NDs wordt beschreven. De verkregen formuleringen werden gebruikt om de 
intracellulaire mechanismen te karakteriseren waarmee DCs PLGA-NDs verwerken, 
en om de immunologische effecten van de combinatie van SLPs met een adjuvans 
te onderzoeken. We toonden aan dat TLR2-stimulatie de MHC-I klasse presentatie 
van SLPs door DCs in vitro versterkte. DCs die geïncubeerd werden met PLGA-SLP(/
TLR2L)-NDs internaliseerden de NDs in endolysosomale compartimenten, wat zorgde 
voor een verlengde MHC-I klasse presentatie. PLGA-SLP-NDs en met name PLGA-SLP/
TLR2L-NDs wekten constante CD8+ T-celproliferatie in vivo op na adoptieve transfer 
van PLGA-SLP(/TLR2L)-ND-beladen DCs. Deze bevindingen tonen aan dat de CD8+ 
T-celrespons versterkt wordt wanneer het antigeen langdurig cross-gepresenteerd is in 
MHC-I klasse moleculen, en dat mede-inkapseling van een TLRL deze effecten verder 
versterkt.
Ten slotte onderzochten we in Hoofdstuk 7 het het vermogen van PLGA-NDs en 
kationische liposomen als afgiftesystemen voor SLP-vaccins voor het opwekken van 
T-celgemedieerde immuniteit. Daarvoor bestudeerden we de inkapseling van twee 
SLPs die een CTL- en een Th-epitoop (respectievelijk OVA24 en OVA17) van OVA 
bevatten, samen met TLRLs PAM3CSK3 en/of poly(I:C) in één deeltje, in een directe 
vergelijking met twee klinisch gebruikte adjuvantia, Montanide (een water-in-olie 
emulsie) en een op squaleen gebaseerde (olie-in-water emulsie) analoog aan MF59. 
De verkregen formuleringen werden in vitro en in vivo beoordeeld op hun capaciteit 
om CD8+ en CD4+ T-celimmuunresponsen op te wekken. De liposomale en PLGA-
ND-formuleringen waren in staat de antigeenopname door DCs en de daaropvolgende 
activatie van T-cellen in vitro te versterken. Subcutane vaccinatie van muizen toonde 




antigeen-specifieke T-cellen in vivo op te wekken minstens zo goed (PLGA NDs) of 
beter (kationische liposomen) was dan SLPs geformuleerd in de emulsies. Hierbij waren 
liposomen het beste in staat om T-cellen te induceren met de hoogste capaciteit om 
overgebrachte doelcellen in muizen te doden. Uit deze bevindingen blijkt dat dat beide 
systemen, kationische liposomen en PLGA-NDs, veelbelovende afgiftesystemen zijn 








ANOVA Analysis of variance
APC Antigen-presenting cell
B3Z B3Z CD8+ T-cell hybridoma cell line, specific for the CTL epitope of ovalbumin SIINFEKL
BCA Bicinchoninic acid protein assay
BMDC Bone marrow-derived dendritic cells
BSA Bovine serum albumin
CD4+ T cell T helper cell
CD8+ T cell Cytotoxic T lymphocyte
CFA Complete Freund’s adjuvant
CFSE Carboxyfluorescein succinimidyl ester 
CLR C-type lectin receptor
CpG ODN Unmethylated cytosine-phosphodiester-guanine oligodeoxynucleotide motif
CTAB Cetyltrimethylammonium
CTL Cytotoxic T lymphocyte










dsRNA Double-stranded RNA 
DSS Dioctylsulfosuccinate
EE Encapsulation efficiency
ELISA Enzyme-linked immunosorbent assay
ER Endoplasmic reticulum 
FACS Fluorescence-activated cell sorting




FDA Food and drug administration
FITC Fluorescein isothiocyanate
GM-CSF Granulocyte-macrophage colony stimulating factor
GMP Good manufacturing practice
gp Glycoprotein
HBcAg Hepatitis B core antigen
HbsAg Hepatitis B surface antigen
HBV Hepatitis B virus 
HEPES  4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
HLA Human leukocyte antigen
HPLC High-performance liquid chromatography





IFA Incomplete Freund’s adjuvant
IgG Immunoglobulin G
IgG1 Immunoglobulin G subtype 1
IgG2a/b Immunoglobulin G subtype 2a/b
IL Interleukin
INF-g Interferon gamma







Men B Neisseria meningitidis serotype B
MHC I/II Major histocompatibility complex class I/II
MP Microparticle
MPLA Monophosphoryl lipid A




OVA17 17-residue synthetic long peptide of ovalbumin (ISQAVHAAHAEINEAGR)
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OVA24 24-residue synthetic long peptide of ovalbumin (DEVSGLEQLESIINFEKLAAAAAK)
Pam3CSK4 Synthetic triacylated lipopeptide
PAMP Pathogen associated molecular pattern
PBS Phosphate buffered saline
PD-1 Programmed cell death protein 1 
PDI Polydispersity index
PD-L1/2 Programmed cell death protein 1 ligand 1/2
PEG Poly(ethylene glycol)
PEI Poly(ethylene imine) 
PLA Poly-lactic acid 
PLA2 Phospholipase A2 
PLGA Poly(lactic-co-glycolic acid)
Poly(I:C) Polyinosinic:polycytidylic acid
PRR Pattern recognition receptor
RGD Arginine-glycine-aspartate 
RNA Ribonucleic acid
RP-HPLC Reversed-phase high-pressure liquid chromatography
s.c Subcutaneous
SD Standard deviation
SDS Sodium dodecyl sulphate 
SEM Scanning electron microscopy
SEM Standard error of the mean
SLP Synthetic long peptide
sSLP Soluble synthetic long peptide
SSP Synthetic short peptide
ssRNA single-stranded RNA 
SWE Squalene oil-in-water emulsion 
TAA Tumor associated antigens 
TAP Transporter associated with antigen processing
TCR T cell receptor
TFA Trifluoroacetic acid
Th T helper 
Th1 Type 1 T helper 
Th2 Type 2 T helper 
TLR Toll-like receptor






TNF Tumor necrosis factor
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